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SUMMARY
The transforming growth factors-type p (TGF-ps) are a group of proteins expressed in 
the developing embryo and the adult. Three TGF-P's exist in vertebrates, TGF-pi, 
TGF-P2, and TGF-P3, all of which have growth inhibitory and stimulatory roles in 
vitro, depending on the target cell type.
In the mouse embryo TGF-p 1 RNA expression is first detected in the haemangioblasts 
of the yolk sac at approximately 7 dpc. These are small cell populations which give rise 
to the vascular endothelial cells and the haematopoietic cells. Later in development 
expression continues in tissues undergoing haematopoiesis and vasculogenesis, and is 
also found during osteogenesis, and in epithelia involved in epithelial / mesenchymal 
transformations (Akhurst etal, 1990). This project was undertaken to investigate the 
function of TGF-P 1 during development by depletion of the protein using molecular 
methods, such as antisense oligonucleotide technology, in conjunction with post­
implantation embryo culture. However, to ensure that any resulting phenotypes were as 
a result of the removal of TGF-p 1, the medium also had to be depleted of TGF-p.
Dulbeccos modified Eagles medium (DMEM) plus rat serum is commonly used for 
embryo culture, and was also examined in this project. However, analysis of the TGF- 
p content in the rat serum using the CCL64 assay revealed that considerable amounts of 
the protein were present (>15ng/ml), thereby rendering serum unsuitable for use in this 
project. Therefore, another medium had to be found. Although previous reports had 
found plasma unsuitable for embryo culture, it was also reported that this biological 
fluid contained negligible amounts of TGF-p. Analysis of rat plasma using the CCL64 
assay in this project detected <10pg/ml, suggesting that plasma was ideal for use as a 
medium depleted of TGF-p 1. However, when the rat plasma was combined with 
DMEM, embryonic development was severely disrupted. Therefore, a completely novel 
medium was devised, utilising Foetal Mouse Palate medium, in combination with rat 
plasma. This medium contained no, or undetectable levels of TGF-p, and supported 
normal development of 8.5 dpc embryo for 24 hours in vitro.
Before the culture system could be used with antisense oligodeoxynucleotides to 
remove TGF-p 1 from mouse embryos, two other groups generated transgenic mice 
with targeted disruption of the TGF-P 1 gene (Shull etal, 1992; Kulkarni etal, 1993). 
50% of the TGF-p 1 homozygous null mice were born, but only survived to 
approximately 3 weeks of age before dying of a wasting syndrome involving a
multifocal, mixed inflammatory cell response, and tissue necrosis. No other gross 
phenotypes were observed. The other 50% of TGF-p 1 nulls died in utero. In 
collaboration with Dr.M.Dickson, I determined the reason for this embryonic lethality.
By performing detailed studies at different developmental stages, it was concluded that 
the embryonic lethality was due to yolk sac abnormalities arising at 9-9.5 dpc. Both the 
vasculature and the blood was affected. The vasculature defects included weak vessels, 
a disorganised vasculature, or a complete lack of vessels altogether. Anaemia was 
observed in a number of yolk sacs. At 9.5jdpc, only if the yolk sac was severely 
defective was the development of the embryo per se affected. Dr.M.Dickson observed 
that by 10.5jdpc, the embryos appeared necrotic and were close to death (Dickson etal, 
1995).
Further experiments were performed to examine the dichotomy in embryonic survival. 
It was suggested that maternal TGF-p 1 was rescuing those TGF-p 1 null embryos that 
survived gestation (Letterio etal, 1994). This was examined in the current study by 
culturing embryos of all genotypes in the medium depleted of TGF-p. The intact 
conceptuses were cultured from 8.5 dpc, when they are all phenotypically normal, to
9.5 dpc, when the defective phenotypes are observable. An increase in the number of 
abnormal phenotypes was expected if maternal TGF-P was responsible for embryonic 
rescue. This was not observed. However, it was possible that the maternal TGF-p had 
already had effect before 8.5 dpc.
The initial effect of TGF-p 1 therefore appears to be in yolk sac vasculogenesis and 
haematopoiesis, coinciding with the expression data. As TGF-p 1 was thought to be a 
potent growth inhibitor of many cell types from in vitro studies (Roberts & Sporn, 
1990, for review), BrDU incorporation was employed to examine cellular proliferation 
rates in the TGF-p 1 knockout conceptuses. The cells of the yolk sac, and two types of 
embryonic epithelial cell types were examined. There was no increase in cell 
proliferation in the TGF-P 1 null samples in comparison with the wild-type samples. It 
is therefore likely that TGF-p 1 has a role in the control of yolk sac endothelial and 
haematopoietic cell differentiation.
TGF-p 1 therefore appears to be crucial for normal yolk sac development. Without a 
functioning yolk sac, the embryo does not receive nutrients and oxygen, and is unable 
to survive this critical gestation period before development of the chorioallantoic 
placenta.
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Chapter 1 
INTRODUCTION
1.1 Cell-Cell Interactions in Embryogenesis.
Inductive interactions between different cell types were initially identified by 
Spemann & Mangold in 1924, and it is now known that they occur throughout 
embryogenesis (Jacobsen & Sater, 1988). Initially, methodological constraints made 
it difficult to identify the signalling molecules, but with the advent of molecular 
biology, the methods improved drastically, with the result that a multitude of 
signalling proteins have since been identified. It has also been possible to compare the 
molecular components of inductive interactions in different animal models.
Molecular investigations have found that many cell signalling molecules, and other 
component proteins of their intracellular signalling pathways, appear to be genetically 
conserved across divergent species, suggesting that they have an important role in 
biology (Smith et al, 1987; Whitman & Melton, 1989, for review). Transforming 
growth factors type-beta (TGF-P) are one such group of highly conserved, secreted 
proteins. They belong to a superfamily of more diverse proteins, which have been 
grouped together due to their high degree of molecular similarity. Although much is 
already known about the in vitro actions and in vivo expression patterns of these 
proteins (Akhurst et al, 1990; Roberts & Sporn, 1990), this project examined the 
function of the TGF-ps, specifically TGF-pi, in vivo during murine embryogenesis.
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1.2 Transforming Growth Factor Superfamily
Members of the TGF-p superfamily have been found in a wide variety of species 
from Drosophila to man. The family members have a high degree of molecular 
homology, with the intron/exon boundaries of every gene essentially identical. 
Proteins share 40-80% amino acid (aa) homology, and all family members share 
seven of nine conserved cysteine residues. Between species, the amino acid homology 
of individual family members can reach 99%. The superfamily has been divided into
5 sub-groups; the TGF-p’s, Mullerian inhibiting substance (MIS), Decapentaplegic- 
Vg related group (DVR), the activins, and the inhibins. Additional members which 
cannot be categorised into any of the above groups have also recently been discovered
(Fig-1)
1.2.1 The Transforming Growth Factors Type-beta.
TGF-pi was molecularly cloned 7 years after initial identification as a co-factor 
capable of transforming normal rat kidney fibroblasts in culture (Delarco & Todaro, 
1978; Derynck et al, 1985). Three TGF-ps have now been cloned in vertebrates, 
TGF-pi, TGF-P2, TGF-p3, and their actions have been extensively studied (Roberts
6  Spom, 1990; Akhurst, 1994, for reviews). Each isoform appears to be able to exert 
inhibitory and mitogenic effects, but the potency varies enormously depending on the 
isoform. For example, TGF-pi has a more potent growth inhibitory effect on foetal 
bovine heart endothelial cells in vitro than does TGF-P2 (Muller et al, 1987; Jennings 
et al, 1988; Cheifetz et al, 1990). TGF-P expression is extensive in both adults and 
embryos, and will be described in more detail at a later stage.
Molecular analysis of the TGF-ps revealed that all three isoforms are very similar to 
one another, each containing seven exons, with conserved splice site junctions. They 
are all synthesised as pre-pro polypeptides, with 390 aa for TGF-p 1, and 414 aa for 
TGF-p2, and 410 aa for TGF-P3 (Derynck et al, 1988; Roberts & Spom, 1990; Pelton 
etal,  1990) (Fig.2). TGF-P2 can undergo differential splicing of the mature domain, 
to produce pre-pro-peptides of 414 and 442 aa in size (Webb et al, 1988). Each 
isoform contains a 20-23 aa signal peptide at the N-terminus, enabling the protein to 
be released from the cell. The precursors dimerise, commonly as homodimers (Fig.2). 
Heterodimers between TGF-pi and TGF-p2 (Cheifetz et al, 1988), and TGF-P2 and 
TGF- p3 (Ogawa et al, 1992) do exist, but are very rare. These pro-peptides undergo 
proteolytic cleavage at an arginine-rich sequence, 112 aa from the C-terminal, to 
release the bioactive form of TGF-p. However, the large N-terminal fragment, the
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Figure 1 - Transforming Growth Factor Type-Beta Superfamily.
Diagram m atical representation o f all know n m em bers o f the TG F-p 
superfam ily, and the subgroups within. T he  m ain branches reveal the four 
m ajor groups; the TG F-ps, the activins, the DVR group, and a group containing 
more diverse m em bers w hich cannot be classified w ith  any o f the others.
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Figure 2 - Diagrammatic Representation of the Different Forms of TGF-p.
T G F -p  is initially translated as a pre-pro  m onom er (A). The NH2 terminal 20-23 aa encode the 
signal peptide, follow ed by approxim ately 250-310 aa encoding the latency-associated peptide 
(LAP). T he  m ature region o f 112 aa  is located at the C-term inal. T w o m onom ers bind to each 
o ther by disulphide bonds, and through proteolytic cleavage at an arginine-rich site, the m ature 
regions are cleaved from the LAPS. However, by rem aining non-covalently  attached, the LA P 
continues to confer latency. This is the small latent TG F-p com plex  (B). A further com plex 
exists, term ed the large latent com plex (C), which has an additional protein, the latency 
associated binding protein (LTBP). The LTBP cannot confer latency, and  only ever binds to the 
LA P by disulphide bond(s). M ature T G F-p is active once released from the LA P (D). 
A ctivation may involve m annose-6-phosphate (P*), plasm in, the LTBP, and transglutam inase.
latency-associated peptide (LAP), remains non-covalently associated with the 
bioactive dimer, retaining the TGF-p in a latent state, the small latent complex.
A possible significant difference between the isoforms is the existence of a potential 
integrin binding site in the LAP of TGF- pi and TGF-P3, which is not present in TGF- 
P2 (Ruoslahti & Pierschbacher, 1987). However, mature bioactive TGF-P2 also has a 
specific amino acid sequence that is not present in either TGF-pi or TGF-P3 (Qian et 
al, 1992). This sequence appears to specify the requirement for betaglycan, a TGF-p 
type III receptor, which enables TGF-P2 to bind to type I or II receptors (see section 
1.3.2). Endothelial and haematopoietic cells both lack betaglycan, and although they 
respond to TGF-p 1 or TGF-P3, they are unable to respond to TGF-P2 (Ohta et al, 
1987; Ottman & Pelus, 1988; Merwin et al, 1991; Qian et al, 1992). However, in 
general, the isoforms are interchangeable in most bioassays (Greycar et al, 1989; 
Roberts etal , 1990).
Interspecies homology of the individual TGF-p isoforms is greater than intraspecies 
homology between the different isoforms. Mature TGF-p 1 is identical in human, 
avian, porcine, simian, and bovine (Derynck e ta l , 1985, 1987; Sharpies etal,  1987; 
Van Obberghen-Schilling et al, 1987; Jakowlew et al, 1988), and there is only one 
amino acid different between man and mouse (Derynck et al, 1986). TGF-P2 and 
TGF-P3 also show extreme conservation between different species (Seyedin et al, 
1985; de Martin et al, 1987; Cheifetz et al, 1987; Madisen et al, 1988; Derynck et al, 
1988, ten Dijke et al, 1988). This evidence suggests that the function of each 
individual TGF-p could be comparable across the species. However, there may be 
differences in the regulation and utilisation of the proteins in different species during 
embryogenesis. For example, the involvement of TGF-P3 during the crucial stages of 
heart development. TGF-P3 is expressed in the chick heart (Runyan et al, 1992), 
whereas TGF-p2 is the predominant isoform expressed in the developing mouse heart 
(Millan etal, 1991; Dickson etal, 1993).
1.2.2 Mullerian Inhibiting Substance.
MIS is a distantly related member of the TGF-p superfamily, involved in the 
development of the reproductive system. During mammalian development, male and 
female embryos have both a Wolffian and a Mullerian duct. The Wolffian duct 
regresses in the female but, in the male, under the influence of testosterone, it 
develops into the vas deferens, seminal vesicles, and epididymus. The Mullerian duct 
develops into the oviducts and uterus of the female, whereas in the male, MIS, a 
protein produced in the sertoli cells of the testis, acts to cause Mullerian duct
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regression (Josso, 1992; Blanchard & Josso, 1974). The MIS is a disulphide-linked 
dimer of 140 kDa, the subunits of which are disparate in size (70 and 74 kDa), 
possibly as a result of different post-translational modification (Cate eta l, 1986).
Like the other TGF-p superfamily members, MIS is initially produced as a large 
precursor protein, which can be post-translationally cleaved to form smaller 
homodimers. However, unlike the other family members, MIS is predominantly 
active as this large precursor form, and the significance of post-translational cleavage 
has not yet been established.
There is significant homology in MIS amino acid sequences across different species. 
For example, bovine and human MIS protein share 78% aa homology, with identity 
between 108 of the last 112 aa. When MIS is compared with the mature form of the 
TGF-ps, sequence homology is restricted to the processed C-terminal.
1.2.3 D ecapen tap leg icg Related Group (DVR group).
Members of the DVR group have been classified together as they are more similar to 
each other than to any of the other superfamily members (Lyons & Moses, 1990). 
They include the Drosophila gene, Decapentaplegic (dpp), the bone morphogenetic 
proteins (BMPs), Xenopus Vg-1, and its mammalian homologue, Vgr-1.
1.2.3.1 Decepentaplegic.
In Drosophila embryos, dpp is involved in the development of the imaginal discs, the 
wings, the gut, and the dorsal/ventral axis, dpp exerts its effect by inducing the 
expression of certain homeobox genes, thereby specifying the fate of certain cells 
(Panganiban et al, 1990; Reuter et al, 1990). For example, dpp and the homeobox 
Ubx are thought to positively regulate one another during the development of the 
midgut (Panganiban et al, 1990). If dpp or Ubx is absent, the midgut develops 
abnormally, dpp is therefore required for normal embryogenesis in Drosophila.
Comparison of the amino acid sequence of dpp with other members of the TGF-p 
superfamily shows extensive homology between dpp and the bone morphogenetic 
proteins 2 and 4. These BMP proteins are now thought to be the mammalian 
homologues of dpp (Gelbart, 1989; Wall & Hogan, 1994). The dpp amino acid 
sequence contains the common features of all the members of the superfamily; the 
conserved C-terminal 112 aa, and the arginine rich region thought to be involved in 
proteolytic processing of the protein (Gelbart, 1989).
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1.2.3.2 Xenopus Vg-1 and Mammalian Vgr-1.
Another member of the DVR group is Vg-1. Found in Xenopus, Vg-1 is translated 
from maternal mRNA localised in the vegetal region of the oocyte (Weeks & Melton,
1987). A closely related gene was recently discovered in mammals by Lyons et al 
(1989) and termed Vgr-1 for Vg-related. As for the other superfamily members, both 
Vg-1 and Vgr-1 contain the common sequence features of the family.
During Xenopus mesoderm formation, a soluble factor released from the endoderm 
(vegetal pole) induces the overlying equatorial cells to become mesoderm 
(Nieuwkoop, 1969). The temporal and spatial expression of Vg-1 suggests that it is a 
candidate for this inducing signal (Weeks & Melton, 1987). When explanted animal 
poles are treated with mature Vg-1 protein dorsal mesoderm is induced, with 
expression of the corresponding markers (Kessler & Melton, 1995). In vitro assays 
have also shown the activins, bone morphogenetic protein 4 (BMP 4), and several 
fibroblast growth factors (FGFs) to be capable of inducing mesoderm formation. 
Furthermore dominant negative mutation of the activin receptors type I and II, BMP 
receptor type II, or FGF receptor 1 block this inductive activity (Amaya et al, 1991; 
Hemmati-Brivanlou & Melton, 1992; Graff et al, 1994; Nakamura et al, 1992; Suzuki 
et al, 1994). This probably occurs by interaction of the dominant negative with an 
endogenous Vg-1 specific receptor (Kessler & Melton, 1995).
Another postulated role for Vg-1 is in the formation of the Nieuwkoop centre 
(Thomsen & Melton, 1993) The Nieuwkoop centre is an area of dorsal vegetal cells 
in the 32-cell blastocyst, which, when transplanted into the ventral vegetal region, can 
induce the formation of an entirely new body axis (Gimlich & Gerhart, 1984; 
Kageura, 1990). This occurs by the induction of dorsal mesoderm by the Nieuwkoop 
centre, which then forms, amongst other structures, Spemann’s organiser, resulting in 
axial formation (Elinson and Kao, 1989; Gerhart, et al, 1989). The hypothesis that 
Vg-1 is involved in the formation of this centre arises because the initial cortical 
rotation during the first cell cycle of the Xenopus embryo would relocalize Vg-1 from 
the vegetal cortex to the region of the future Nieuwkoop centre. Also, an injection of 
mature Vg-1 can rescue UV ventralised embryos, inducing the formation of the 
Nieuwkoop centre, and returning the axes to normal (Thomsen & Melton, 1993). 
However, further experiments are being performed to determine if Vg-1 is 
endogenously involved in this process.
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1.2.3.3 Bone Morphogenetic Proteins.
BMP’s were first identified by Urist (1965), although at that time the proteins were 
not purified. Urist implanted extracts of demineralised bone into ectopic sites in 
rodents, and found that new bone formed. Mesenchymal cells invaded the implant 
and differentiated into chondrocytes, followed by the differentiation of osteoblasts 
and osteoclasts. The inducing component in the extract was identified as protein, but 
whether it was a single protein or many working together was not known.
In 1988 Wozney cloned the BMP cDNAs and identified these proteins as the inducers 
of bone formation. Eight BMP’s have since been isolated, seven of which are related 
to the TGF-p superfamily of proteins, and belong in the DVR group (Wozney et al,
1988). Mature BMP 2 and 4 are 75% identical to Drosophila dpp protein, and 
therefore are classified along with dpp, while BMP 3, 5, 6, 7, and 8 are in other 
subgroups of DVR (Fig. 1).
The RNA expression pattern of BMP 2 during embryogenesis was found to overlap 
with patterns for other TGF-p superfamily members (Lyons et al, 1990). However, 
this is not conclusive evidence for interaction between BMP 2 and the other members, 
and may actually represent functional redundancy.
1.2.4 The Activins.
Activins are dimers of two p chains, and exist as activin A (paPaX activin B (PbPb)> 
and activin AB (PaPb)- As well as promoting the release of follicle stimulating 
hormone (FSH) from the pituitary (Mason et al, 1985), studies have shown that the 
activins are capable of inducing mesoderm formation, and structures derived from 
mesoderm (Albano et al, 1990; Smith et al, 1990; Mitrani et al, 1990; Mitrani & 
Shimoni, 1990; Nakamura et a l , 1992). Expression studies have also shown that the 
activins are expressed in several tissue types during postimplantation development 
(Feijen et al, 1994). At 6-9.5 dpc the subunits are expressed exclusively in the 
decidua. However, by 10.5 dpc activin A is found in the mesenchymal tissues of the 
embryo, in the same tissues, or adjacent to tissues expressing TGF-ps. Activin B is 
expressed in the central nervous system at this stage. There are several regions where 
both the Pa and Pb subunits are expressed, including the oesophagus, the 
mesenchyme of blood vessel walls, and the pleuroperitoneal membrane, which could 
suggest that all three activin isoforms are present. By comparing this data with activin 
receptor expression patterns, Feijen et al (1994) suggested that activin A could be 
involved in craniofacial development, and the formation of the inner ear, the tongue,
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and the lung; activin B in the development of the central nervous system, the 
stomach, and the eyelids; and activin AB in the development of the limb and 
shoulder.
Knockout mice deficient in activin A, B, AB, or the activin type II receptor were 
recently generated, and all mutants developed to term (Vassalli et al, 1994; Matzuk et 
al, 1995a,b). The initial observation was that zygotic activins were not required for 
mesoderm formation (Albano etal, 1990; Smith etal, 1990; Nakamura et al, 1992). 
However, as occurs with TGF-pi knockout mice, it is possible that there is maternal 
protein crossing the placenta which rescues the mutant embryos at this stage (Letterio 
et al, 1994). Mice which lacked activin A, or A and B, exhibited the same phenotype; 
they lacked whiskers, lower incisors, and had defects in their secondary palate 
resulting in failure to suckle and difficulty in breathing. The mice died at 
approximately 24 hours post-partum (Matzuk et al, 1995a). The defects are consistent 
with the observed expression of activin A in development (Feijen et al, 1994), and in 
vitro effects of the activins on chondrogenesis and osteogenesis (Centrella etal, 1994; 
Luyten et al, 1994). Activin B mutants were viable but had reduced female fertility 
and defective eyelid development (Vassalli etal, 1994).
The activin type II receptor knockouts were expected to exhibit a phenotype like the 
activin mutants, but although there were a few with facial and skeletal abnormalities, 
the vast majority were overtly normal, with only a decrease in the levels of FSH, and 
reduced reproductive capabilities (Matzuk et al, 1995b). This data suggests that the 
activins signal through the activin type II receptor for their FSH activity, but not for 
their role in embryonic development. As deletion of activin B also resulted in reduced 
fertility this may be the only isoform to signal through the activin type II receptor, 
and other receptor heterodimers may be required for activin A and AB. However, this 
data is difficult to interpret for activins alone because mutations in either p subunit 
also disrupts the expression of the inhibins.
1.2.5 The Inhibins.
Inhibin exists as two heterodimeric isoforms, inhibin A (aPa) or inhibin B (cxpb), 
consisting of one inhibin a  subunit, plus one of the two activin p subunits (pa or pb)- 
The a  chain is relatively distinct, whereas the p chains exhibit 46% and 38% 
homology to TGF-p.
Inhibin functions as a hormone to inhibit the release of FSH from the pituitary, 
thereby preventing the expulsion of an oocyte from the ovary (Mason et al, 1985).
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The inhibin subunit has also been identified in other tissues such as brain, kidney, 
placenta, adrenal gland and the pituitary, and it is therefore likely that inhibins are 
growth and/or differentiation factors as well as hormones (Meunier et al, 1988). 
However, mice deficient for inhibin a  were viable, and only developed gonadal 
stromal tumours (Matzuk et al, 1992). This observation suggests that either the 
widespread expression of inhibin a  represents non-functional protein and the only 
function of inhibin is as a reproductive hormone, or that there is functional 
redundancy with other molecules in the knockout mice. The mild phenotype of the a  
mutants also suggests that the defects observed in the activin mutants were as a result 
of the removal of the activin isoforms, and not the inhibin isoforms (Matzuk et al, 
1995a,b).
1.2.6 Recent Additions to the Superfamily.
There are several new additions to the TGF-p superfamily, most belonging to the 
DVR subgroup (Fig.2). They include 60A, a Drosophila BMP (Doctor et al, 1992); 
dorsalin-1, and nodal (Basler et al, 1993; Zhou et al, 1993), both of which are 
thought to be involved in the dorsal/ventral patterning of the mouse embryo; and 
growth/differentiation factor-3/Vg-related 2 (GDF-3/Vgr-2) (Jones et al, 1992). GDF- 
9, and glial-derived neurotrophic factor (GDNF) are also recent additions, but cannot 
be classified into any of the existing subgroups (McPherron & Lee, 1993; Lin etal, 
1994). Further research is required to identify the exact roles of these proteins, 
especially during development where they are found to be expressed in embryonic 
tissues undergoing inductive interactions and patterning.
Based on sequence similarities, new members of the TGF-p superfamily continue to 
be identified, but their functions are as yet unknown. The TGF-ps however, have 
obviously been studied over a longer period of time, and a plethora of molecular and 
functional information has already been obtained for these proteins.
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1.3 Transforming Growth Factors Type-beta 
Latency, Activation, and Ligand/Receptor 
Interaction.
1.3.1 TGF-p Latency.
As discussed in section 1.2.1, TGF-p is synthesised as a large precursor, which is 
proteolytically processed to form an inactive complex, held together by hydrophobic 
bonds (Fig.2). This complex, which contains the TGF-p gene product alone, is termed 
the small latent complex.
Another form of latent TGF-p is released from platelets (Assoian & Spom, 1986; 
Fava et al, 1990) (Fig.2). This form is termed the large latent TGF-p complex and 
contains a third component called the latent TGF-p binding protein (LTBP) 
(Miyazono et al, 1988, Wakefield et al, 1988, Okada et al, 1989). LTBP is a separate 
gene product of 125-160 kDa, and is bound to one of the LAP monomers by 
disulphide bonds. LTBP is only ever bound to latent TGF-p via the LAP, never to 
mature TGF-p. Furthermore, LTBP cannot confer latency alone. This has been shown 
by incubation of 125I-labelled active TGF-p with LTBP followed by the 
immunoprecipitation of the TGF-p with antibody. LTBP was not observed to have 
bound to any of the mature TGF-p (Kanzaki et al, 1990). The LAP is sufficient to 
confer latency (Miyazono etal, 1993).
LTBP cDNA was cloned from human foreskin fibroblasts and rat kidney cDNA 
libraries (Kanzaki et al, 1990; Tsuji et al, 1990). There are 1394 aa in the open 
reading frame of the human LTBP. When the cDNA was transfected into COS cells 
or HEL cells, the resulting protein was 190-205 kDa (Kanzaki et al, 1990; Miyazono 
et al, 1991). This suggests that the 125-160 kDa LTBP retrieved from platelets must 
have sustained proteolytic processing.
The amino acid sequence of the LTBP is highly repetitive, and consists of sixteen 
epidermal growth factor (EGF)-like repeats and three “LTBP-like” repeats (Kanzaki 
et al, 1990; Tsuji et al, 1990). These cysteine-rich repeats constitute more than 60% 
of the LTBP protein. EGF-like repeats have been observed in a wide variety of 
proteins that are functionally unrelated, such as blood coagulation factors, growth 
factors, homeotic gene products, receptors, and extracellular matrix proteins (Davis, 
1990). The presence of consensus amino acid sequences in some of the EGF-like 
repeats suggests that Ca2+ can bind to the LTBP (Colosetti et al, 1993). The function 
of the EGF-like regions is not fully understood, but it has been postulated that they
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may be involved in homophilic and/or heterophilic protein interactions. In vitro, cells 
which express Notch, a Drosophila protein with EGF-like repeats, are found to 
aggregate with other Notch -expressing cells or even other proteins that contain EGF- 
like repeats. This occurs in a Ca2+-dependent manner (Rebay etal, 1991).
The other repeats in the LTBP are the “LTBP-like” motifs, which consist of eight 
cysteine residues. They are observed three times in LTBP, and have also recently 
been found in a related protein, fibrillin (Maslen etal, 1991). Fibrillin is a 350 kDa 
glycoprotein and is a constituent of the extracellular matrix (ECM) in elastic tissues. 
A genetic defect associated with abnormalities in fibrillin is Marfan’s syndrome. This 
syndrome is typified by skeletal abnormalities, dislocation of the lens of the eye, and 
aortic aneurysm and dissection. Immunohistochemical studies had shown that LTBP 
was frequently localised in connective tissues (Waltenberger et al, 1993; Mizoi et al, 
1993), and so Taipale et al (1994) investigated whether LTBP was also a constituent 
of the ECM, or just interacted with matrix components. The evidence demonstrated 
that the LTBP binds to the ECM and enables TGF-p to associate with the ECM after 
secretion without any activation step. Release of the TGF-p is via proteolytic 
cleavage of the LTBP (Taipale etal, 1994).
1.3.2 TGF-p Activation.
Activation of TGF-P requires the complete dissociation of the LAP from the mature 
region of the protein. The process by which this occurs in vivo is not yet fully 
understood, although there are several suggestions. Recent studies have proposed a 
role for mannose-6-phosphate (Dennis & Rifkin, 1991). Mannose-6-phosphate is a 
signal, targeting proteins for transport to the lysosomes of the cell, and LAP contains 
mannose-6-phosphate residues (Fig.2) (Purchio et al, 1988; Kovacina et al, 1989). It 
is possible that the LAP binds to the mannose-6-phosphate/IGFII receptor, and is 
redirected either to the cell surface or into a lysosomal compartment for activation 
(Taipale etal, 1994).
It is also feasible that the cation independent mannose-6-phosphate receptor acts 
indirectly in the activation of TGF-p by limiting the supply of latent TGF-p. This 
receptor is known to participate in the degradation of the ECM (Brauker et al, 1986; 
Chao et al, 1990). If this activity was inactivated by the binding of ligand, ie LAP, 
then ECM degradation would be prevented, and the supply of matrix-derived latent 
TGF-p would be restricted. The requirement for the proper assembly of the 
extracellular matrix is shown by the repression of TGF-p activation when the matrix 
cross-linking enzyme, transglutaminase, is inhibited (Kojima et al, 1993).
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Nevertheless, mannose-6-phosphate does appear to be a prerequisite for activation 
from the finding that latent TGF-p requires binding to the mannose-6-phosphate/IGF- 
II receptor in co-culture of endothelial cells and smooth muscle cells for activation to 
occur (Dennis & Rifkin, 1991).
However, the above data only suggests mechanisms for directing the latent form for 
activation, and not activation itself. Early investigations found that recombinant latent 
TGF-pi or TGF-pi from fibroblast conditioned medium can be activated by plasmin 
(Lyons et al, 1988, 1990), suggesting a role for proteases in the activation process. 
Plasmin is located at the cell surface, thus the importance of targeting of latent TGF-p 
to the cell surface by the mannose-6-phosphate receptor, or LTBP becomes more 
obvious (Flaumenhaft et al, 1993). Further evidence for a role for plasmin is the 
inhibition of TGF-p activation if either plasminogen, or the receptor-bound urokinase 
are omitted (Odekon et al, 1994). Acid conditions (pH3.6), and heat treatment can 
also activate latent TGF-p in cultured cells (Lawrence etal , 1985; Brown eta l , 1990). 
However, it is unlikely that these factors are involved in vivo .
1.3.3 TGF- p Receptors.
Molecular cloning of the receptors for various members of the TGF-p superfamily has 
only recently been performed. Three receptor types were originally identified on the 
basis of their differential sizes in chemical crosslinking studies using radio-iodinated 
TGF-p. These were Types I (53-65 kDa), II (85-95 kDa), and III (200-400 kDa) 
(Massagud, 1992; Lin & Lodish, 1993; for reviews).
The first receptor of the TGF-p superfamily to be cloned was the activin type II 
receptor, ActRII, followed shortly by a second activin receptor, ActRIIB (Mathews & 
Vale, 1991; Attisano et al, 1992; Mathews et al, 1992). The sequencing of these 
receptors identified the first transmembrane serine/threonine kinase molecules and 
thus a completely novel form of growth factor receptor. All of these proteins contain 
an extracellular domain, a transmembrane region, and an intracellular domain. This 
latter region contains the serine/threonine kinase domain.
The TGF-p type II receptor was the next serine/threonine kinase receptor to be 
identified (Lin et al, 1992), and was found to have limited homology to the activin 
receptor in the extracellular domain (<10%), but extensive homology in the 
intracellular domain (47%). This evidence suggested that the TGF-p superfamily 
signalled through a novel type of receptor group, the serine/threonine kinases, and not 
the more common tyrosine kinases.
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On identification of the type I receptors, their intracellular regions were also found to 
contain serine/threonine kinase domains (Attisano et al, 1993; Ebner et al, 1993; 
Franzen et al, 1993). However, these kinase sequences were different than those of 
the type II receptors, and therefore the receptors were classified into a separate 
subgroup.
Type I receptors so far identified include ActRI, ActRIB, BMPRI, BMPRIB, TfRI, 
and TSR (Frolik etal,  1984; Attisano etal, 1993; ten Dijke etal, 1993; Carcamo et 
al, 1994). Type II receptors include ActRII, ActRIIB, TfJRII, and BMPRII (Mathews 
& Vale, 1991; Lin etal, 1992; Attisano etal, 1992; Estevez etal, 1993).
Although both type I and type II receptors contain potential signalling sequences, 
recent studies have shown that both receptor types are required for signalling to occur. 
An exception to this rule are the type I and type II BMP receptors, daf-1 and daf-4 
(Georgi et al, 1990; Estevez et al, 1993). It appears as if daf-4 is capable of binding 
the ligand and transduction of the signal without daf-1 (Estevez et al, 1993). 
However, for all of the other receptors identified so far, if either receptor type is 
present alone, there is no response to ligand binding.
Mutant mink lung epithelial cells with defective TGF-p type I or type II receptors 
were generated by chemical mutagenesis (Laiho et al, 1990, 1991). The R clones had 
a severe reduction or complete loss of type I receptors, and the DR clones had 
reductions in both receptors. Wild-type mink lung epithelial cells are inhibited by 
TGF-pi, but the TGF-p response was not observed when the ligand was applied to 
either of the mutant clones (Laiho et al, 1990, 1991). In the R mutants, the ligand 
could bind to the type II receptor but there was no signal transduction, whereas in the 
DR mutants, the TGF-p could not even bind to either receptor. However, if wild-type 
type I receptors were transfected into the R mutants, the TGF-p response was 
observed. This was also seen with the transfection of wild-type type II receptors into 
the DR mutants (Wrana et al, 1992; Inagaki et al, 1993). These observations 
suggested that the type II receptor was imperative for signalling, but that it needed the 
type I receptor in order to do so, and that the type I receptor required the presence of 
type II to bind the ligand.
As identified by ligand-binding, the study with the DR mutants also suggested that 
the type II receptor is required for the appearance of the type I receptors on the cell 
surface (Kingsley, 1994). Antibodies to either receptor type will coimmunoprecipitate 
both type I and type II receptors after crosslinking in the presence of ligand (Wrana et 
al, 1992; Attisano et al, 1993; Franzen et al, 1993) suggesting that they form a
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heteromeric complex, but whether this exists only in the presence of ligand is not yet 
known.
As well as TGF-p type I and type II receptors, there are type III receptors. Betaglycan 
was first to be identified (Lopez-Casillas et al, 1991; Wang et al, 1991), and will be 
discussed below. Endoglin is also a type III receptor (Cheifetz et al, 1992), and much 
of the information regarding betaglycan also refers to endoglin. However, endoglin 
differs from betaglycan in that it is only expressed in vascular endothelial cells, it can 
only bind TGF-p 1 and TGF-p3, and it does not exist in a free floating form.
The type III receptor is often the most abundant TGF-p receptor present on the cell 
surface with as many as 200,000 molecules per cell (Massague, 1985; Fanger et al, 
1986; Cheifetz et al, 1992). Betaglycan is a membrane protein (Cheifetz et al, 
1988a,b), but unlike types I and II, type III does not have a serine/threonine kinase 
intracellular domain. This protein consists of an extracellular domain and the 
transmembrane region to anchor it into the membrane (Gougos & Letarte, 1990; 
Lopez-Casillas et al, 1991; Wang et al, 1991). There is no substantial intracellular 
region. It consists of only 43 amino acids, 42% of which are serine/threonine 
residues. The extracellular domain is heavily modified by glycosaminoglycans, but 
after treatment with chondroitinase ABC and heparitinase, a 120 kDa protein is 
obtained, the core protein, to which TGF-p binds (Segarini & Seyedin, 1988; Cheifetz 
etal, 1988).
The type III receptor is found in many different cell types, but certain cell types such 
as haematopoietic progeniter cells (Ohta et al, 1987), and endothelial and epithelial 
cells in primary or early passage cultures (Segarini et al, 1989) do not express 
betaglycan, although they do have the type I and type II receptors. These cells still 
exhibit a TGF-p response, suggesting that type III receptors are not directly involved 
in the signalling of TGF-p (Cheifetz etal, 1990; Massague etal, 1990). Betaglycan 
binds TGF-p and then presents it to the type II receptor (Lopez-Casillas et al, 1993; 
Yamashita etal, 1994).
However, as well as being bound to the membrane, betaglycan can be “shed” and 
float free (Andres et al, 1989; Lopez-Casillas et al, 1991). This form can still bind 
ligand, but does not present it to the signalling receptors (Lopez-Casillas et al, 1994). 
It therefore appears as if betaglycan in this soluble, free-floating form is removing 
excess ligand, or is a method for controlling the actions of the ligand. It is a dual 
modulator of TGF-p access to the signalling receptors.
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The affinity for ligand varies between the different receptors. Some TGF-p type I and 
type II receptors bind all three TGF-p isoforms equally, but there are subsets which 
have a higher affinity for TGF-pl and TGF-P3 (Cheifetz et al, 1990; Segarini et al, 
1989). It is likely that this subset of receptors is present in haematopoietic and 
endothelial cells which do not respond to TGF-P2 (Ohta et al, 1987; Ottman & Pelus, 
1988; Merwin et al, 1991; Qian et al, 1992|). However, in the presence of betaglycan 
the affinity for TGF-p2 in this subset of type I and type II receptors increases. 
Betaglycan itself binds to all TGF-p isoforms equally.
It has recently been suggested that type I receptors can interact with different ligands, 
depending on the type II receptors present, for example, an activin type I receptor will 
bind activin or TGF-p depending on whether there are activin or TGF-p type II 
receptors expressed (Attisano et al, 1993; Ebner et al, 1993). Converse to this, the 
intracellular response resulting from type II receptor binding is determined by the 
type I receptor that it complexes with (Attisano et al, 1993). This phenomenon is 
already known to occur with the TSR type I receptor, which binds both activin and 
TGF-p ligands, and activin and TGF-p type II receptors (Attisano etal, 1993).
The evidence so far suggests that a ligand will evoke different cellular responses by 
binding to different combinations of receptor subunits. The members of the TGF-P 
superfamily also form homo- or heterodimeric complexes, and it may be that different 
combinations of ligand subunits drive the formation of specific receptor complexes, 
which in turn give rise to a specific cellular response (Kingsley, 1994). It is also 
possible that the cells produce different receptors for the same ligands, thereby giving 
rise to a diverse range of responses from the same ligand (Kingsley, 1994). Many 
members of the TGF-p superfamily do exhibit a wide range of actions, and perhaps 
this is the method through which they do so. Even the actions of the TGF-p isoforms 
themselves, which have been studied in detail, show great diversity from cell-type to 
cell-type, and between adults and embryos.
1.4 Actions of Transforming Growth Factors Type- 
Beta.
1.4.1 The Extracellular Matrix.
Initial expression studies for TGF-p found that the protein was localised in the 
mesenchyme of embryonic and adult tissues (Ellingsworth et al, 1986; Heine et al, 
1987; Flanders et al, 1989; Thompson et al, 1989). It is now known that TGF-p
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controls growth, differentiation and function of the mesenchymal cells predominantly 
indirectly via the extracellular matrix (Roberts & Spom, 1990).
Many of the matrix proteins which constitute the ECM are produced in response to 
TGF-p. Collagen types I, III, IV, and V, chondroitin/dermatan sulphate 
proteoglycans, fibronectin, osteopontin, thrombospondin, tenascin, and elastin are all 
upregulated by TGF-p (Seyedin et al, 1985; Ignotz & Massague, 1986; Chen et al, 
1987; Falanga et al, 1987; Varga et al, 1987; Rossi et al, 1988; Madri et al, 1988; 
Hiraki et al, 1988; Noda et al, 1988; Penttinen et al, 1988; Pearson et al, 1988; Lui & 
Davidson, 1988). Normally, to control the amount of ECM present, ECM proteins are 
degraded by proteases. However, TGF-p also controls this degradation by 
downregulating the synthesis of proteases, such as plasminogen activator, 
collagenase, and elastase, as well as inducing the production of protease inhibitors 
including plasminogen activator inhibitor, and tissue inhibitor of metalloproteinases 
(Laiho etal, 1986; Lund etal, 1987; Edwards etal, 1987; Overall etal, 1989).
One TGF-p effect that has a direct consequence on the cell is the ability of TGF-pi 
and TGF-P2 to increase the expression of integrins, cell membrane receptors for 
extracellular matrix proteins, thereby increasing the interaction of cells with the ECM 
(Hynes, 1987; Ignotz & Massague, 1987; C.J.Roberts et al, 1988). The regulation of 
fibronectin and its integrin, VLA-5, by TGF-p is a well documented example 
(McDonald et al, 1987; C.J.Roberts et al, 1988). By affecting the ECM in these ways 
TGF-p indirectly and directly affects the behaviour and phenotype of the cells.
1.4.2 Skeletal and Smooth Muscle.
The majority of work investigating the effect of TGF-p on muscle has been 
performed in vitro. The data presented here will focus on skeletal and smooth muscle, 
while cardiac muscle will be discussed in section 1.4.5.
Initial investigations had suggested that TGF-p was a growth and differentiation 
inhibitor of skeletal muscle cells (Florini et al, 1986; Massague et al, 1986; Olson et 
al, 1986). However, this interpretation has since been questioned. When TGF-pi was 
added to L6E9 rat skeletal myoblasts in a mitogen-rich medium, the cells were 
growth inhibited, but were also induced to differentiate into multinucleated myotubes 
(Zentella & Massague, 1992). This result suggested that under mitogen-rich 
conditions in vivo, TGF-p 1 may be an endogenous inducer of myogenic 
differentiation. However, the effect of TGF-p on smooth muscle cells does not appear 
to affect differentiation, but proliferation. In porcine aortic smooth muscle cells
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(ASMC) the activity of TGF-p is concentration dependent (Hwang et al, 1992). At 
25pg/ml the cells are growth stimulated, whereas at lOOpg/ml or above, they are 
growth inhibited. In human adult ASMCs, the population doubling time is controlled 
by endogenously produced TGF-p, acting in an autocrine growth inhibitory loop 
(Kirschenlohr et al, 1993). The doubling time in the human cells is approximately 
twice that found for adult rat ASMCs, which do not produce TGF-p. Therefore, the 
action of TGF-p on muscle cells can vary depending on the type of cell, the 
concentration of TGF-p, and the species from which the cells were obtained.
TGF-ps are also expressed in the developing muscle of the embryo (Pelton et al, 
1991; Millan etal, 1991). TGF-p2 was initially identified in the developing somites at
8.5 dpc by in situ hybridisation, and at later stages in the smooth muscle of the body 
wall (Dickson et al, 1993). In vitro studies also found that TGF-p can exert an effect 
on developing limb bud myoblasts. When TGF-p was added to cultured limb buds, 
embryonic myoblasts formed, but foetal myoblast formation was inhibited. However, 
if anti-TGF-p antibody was added to the cultured limb buds, foetal myoblasts 
appeared (Cusella-De Angelis et al, 1994). This suggested that the differentiation of 
foetal myoblasts, as opposed to embryonic myoblasts, is normally controlled by 
endogenously produced TGF-p. In addition, a role for TGF-p in myogenesis was 
further substantiated by the finding that TGF-p 1 and TGF-P2 are capable of inducing 
embryonic stem cells to differentiate into cardiac and skeletal muscle cells (Slager et 
al, 1992). Therefore, taken together, the expression patterns of TGF-P2, the response 
of the ES cells, and the differential response of different myoblasts implies that TGF- 
P may regulate muscle histogenesis in the embryo.
1.4.3 Bone.
Bone is the most abundant source of TGF-p in the body, containing approximately 
0.3mg/kg (Seyedin et al, 1986). It is hypothesised that TGF-p has a role in the 
formation and remodelling of mineralised tissues by acting on mesenchymal 
precursor cells, chondrocytes, osteoblasts, and osteoclasts (Centrella etal, 1988), cells 
which, in the developing embryo, do express TGF-pi (Heine etal, 1987). TGF-p may 
also be involved in bone growth, remodelling and repair in the adult, probably by the 
same methods employed during embryogenesis (Seyedin et al, 1985, 1986; 
Carrington et al, 1988). Evidence for the osteoinductive role of TGF-p was obtained 
when TGF-p was repeatedly injected into the periostea of rat parietal bones, or 
subperiosteally into the rat femur, resulting in new bone formation (Noda & 
Camilliere, 1989; Joyce et al, 1990). TGF-p is also capable of closing non-healing 
skull defects in experimental rabbits (Beck et al, 1991). One hypothesised action for
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TGF-p in bone involves the activation of latent TGF-p in the acidic, proteolytic 
environment created by osteoclast activity (Oreffo et al, 1989). Active TGF-p then 
inhibits the osteoclasts, but promotes osteoblast activity. Matrix deposition would 
also occur which would serve as a centre for mineralisation.
1.4.4 Immune System.
In the immune system, TGF-p appears to have an inhibitory effect on numerous cell 
types. In vitro, it inhibits the proliferation of certain cells, such as thymocytes, and T 
and B lymphocytes (Ristow, 1986; Kehrl et al, 1986,a,b, 1989); it inhibits the activity 
of natural killer cells (Rook etal, 1986); and inhibits the production of lymphokine- 
activated killer cells and allospecific cytotoxic T lymphocytes (Mule et al, 1988; 
Espevik etal, 1988). TGF-p also has an antagonistic effect on the interleukins IL-1, 
IL-2, and IL-3, tumour necrosis factor and the interferons (Kehrl et al, 1986; Wahl et 
al, 1988; Roberts & Spom, 1990). A bifunctional action is observed for the effect of 
TGF-p on IgG secretion; it upregulates IgG secretion from splenic lymphocytes from 
0.1% to more than 10%, whereas if B cells expressing IgG are treated with TGF-p, 
then IgG secretion is inhibited (Coffman et al, 1989). Therefore, with the ability to 
exert this range of inhibitory effects, TGF-p appears capable of extensive 
immunosuppressive activity.
Further data suggests that, in vivo, TGF-p acts as an autoregulatory lymphokine that 
regulates T-cell clonal expansion, and can also suppress immune cell function (Kehrl 
et al, 1986). Sufferers of glioblastoma often have reduced cell-mediated immune 
responses (Wrann et al, 1987), and on purification of this immune suppressor from a 
glioblastoma cell line, it was identified as TGF-P2 (De Martin et al, 1987). Other 
TGF-ps may be secreted from other tumours, with the same immune repressing 
capacity.
Positive activities of TGF- p in the immune system include the chemoattractant effect 
on monocytes, and at higher concentrations, the stimulation of monocytes to increase 
the mRNA expression of certain growth factors (Wahl etal, 1987; McCartney-Francis 
et al, 1989). TGF-p also inhibits hydrogen peroxide release from macrophages 
(Tsunawaki et al, 1988), which may have a beneficial effect during wound healing by 
removing the killing capacity of the cells, while allowing the growth factors released 
from the cells to act.
Potent evidence for the involvement of TGF-p in the immune system was recently 
obtained when mice deficient for TGF-p 1 (TGF-pi_/L) were created by homologous
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recombination (Fig.3). TGF-p l /_ mice which survived gestation, died approximately 
3 weeks after birth (Shull et al, 1992; Kulkarni et al, 1993). Morphological 
examination of these mice revealed that there had been massive infiltration of 
lymphocytes and macrophages into multiple organs, which had led to a wasting 
syndrome, tissue necrosis, and organ failure, followed by death. It appeared as if the 
immune system had gone awry.
All of the evidence provided from in vitro and in vivo studies suggests that TGF-p 
controls the detrimental aspects of the inflammatory response while helping the 
anabolic effects of growth factors on tissue repair.
1.4.5 Heart.
During development of the mouse heart, angiogenic clusters and promyogenic 
precursors located in the mesenchyme on the lateral sides of the presomite embryo, 
rapidly spread in the cephalic direction, fuse, and form the primitive heart tube at 
approximately 7.5-7.75 days post-coitum (dpc). This tube consists of endocardium 
and myocardium separated by acellular cardiac jelly. From 7.5 to 11 dpc major 
morphogenetic movements occur which change this simple heart tube into a 
convoluted, 4 chambered, contracting organ (Viragh & Challice, 1980).
TGF-pl and TGF-p2 are the major isoforms expressed in the developing mouse heart 
at these early stages (Akhurst et al, 1990). TGF-P3 is restricted temporally and 
spatially to 14.5-16.5 dpc in the mesenchymal condensations at the base of the heart 
valves (Millan et al, 1991). TGF-ps 1 and 2 however, have been detected by in situ 
hybridisation as early as 7 dpc in the cardiac mesoderm, and by 7.5-8 dpc TGF-pi 
expression was detected in all endocardial components, with TGF-P2 in the 
myocardium (Akhurst et al, 1990; Dickson et al, 1993). By 8.5 to 9.5 dpc, although 
still expressed in the same cell types, TGF-p 1 and TGF-P2 expression becomes 
restricted to the outflow tract and atrioventricular regions. It is at this time that the 
cardiac jelly in these regions is invaded and replaced by mesenchyme, forming the 
septae of the heart (Dickson etal, 1993).
The precise actions induced by the TGF-ps in heart development are not known, 
although it has been suggested that during early stages TGF-P2 induces the 
differentiation of myocardium from cardiomyocytes (Dickson et al, 1993). In vitro 
studies do support a differentiative function for TGF-p in cardiac muscle cells. As 
mentioned previously (section 1.4.2), addition of TGF-pl or TGF-P2 to ES cells in 
culture induces the formation of cardiac and skeletal muscle, with TGF-P2 increasing
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the beating rate of the cardiac muscle formed (Slager et al, 1992). In addition, TGF- 
pi induces the expression of genes for myocardial contractile proteins in cultured 
neonatal rat cardiomyocytes, and augments cardiac cell differentiation in cultured 
cardiac mesoderm of the axolotl (Parker et al, 1991; Muslin & Williams, 1991). 
Therefore, unlike its effect on other muscle cell types, the effect of TGF-p in cardiac 
muscle does not seem to be growth inhibitory, but rather, differentiation inducing.
Later on in the development of the heart, TGF-p 1 and TGF-p2 may interact to form 
the cushion tissue (Dickson et al, 1993). It is postulated that by inducing changes in 
the ECM, TGF-pi enables the endothelial cells to migrate into the cardiac jelly 
(Runyan & Markwald, 1983), while TGF-P2 diffuses from the myocardium into the 
jelly and induces an endothelial-mesenchymal transition. Studies have shown that 
there is a signal emanating from the myocardium adjacent to the cardiac jelly, and 
that it has inductive capabilities, but whether TGF-P2 is a component of this signal is 
not yet known (Krug et al, 1985; Mjaatvedt & Markwald, 1989; Potts & Runyan, 
1989; Lyons etal, 1990; Millan etal, 1991).
Continued expression of the TGF-ps in the developing heart appears to be limited. 
TGF-P2 and TGF-p3 are not expressed after days 17.5, and 16.5 dpc respectively, 
whereas TGF-p 1 expression is restricted to the endothelial cells overlying the cardiac 
cushions until 7 days after birth (Pelton et al, 1991; Millan et al, 1991). However, in 
the adult heart, expression is switched back on in the myocardium (Roberts et al, 
1981), and is up-regulated in response to mechanical load, infarction, and adrenergic 
agonists (Thompson etal, 1988, 1989; Bhambi & Eghbali, 1991). A role for TGF-p 
in the adult heart is supported by the finding that TGF-p can control the expression of 
at least six cardiac restricted genes, and can also convert isolated adult rat cardiac 
fibroblasts into cells with a cardiac myocyte phenotype which retain the ability to 
proliferate (Parker etal, 1990a,b; Eghbali etal, 1991). Therefore, from in vitro, and 
expression studies, it appears that in the adult, the TGF-ps are involved in 
differentiation and disease of the heart (Parker & Schneider, 1991).
1.4.6 Epithelium.
Most epithelial cells appear to be growth inhibited by TGF-p. In vitro, all three TGF- 
P isoforms inhibit the proliferation of keratinocytes, intestinal epithelial cells, prostate 
epithelial cells, mammary duct epithelial cells, and renal proximal tubular cells (Fine 
et al, 1985; Moses et al, 1985; Reiss & Sartorelli, 1987; Kurokowa et al, 1987; 
Silberstein & Daniel, 1987; McKeehan & Adams, 1988). TGF-p can also induce 
differentiation of certain epithelial cells (Jetten etal, 1986; Masui etal, 1986).
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In vivo studies support the growth inhibitory and differentiation inducing effects of 
TGF-p on epithelial cells. An inverse correlation between the number of dividing 
cells and expression of TGF-pi mRNA in intestinal enterocytes was found in a study 
by Barnard et al (1989), while another group found that mammary growth and 
morphogenesis was inhibited by the release of TGF-p from pellets (Silberstein & 
Daniel, 1987). Transgenic mice have also been utililised to study the effect of TGF-p 
on epithelial cells. Mice expressing active TGF-p under the control of the mouse 
mammary tumour virus exhibited hypoplasia of the mammary duct tree, whilst 
inhibition of cell proliferation was also observed in the skin of Kl-TGF-pi transgenic 
mice (Pierce Jr et al, 1993 ; Sellheyer et al, 1993). The increase in epidermal cell 
proliferation observed in the TGF-p 1-/- mice also supports the inhibitory role of TGF- 
pi (Glick et al, 1993). There are however, exceptions to the rule. An example is the 
increase in cell proliferation observed by BrDU incorporation when TGF-pi was 
overexpressed in the suprabasal keratinocytes in the skin of transgenic mice under the 
direction of the K10 promoter (Cui et al, 1995). This is in direct contrast with the 
results of Sellheyer et al (1993), as mentioned above, but may be as a result of the 
different promoters used, or the stability and level of TGF-p 1 expressed (Cui et al, 
1995).
Converse to the in vitro or in vivo data for adult epithelial cells, the expression of the 
TGF-ps in many embryonic epithelia is not obviously associated with growth 
inhibition (Millan et al, 1991; Pelton et al, 1991). TGF-pi is expressed in the 
epithelia of morphogenetically active structures, such as whisker follicles, salivary 
glands, and tooth buds, in conjunction with TGF-P2 and/or TGF-p3 (Lehnert & 
Akhurst, 1988; Millan et al, 1991). In contrast, TGF-pi is not expressed in the 
epithelia of developing sense organs, whereas TGF-p2 and TGF-P3 proteins are 
present (Millan et al, 1991; Pelton et al, 1991). It has been postulated that in 
development, TGF-p acts in an autocrine way to regulate the growth and 
differentiation of embryonic epithelia, and/or in a paracrine manner to induce 
interactions between the epithelium and underlying mesenchyme (Lehnert & Akhurst, 
1988; Pelton et al, 1989, 1991). Recent studies investigating the distribution of the 
TGF-p receptors found they were localised in the mesenchyme, and absent from the 
epithelium, supporting the paracrine model of Lehnert & Akhurst (1988) (Lawler et 
al, 1994).
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1.4.7 Haematopoiesis.
Haematopoiesis is the formation of blood. Studies using bone marrow cultures 
suggest that TGF-p is an inhibitor of haematopoiesis, but only has effect on certain 
immature cell populations (Ohta et al, 1987; Ottman & Pelus, 1988; Chenu et al, 
1988). For example, murine cells induced to proliferate by IL-3, and human cells 
induced by IL-3 plus granulocyte/macrophage-colony stimulating factor (GM-CSF) 
were inhibited by TGF-pl and TGF-P2, whereas murine cells induced by GM-CSF, 
or the human line stimulated by G-CSF were not (Chenu et al, 1988; Keller et al, 
1988,1989; Hampson et al, 1988). TGF-p also effects the differentiation of certain 
cells in the haematopoietic lineage (Chenu et al, 1988). For example, the maturation 
of erythroid progenitor cells was reversibly inhibited when mice were given daily 
injections of TGF-lpi (Miller et al, 1992). However, these postulated activities of 
TGF-pi in haematopoiesis could be completely artefactual due to the experimental 
conditions.
In embryogenesis, haematopoiesis begins in the yolk sac (primitive haematopoiesis), 
with the stem cell population initially observed at 7 days post-coitum (dpc) in the 
mouse (Moore & Metcalf, 1970). In situ hybridisation detects TGF-p 1 at 7 dpc within 
the blood islands of the yolk sac (Akhurst et al, 1990). These blood islands contain 
the mesodermal haemangioblasts of the yolk sac which give rise to both endothelial 
and haematopoietic cell lineages, and progeny in each lineage express TGF-pi RNA 
and protein (Sabin, 1920; Wilt, 1965; Miura & Wilt, 1969; Akhurst et al, 1990). Later 
in development, TGF-pi RNA is also detected in the foetal blood cells of the liver 
(definitive haematopoiesis) (Heine etal, 1987; Akhurst etal, 1990).
These results suggest a role for TGF-p 1 in haematopoiesis, but whether it has an 
effect in both primitive and definitive haematopoiesis is unclear, as there are genes 
which are required for only one or other haematopoietic event, for example, c-myb. 
Transgenic mice completely deficient for c-myb exhibit normal primitive 
haematopoiesis in the yolk sac, but by day 15 the embryos are severely anaemic 
(Mucenski et al, 1991). The adult-type haematopoiesis, but not the primitive 
haematopoiesis, is severely affected. This is also observed in dominant white spotting 
and steel mutants, and when either erythropoietin (EPO) or the erythropoietin receptor 
(EPO-R) is knocked out (Bennett et al, 1956; Wu et al, 1995). The EPO and EPO-R 
heterozygote embryos were normal and viable, and although the homozygote nulls 
exhibited a reduced primitive erythropoiesis, it was the complete block to defintive 
erythropoiesis which resulted in lethality at approximately day 13. In contrast, when 
the GATA-2 gene is disrupted, primitive haematopoiesis is affected, leading to
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embryonic death at day 10-11 (Tsai et al, 1994). Many of these mutants appear to 
have abnormal haematopoiesis as a result of defective proliferation of the cells, and 
because the different cell types arise at different stages of development, only 
primitive or definitive haematopoiesis is affected.
1.4.8 Endothelium.
In vitro studies have suggested that TGF-p is inhibitory to endothelial cells. Most 
analyses have examined the effect of TGF-p on vascular endothelial cells, and 
although TGF-pi is almost 100 times more potent than TGF-p2, both isoforms inhibit 
the proliferation, and migration of bovine vascular endothelial cell monolayers in 
culture (Heimark et al, 1986; Baird & Durkin, 1986; Frater-Schroder et al, 1986; 
Jennings et al, 1988). TGF-pl was also found to effectively inhibit phorbol ester- 
induced invasion of foetal bovine heart endothelial cells into collagen (Muller et al, 
1987). However, if the endothelial cells were seeded in the collagen gel before 
treatment with TGF-pi, they were not growth inhibited, but formed tube-like 
structures as ifmimickingangiogenesis (Madri et al, 1988). Therefore, as vascular 
endothelial cells in vivo, like the cells in the collagen gel, are surrounded on all sides, 
TGF-p may actually have a role in the formation of vessels. Gene expression is also 
modulated by TGF-P 1, with increasing expression of ECM proteins, growth factors, 
and protease inhibitors in capillary endothelial cells (Starksen et al, 1987; Daniel et 
al, 1987; Saksela etal, 1987; Madri etal, 1988).
As mentioned previously, during embryogenesis the endothelial cells of the yolk sac, 
which arise from the mesodermal haemangioblasts, express TGF-p 1 RNA and protein 
(Sabin, 1920; Wilt, 1965; Miura & Wilt, 1969; Akhurst etal, 1990). TGF-pi mRNA 
is expressed in the endothelial cells from the pro-angioblast stage through to the stage 
when the activated endothelial cells are forming tubes. This data, and the evidence 
provided in this thesis, support the idea that TGF-p 1 has autocrine activity in 
vasculogenesis and angiogenesis.
1.4.9 TGF-pi Knockout Mice.
In an attempt to determine the actual role of TGF-p 1 in vivo, TGF-p 1 knockout mice 
were generated by homologous recombination. In two independent studies, exon 6 
(Shull et al, 1992) and exon 1 (Kulkarni et al, 1993) of the TGF-pi gene were 
mutated in vitro by the insertion of a neo-cassette (Fig 3), thereby disrupting 
expression of the wild type protein. Chimeric mice were generated with the transgene 
inserted into the germ line enabling TGF-pl knockout lines to be propagated. Both
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groups found that on analysis of the transgenic offspring, mice lacking any functional 
TGF-pi protein were bom and appeared overtly normal. They were indistinguishable 
from their wild-type (TGF-p 1+/+) or heterozygote (TGF-pi+/_) littermates. This was 
very unexpected after the TGF-p 1 expression pattern analyses, and the results of in 
vitro and in vivo studies, as mentioned in the sections above. However, at 
approximately three weeks of age, all of the TGF-p 1_/- mice exhibited severe wasting 
and died.
Anatomical analysis of the TGF-p l' /_ mice revealed that there were no gross 
phenotypic abnormalities, although the TGF-p l _/_ mice with exon 6 mutated did have 
smaller spleens and a reduced number of Peyer’s patches in comparison with their 
normal littermates (Shull et al, 1992). However, on histological analysis, it was 
revealed that the wasting syndrome was accompanied by massive infiltration of 
inflammatory cell types, such as macrophages and lymphocytes, into multiple organs, 
and tissue necrosis, leading to organ failure, and death. The main organs affected 
were the heart, lungs, stomach, liver, salivary gland, pancreas, and striated muscle. 
Therefore, a role for TGF-p 1 in the immune system was the only action supported by 
the depletion of TGF-p 1 in the transgenic knockout mice. The immune phenotypes 
observed were similar to those found in autoimmune or graft versus host diseases, 
suggesting that TGF-p was involved in homeostasis of the cells in the immune 
system.
To investigate whether death of the TGF-pi-yL mice was as a result of an autoimmune 
response, the expression of major histocompatibility genes (MHC) was examined 
(Geiser et al, 1993). MHC Type II are normally expressed on a limited number of cell 
types which present antigen, enabling these cells to be identified by CD4+ T cells, 
which remove the “suicide” cell plus antigen by phagocytosis. However, in 
autoimmune diseases, MHC Type II are expressed on cells which normally do not 
express these molecules, and are not presenting any antigens. The CD4+ T cells will 
remove any cell expressing these MHC molecules. Therefore, the body is essentially 
fighting against, and removing healthy, normal cells. On analysis of the infiltrated 
TGF-pi'/_ tissues, it was found that there was an increase in MHC Type II expression 
in these tissues in comparison to TGF-pi+/+ or TGF-p l +/_ littermates. This was 
observed prior to the inflammatory response, suggesting a correlation between the 
increase in MHC Type II expression and activation of the immune system. It appears 
therefore, that TGF-pi may also regulate the normal expression pattern of MHC Type 
II in the immune system.
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The effect of depletion of TGF-p 1 in embryogenesis was not examined in any of the 
above studies, but was the subject matter of this project (section 1.8.2).
Although the phenotypes in the TGF-pi_/_ mice were not as predicted from 
developmental studies, the results do not mean that the postulated roles for the 
protein, gained from in vitro and in vivo studies, are incorrect. There are numerous 
other proteins in vivo, such as the other members of the TGF-p superfamily, which 
may interfere, and rescue some of the effects of depletion of TGF-pi. However, by 
utilising additional investigative methods, the role of other proteins in the TGF-pi 
knockouts could be examined. Some of these methods are discussed in the following 
section.
1.5 Methodological Approaches to Dissection of Gene 
Function During Embryogenesis.
A number of approaches may be taken to examine gene function in embryogenesis. 
There are several technological approaches to the manipulation of gene expression 
which will be reviewed below. Complementing these technological approaches, post­
implantation embryo culture systems have been developed. In vitro culture enables 
the phenotype of an embryo to be examined over time as the embryo develops outside 
the uterus. Together these two approaches provide powerful tools with which to 
examine genetic manipulation and its consequences in embryogenesis.
1.5.1 Gene Knockout Methodologies.
One way to assess the function of a protein in vivo is to prevent its expression, 
essentially knocking out its function, and then examine the phenotypic result. There 
are several methods available to selectively knockout protein expression; antisense 
oligodeoxynucleotides, dominant-negative mutations, or gene knockout by 
homologous recombination.
1.5.1.1 Antisense Oligonucleotides (ODN’s).
Antisense ODNs have been used to inhibit gene expression in a wide range of studies, 
mainly in vitro (Zamecnik & Stephenson, 1978; Miller et al, 1985; Matsukura et al, 
1987; Burch & Mahan, 1991). Short sequences of single-stranded DNA (16-27 
nucleotides), complementary to the mRNA of choice, are applied intracellularly (by 
microinjection) or extracellularly (in the medium) to the cells (Hdlbne & Toulme,
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1990; Crooke, 1992). Theoretically, the ODNs enter the cell and bind with the mRNA 
forming a DNA-RNA duplex. Translation of the RNA is then prevented if the DNA- 
RNA duplex has formed over the ATG region thereby obstructing the translational 
apparatus by steric hindrance, and/or the duplex is degraded by RNAse H (Eder et al, 
1993).
As well as being specific for a mRNA sequence, functional antisense ODNs must be 
stable to nucleases in order to reach the target. They must also be soluble, but still 
able to pass through the cell membrane (Stein & Cohen, 1988, for review). Normal 
ODNs were found to be extremely sensitive to nucleases, and so modified ODNs such 
as methylphosphonates, and phosphorothioates were devised which have been shown 
to have a prolonged half-life within the cell (Miller et al, 1985; Matsukura et al, 
1987).
Antisense ODNs have been used to investigate the function of proteins in early 
development, the role of growth factors, and ECM molecules, and as potential 
therapeutic agents to fight disease (Matsukura et al, 1987; Agrawal et al, 1989, 1991; 
Woolf et al, 1990; Burch & Mahan, 1991; Potts et al, 1991; Heasman et al, 1992; 
Lallier & Bronner-Fraser, 1993). However, there are several problems with the use of 
antisense ODNs (Albert & Morris, 1994). Sufficient penetrance of the ODN is 
obtained if it is applied to cells in culture, or to surface structures, but for internal 
structures the number of cells affected by the ODN will be limited. Injection of the 
ODN into the internal tissue or organ will overcome this problem to a degree, but 
may result in leakage, or damage to the tissue, and is therefore not particularly 
efficient. If the application of the ODN is successful, the effects are usually transient, 
only observed within 24-48 hours. To overcome either of these problems a high 
concentration of ODN may be applied, and over a longer period of time, but this can 
be toxic. However, if too little is used, then there is no effect.
DNA-RNA hybridisation may also be problematic due to unpredicted mRNA 
secondary structures. To overcome this, an excess of ODN is applied (several hundred 
fold), which, in turn may be toxic, or promote cross hybridisation to related 
sequences. However, by directing the ODN at nonconserved, nonrepetitive regions of 
the mRNA, for example, 5 ’ or 3 ’ untranslated regions, the specificity is increased.
Quantitative analysis of the target protein by binding or immunoblot assays needs to 
be performed to assess the success of the knockout, while the specificity of the ODN 
can be measured by investigating the levels of related, or associated proteins. While 
analysing target protein levels, the turnover rate also needs to be taken into
25
consideration as although there may be a 100% block to new protein formation, 
protein formed before the application of the ODN may still remain. This “old” protein 
would also affect acute, transient antisense experiments, such as ODN injection.
Therefore, although the ease of application of antisense ODN’s is appealling, all of 
these problems need to be taken into consideration before choosing this method. They 
also need to be noted when analysing the results from antisense ODN experiments.
1.5.1.2 Dominant Negative Mutations.
Dominant negative gene mutations result in a non-functional protein product which 
then competes with, and inhibits the function of the wild type protein (Herskowitz, 
1987). Naturally occuring dominant negative mutations include the thyroid hormone 
receptor a2 (TRa2), an endogenous mutant of TR al, and the v-erbA oncogene, a 
mutant of c-erbA (Katz & Lazar, 1993; Zenke et al, 1990). However, it is now 
thought possible to create dominant negative mutations in any gene, especially those 
whose product requires dimerisation, and thereby attempt to reveal the nature of the 
wild-type protein. The cDNA is mutated in vitro, transfected into cells, and then 
expressed in excess so that the translated mutant protein suppresses the action of the 
wild type protein.
One example of a synthesised dominant negative mutation is the retinoic acid 
receptor type-alpha (RARa). Although RARa is expressed in almost all 
haematopoietic cell lineages, its function is unknown (Gallagher et al, 1989). When a 
non-functional dominant negative mutation of RARa was transfected into the 
multipotent interleukin-3-dependent FDCP mix A4 murine haematopoietic cell line, 
basophils and mast cells developed, instead of neutrophils and monocytes (Tsai et al,
1992). This suggested that RARa promotes the differentiation of neutrophils and 
monocytes, but suppresses basophil and mast cell development.
Proteins which interact with others to exert an effect are very accessible to 
investigation by dominant negative mutation analysis (Herskowitz, 1987). When a 
dominant negative mutation was created in the A subunit of platelet derived growth 
factor, the activity of the protein dimer was inhibited (Mercola et al, 1990). Fibroblast 
growth factor receptor, and transforming growth factor type-beta receptor type II have 
also been examined by this method (Amaya et al, 1991; Brand et al, 1993). The 
potential for dominant negative mutational analysis is widespread, from in vitro 
studies on cells, tissues or organs, to the generation of transgenic mice to investigate 
the role of a protein in vivo (Pratt etal, 1990; Amaya etal, 1991; Brand etal, 1993).
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As for most methods, there are advantages and disadvantages in the use of dominant- 
negative mutations. One of the major advantages is that the mutated cDNA can be 
used to create transgenic mice. The construct can also contain a sequence that directs 
the expression of the gene in a specific tissue type only. For example, a mouse 
mammary tumour virus would only be switched on in the mammary gland, and 
therefore drive the expression of the mutated cDNA at that site.
Nevertheless, whether the mutation is transfected into cells in culture, embryos in 
culture, or expressed in transgenic mice, there are several drawbacks. The 
effectiveness of the mutant protein may be questionable. It is possible that the mutant 
protein will not be able to compete with the wild-type protein, with the result that the 
wild-type protein will continue to perform its function. However, even if the mutant 
protein is functional, another difficulty is whether its expression level is high enough 
for dominance. Associated with this is the fact that there is always a degree of 
“leakage” with dominant-negative mutations, because the wild-type protein is not 
removed. Therefore, any result gained from a dominant negative mutation may not 
reveal the full and entire nature of the wild-type protein.
1.5.1.3 Generation of Knockout Mice by Homologous Recombination.
Transgenic animal production is defined by the physical integration of a segment of 
exogenous DNA into the genome of the germ line for transmission to the next 
generation (Sigmund, 1993). The DNA may be an entire cloned gene, a cDNA, or a 
region of a gene that has been mutated in vitro. There are a number of methods which 
can be used to deliver the DNA; microinjection into the fertilised egg, gene transfer 
into embryonic stem (ES) cells, or using retroviruses. Microinjection is the method 
normally used to “add” an exogenous gene in order to increase the expression of the 
protein, whereas ES cell methods are generally used to delete or “knockout” an 
endogenous gene. All of these methods have advantages and disadvantages, but since 
this project involved the use of transgenic mice generated by the ES cell method, only 
this system will be described in detail.
ES cells are derived from the inner cell mass of a blastocyst, can reintegrate into the 
inner cell mass of another blastocyst, and are totipotent. Under certain culture 
conditions ES cells do not differentiate thereby retaining the ability to become any 
cell in the entire embryo, and while in culture, modified DNA can be transfected or 
infected into the cells. One of the advantages of this system is that the DNA can be 
targeted to a specific site and disrupt a specific gene in the host genome by 
homologous recombination. Although there is a high incidence of random integration,
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homologous recombinants can be identified by double selection with drug resistance 
genes, such as neomycin and gancyclovir (see below). The genetically modified ES 
cell is then injected into the inner cell mass of a blastocyst before implantation into a 
host mother, resulting in chimeric offspring. If the chimeras contain the mutation in 
their germ cells, the mutation can be transmitted to the next generation, and the 
phenotype of heterozygote or homozygote offspring should provide evidence for the 
function of the protein in vivo (Sigmund, 1993).
The ES cell method is now widely used to create transgenic mice. There are 
knockouts for growth factors, receptors, cell-cell adhesion molecules, cell-ECM 
adhesion molecules, and ECM proteins, among others. However, the results obtained 
with transgenic knockouts are not always as expected. Whereas the phenotypes of the 
IGF-II, a5-integrin, and fibronectin knockouts did agree with the postulated role of 
the protein (DeChiara et al, 1990; Yang et al, 1993; George et al, 1993), the 
phenotypes obtained for tenascin, c-src, the activins, and TGF-p 1 knockouts did not 
(Soriano et al, 1991; Saga et al, 1992; Shull et al, 1992; Kulkami et al, 1993; Vassalli 
et al, 1994; Matzuk et al, 1995a). These latter proteins were thought to be critical for 
embryonic development, but resulted in the birth of phenotypically normal mice of all 
genotypes. It is possible that these proteins are no longer required due to evolutionary 
change, or there may be functional redundancy with like proteins in the knockout 
embryos (Erickson, 1993). However, this surprising result shows that the results 
obtained from in vitro and expression studies should not be taken as indicative of 
function.
The greatest advantage of using ES cells and homologous recombination to create a 
transgenic mouse, is the ability to specifically mutate the gene of choice. However, as 
mentioned above, homologous recombination does not always occur, with random 
integration a more common event. It is now possible though, to identify homologous 
recombinants (Sigmund, 1993). Firstly, a neo cassette is included in the targeted 
cDNA, providing neomycin resistance to any cell with transgene integration and 
expression. To differentiate between random and homologous recombination events, 
the herpes simplex virus thymidine kinase (HSV-TK) gene is placed at one or both 
ends of the targeted cDNA construct. When the HSV-TK is expressed, the cell is 
rendered sensitive to the drug, gancyclovir. However, the HSV-TK is removed if the 
cDNA integrates to its homologous site. Therefore, only homologous integrations will 
survive exposure to gancyclovir. The inclusion of both the neo cassette and HSV-TK 
in the cDNA enables a greater percentage of the rare homologous recombinants to be 
identified.
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One other benefit of creating transgenic animals is that the observed phenotype is 
likely to be a result of the transgene, rather than artefactual conditions as can occur in 
vitro. However, as mentioned previously, there are many other proteins in vivo, one or 
more of which may mask the phenotype resulting from depletion of the protein of 
interest. But by creating transgenic lines for each of the related proteins, and then 
mating them, double or multiple knockout mice can be made. Without any of the 
proteins which perform the same role, the knockout phenotype would almost certainly 
be observed.
The major disadvantage of transgenic knockout technology is that if a gene has been 
silenced by the insertion of a transgene, the endogenous protein is removed from that 
animal forever. However, attempts have been made to design methods which would 
enable the expression of a transgene to be controlled, using both the ere and FLP 
recombinases (Fig.4) (Kilby etal, 1993, for review).
ere is the recombinase of the bacteriophage PI, and recognises a site called loxP. FLP 
is from a yeast plasmid, and recognises FRT sites. Conventional homologous 
recombination techniques are used to insert a transgene containing lox or FRT sites 
into ES cells, which are then used to create transgenic mice. Another transgenic line is 
generated which expresses ere or FLP. Once the ere and lox, or FLP and FRT lines 
are mated, activation of the recombinase results in excision of the segment of cDNA 
between the recombinase recognition sites (Fig.4). This method can be used to switch 
genes on or off. If the sites are at either end of the cDNA, excision by ere or FLT 
would switch off the transgene as the whole construct is removed (Fig.4). However, 
the FRT or lox sequences can be within the transgene, with the result that excision 
only removes a section of the construct. This arrangement enables transgenes to be 
switched on (Fig.4). For example, ere mice were mated with a line carrying a lens- 
specific aA-crystallin promoter followed by a stop codon, then a dormant SV40 T 
antigen coding sequence (Lakso et al, 1992). The stop codon was flanked by lox sites, 
and after excision of the stop region by ere, the dormant T-antigen was activated, 
resulting in the formation of lens tumours in the doubly transgenic animals. So far, 
the recombinases appear to have great potential in transgenesis, but they need to be 
investigated further, and the methods refined.
Once the transgenic lines are generated, it is also possible to examine the transgenic 
embryos, and determine whether there are any developmental abnormalities. By using 
in vitro culture of the post-implantation embryos, the onset of these defects can be 
observed outside the uterus.
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Figure 4 - The use of Cre-LoxP as a Control Switch in Transgenic Mice.
Cre is a recom binase found in the bacteriophage P I , and recognises the site LoxP. By m ating 
mice transgenic for cre w ith a line containing the LoxP sequences, this system  can be used to 
control the expression of a transgene in a transgenic mouse. T he LoxP sequences are 
contained within the transgene. A) show s how cre can be used to  switch off the expression of 
a transgene when the LoxP sites at either end o f the cD N A . The whole transgene is rem oved. 
In B), the coding sequence is expressed after the rem oval o f the stop codon by cre.
A, X, a n d T  are random  sites in the genome.
The FLT-FRT system can be used in place o f crc-LoxP. FRT is the recom binase, and 
recognises the site FRT.
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1.5.2 Post-Implantation Embryo Culture.
In the past, the major problem with studying embryonic development was that most 
vertebrate embryos were hidden away, either inside the uterus or a shell. Therefore, 
there was a great need to develop in vitro embryo culture systems to examine and 
follow developmental processes as they occurred. The first successful in vitro 
methods were devised in the sixties in response to the requirement to study the effects 
of drugs, such as thalidomide, on the embryo and foetus (New, 1978, for review). 
Since that time, embryo culture has been used to study a wide range of events 
including teratogenesis, specific developmental processes, such as NT closure or 
mesoderm formation, and the role of certain proteins in development, either by 
adding to the culture, or via knockout methodology (Tam & Beddington, 1987; 
Pratten et al , 1988; Gressens et al, 1993; Augustine et al, 1993; Guest et al, 1993; 
Smoak, 1993; Abbott etal, 1994).
8.5 to 12.5 dpc mouse embryos are most amenable to in vitro culture, enabling the 
period of major organogenesis to be studied. The culture medium initially used was 
100% rat serum, which is still used today (Steele & New, 1974; New et al, 1976; 
Pratten et al, 1988; Walsh et al, 1993). However, to support normal development the 
serum must be immediately centrifuged, and heat-inactivated (Steele & New, 1974; 
New et al, 1976). Immediately centrifuged serum diluted with a chemically defined 
medium, or with saline can also be used, but as yet a fully defined medium able to 
support in vitro development is not available (Tam & Beddington, 1987; Savatier et 
al, 1990; Shepard et al, 1993; Guest et al, 1993; Smoak, 1993; Augustine et al, 1993; 
Akazawa etal, 1994).
Steps have been taken to determine the crucial components of rat serum, which are 
absent from chemically defined media. By adding various energy sources, vitamins, 
and amino acids to extensively dialysed serum, it was found that glucose, and 
numerous vitamins, including pantothenic acid, riboflavin, i-inositol, and folic acid 
are essential for normal development (Tanimura & Shepard, 1970; Cockroft, 1979; 
Sanyal, 1980; Akazawa et al, 1994). Analysis of serum during the culture period 
shows that glucose and proteins, such as a2-macroglobulin and transferrin are 
depleted, indicating that the embryo is utilising these factors (Sanyal, 1980; Priscott et 
al, 1983). Interestingly, amino acids do not appear to be required in the medium 
(Cockroft, 1979). The embryo may obtain amino acids from serum protein breakdown 
in the yolk sac (Freeman etal, 1981).
There are several other requirements for successful in vitro embryo culture. The most 
suitable oxygen (O2) tension varies with the developmental stage of the embryo, and
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should be regulated as excessive O2  can be detrimental to the culturing of embryos 
(Morriss & New, 1979). 5% O2  is required for normal neural tube closure in early 
somite stage embryos, and should be increased to 20% for 10-15 somite embryos, 
40% for 20-30 somite embryos, and 95% for 30 somites and above (New et al, 1976; 
Cockroft, 1991). The temperature is also important and should be a constant 37- 
37.5°C as heat shock results in embryonic cell death and severe developmental 
defects (Walsh etal, 1993). Normal in vitro development can last for up to 72 hours if 
the medium is gassed every 12-16 hours, and changed after 24 hours, and the gas 
mixture is of the correct combination for the embryonic age.
Using the post-implantation embryo culture system in conjunction with the gene 
knockout technologies enables any effect to be observed directly. Although embryos 
removed from transgenic mice will already be genetically affected in the uterus, for 
antisense ODNs, and dominant negative mutations, the culture system can be used as 
an application system. By adding the ODN or cDNA to the culture medium, and 
culturing the embryos for 24-72 hours, at least a percentage of the cells would be 
affected. However, the embryos could also be injected before culture to allow any 
internal structures to be exposed to the cDNA or antisense ODN. By either method, 
any transient, or acute effect would be observed as it occurred. Culture of transgenic 
embryos made by homologous recombination enables the progression of a 
developmental defect to be followed. Removing the embryo from the uterus also 
allows its environment to be controlled by the investigator. In the uterus, the embryo 
receives many proteins, including nutrients, hormones, and growth factors from the 
mother, any of which may affect the knockout phenotype. In this project, the culture 
system was adapted to study the developmental defects in embryos from transgenic 
TGF-pi knockout mice, as described in the next section.
1.6 Project Aims.
1.6.1 Development of a Culture System Lacking Transforming 
Growth Factors Type-beta.
A major aim of the project was to investigate the role of TGF-pi in development by 
interfering with the function of this ligand/receptor system in culture utilising 
molecular biological techniques. At the start of the project, there was no molecular 
information on TGF-p receptors, thus the ligands, TGF-pl, 2, or 3, had to be the 
target for the disruption of TGF-p function.
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The first high level gene expression of TGF-p 1 and TGF-P2 is reported to be 7-8 days 
post-coitum (Lehnert & Akhurst, 1988; Millan et al, 1991). It therefore seemed 
pertinent to examine embryos over this period of embryogenesis if addressing the 
function of these genes in development. Culture of mouse and rat embryos over the 
period equivalent to 7-9.5 dpc in the mouse has been widely documented. However, 
in all previous studies, rat serum, which contains large quantities of TGF-p 1, has been 
a major component of the culture medium (50-100%) (Steele & New, 1974; New et 
al, 1976; Tam & Beddington, 1987; Pratten et al, 1988; Savatier et al, 1990; Walsh et 
al, 1993; Shepard etal,  1993). Soluble ligand might act to “rescue” TGF-p-deficient 
embryos (Letterio et al, 1994). Consequently, to analyse the effects of TGF-p 
deficiency on embryos in culture, whether using an antisense or transgenic approach, 
a culture medium containing no exogenous TGF-p was required. A major part of the 
project was therefore devoted to establishing a culture system either depleted of 
serum or depleted of the TGF-p therein.
1.6.2 Analysis of TGF-pi Deficient Embryos.
The first approach taken to deplete TGF-p in the embryo was the use of antisense 
oligodeoxynucleotides to selectively disrupt the translation of TGF-p mRNA. It soon 
became apparent that the disadvantages of this system outweighed the effort required 
to gain meaningful results. Moreover, during the course of the project, TGF-pi 
knockout mice, generated by homologous recombination, became available via a 
collaboration with Dr A Kulkami and Dr S Karlsson at the NIH, USA (Kulkami et al,
1993).
To generate the TGF-p 1 knockout mice that were used in this study, exon 1 of the 
TGF-pl gene was mutated in vitro by the insertion of a neo-cassette, thereby 
disrupting expression of the wild type protein (Fig 3) (Kulkami etal, 1993). Although 
there were TGF-pi_/_ offspring, genotypic analysis showed that only 50% of the TGF- 
pl"/", and 75% of the TGF-p 1+/' embryos were surviving gestation, and all of the 
others were dying in utero or early post-natally. This project was undertaken to 
determine the cause of death of the 50% TGF-p'/" and 25% TGF-p+Z" embryos, and 
to examine why a percentage managed to survive. Letterio et al (1994) postulated that 
the surviving embryos were rescued by maternal TGF-p crossing the placenta. 
Therefore, to investigate this hypothesis, embryos from TGF-P+/" matings were 
removed from the uterus and cultured in a medium lacking TGF-p. An increase in the 
incidence of abnormal phenotypes would suggest that the embryos were indeed 
rescued by maternal TGF-p. Preliminary experiments were also performed to 
determine whether the lack of TGF-P affected the expression of other genes.
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Chapter 2 
MATERIALS AND METHODS
2.1 Medium Preparation.
2.1.1 Preparation of Rat Serum for Use in Post-Implantation 
Embryo Culture.
The method used to prepare rat serum was that described by Cockroft (1991). Male 
albino rats, average weight 550g, (Harlan Olac) were anaethetised in ajar containing 
ether. A ventral incision was made through the body cavity, the internal organs 
moved to one side, and the dorsal aorta exposed. A 21 gauge syringe needle was 
inserted, bevel side down, into the aorta, and the blood gently drawn into the syringe 
until the animal was completely bled. Blood was transferred into a centrifuge tube 
(Nunc), and spun immediately in a bench-top MSE centrifuge, at 2300 rpm for 20 
minutes at room temperature. After centrifugation the blood was left on ice for up to 
16 hours before the next step. The fibrin clot was squeezed using small “paddle­
shaped” forceps to release any trapped serum, and removed before further 
centrifugation at 2300 rpm for 10 minutes. A sterile, plugged Pasteur pipette was used 
to pool the serum from several bleeds, which was centrifuged once more at 2300 rpm 
for 10 minutes to pellet any red blood cells remaining. The serum was aliquoted into 
5-10ml amounts, and then heat-inactivated at 56°C for 40 minutes during which time 
it was gassed twice with 5% O2 , 5%\ CO2 , and 90% N 2  (BOC) to get rid of any ether. 
It was then placed at -70°C until required. Before using, the serum was passed 
through a 0.22 pM Millipore filter unit to remove any particles formed while thawing.
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COMPONENT CONCENTRATION
M-g/ml
COMPONENT CONCENTRATION
[xg/ml
NaCl 6,400 L-Valine 94
K d 400 L-Serine 42
C ad 2 (anhydr.) 200 Nicotinamide 4
FeN0 3 .9H2 0 0.10 Thiamine hydrochloride 4
MgS0 4  (anhydr.) 97.67 D-Ca pantothenate 4
NaH2P 0 4 .H2O 125 Riboflavine 0.40
D-Glucose 4,500 Pyridoxal hydrochloride 4
L-Lysine hydrochloride 146 Folic acid 4
L-Histidine hydrochloride 42 Choline chloride 4
T .-Arginine hydrochloride 84 Inositol 7.20
L-Threonine 95 Phenol red 15
Glycine 30
L-Valine 94
L-Leudne 105
L-Isoleucine 105
L-Methionine 30
L-Phenylalanine 66
L-Tryptophan 16
L-Glutamine 584
L-Cysteine hydrochloride 62.75
Table 1 - Components for Dulbecco's Modified Eagles Medium (DMEM).
List of components of DMEM. There are many factors common to both DMEM and FMP (see 
opposite), although the quantities vary greatly in some instances, eg. L-Glutamine. FiMP 
contains more components than the DMEM, for example, bovine serum albumin, possibly 
accounting for the difference in survival of the 8.5 dpc embryos when cultured in DMEM : 
50% dCP, and FMP: 50% dCP (see section 3.2.3).
COMPONENT CONCENTRATION
[xg/ml
COMPONENT CONCENTRATION
Hg/ml
N ad 6,400 Ca lactate 5H2O 600
K d 425 Ascorbic acid 150
M gS027H 20 330 Bovine serum albumin 6,000
NaHC03 2,800 Nicotinamide 15
KH2FO3 113 Thiamine hydrochloride 3
Glucose 4,400 Ca pantothenate 0.15
L-Lysine hydrochloride 225 Riboflavine 0.15
L-Histidine hydrochloride 150 Pyridoxal hydrochloride 0.15
L-Arginine hydrochloride 70 Folic acid 0.15
L-Threonine 60 D-Biotin 0.15
L-Tyrosine 30 p-aminobenzoic add 1.5
L-Valine 50 DL-a-tocopherol 0.75
L-Leucine 40 Cholin chloride 38
L-Isoleucine 23 Inositol 0.15
L-Methionine 40 Cyano-cobalamine 0.03
L-Phenylalanine 40 Phenol red 16
L-Tryptophan 30
L-Glutamine 150
L-Cysteine hydrochloride 135
Table 1 - Components for Foetal Mouse Palate Medium (FMP).
FMP was initially used as a serum-free medium to culture foetal mouse palates 
(Shiota etal, 1990), and was therefore tried for culturing whole post-implantation 
embryos. Made on request from Gibco, BRL.
DMEM :|50% RAT SERUM FMP:/ 50% RAT SERUM
DMEM : 25% RAT SERUM FMP: 25% RAT SERUM
DMEM : 10% RAT SERUM FMP: 10% RAT SERUM
DMEM:,50% dCP FMP \ 50% dCP
DMEM: 25% dCP FMP: 25% dCP
DMEM: 10% dCP FMP: 10% dCP
Table 2 - Post-Implantation Embryo Culture Media.
The table shows the different combinations of DMEM, FMP, rat serum, and dCP 
which were used to culture 7.5 dpc and 8.5 dpc embryos for 24 hours.
2.1.2 Preparation of Rat Plasma.
The blood was extracted from the rats as described above. To prepare plasma instead 
of serum, the blood was transferred into a tube containing heparin-coated beads (10 
IU lithium heparin/ml blood) (Sterilin, Cat.No. 46.363.001) to prevent the blood from 
clotting. The blood was left on ice until several tubes were ready for centrifugation. It 
was then processed as for the rat serum above.
2.1.3 Preparation of dCP (doubly centrifuged plasma).
The required amount of plasma was allowed to thaw at room temperature before 
aliquoting into 1.5ml eppendorf tubes. This was performed under very basic sterile 
conditions. The samples were then microcentrifuged at 14000 rpm for 15 minutes at 
room temperature in an Eppendorf benchtop microcentrifuge. After centrifugation, 
the plasma was decanted into fresh eppendorf tubes, avoiding the diffuse pellet, and 
fatty layer on the top of the plasma. It was centrifuged again at 14000rpm for 15 
minutes. The plasma was then pooled, avoiding any debris which precipitated during 
centrifugation.
Unlike the serum, the plasma was not able to be filtered through a 0.22pM Millipore 
filter unit, probably as a result of the clotting factors which are still present in the 
fluid. Plasma was therefore not filtered.
2.1.4 Preparation of Culture Medium.
Rat serum or dCP was combined with either Foetal Mouse Palate Medium (FMP) or 
Dulbecco’s Modified Eagles Medium (DMEM), in varying concentrations on the day 
that it was required (Table 1,2). 1ml of medium was prepared in 20ml polypropylene 
universal tubes (Nunc, Cat.No. 3-64238A), and equilibrated in a 5% CO2 , 37°C 
incubator for between 2-4 hours, before being used to culture a single embryo. 
Medium that was not used was frozen at -20°C, until the next culture. If not used for 
the next culture, the medium was not frozen again, but discarded.
2.1.5 Addition of TGF-pi to the Culture Medium.
TGF-pi protein (British Biotechnologies) was frozen in aliquots of lpg/ml. 7.5pl of 
this stock was added to 1.5ml of FMP : dCP to give 5ng/ml. This solution was then 
diluted into the 1ml of culture medium to give lng, 800pg, 750pg, 500pg, 300pg,
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250pg, 200pg, 150pg, lOOpg, 50pg, 35pg, and 25pg/ml concentrations of TGF-pi in 
an attempt to discover how much TGF-p 1 could be tolerated by the culturing embryo.
2.2 Post-Implantation Embryo Culture.
2.2.1 Mouse Husbandry.
For each line, the male mice were mated with females to obtain embryos 7.5 to 9.5 
days post coitum (dpc). Mice were housed in a conventional room (light 5am-7pm), 
or on a reversed light/dark cycle (dark 6am-4pm). For conventional animals, noon on 
the day the copulation plug was found was taken as 0.5 dpc, whereas for reversed 
cycle animals, midnight on the day the plug was found was taken as 0.5 dpc.
Several lines of mice were used in this study; Parkes/NIH/J/Ola, NIH/J/Ola, 
129/sv/J/Ola, C57Bl/6J/01a, and TGF-p 1 knockouts (TNull). The TGF-p 1 knockouts 
were originally generated on a 129/Sv/Ev genetic background (Kulkami e ta l , 1993). 
These mice were then mated for 2 generations onto a C57B1/6J background, then 
crossed once with an inbred NIH/Olac (Harlan Olac Ltd., UK). TGF-p 1 knockout 
embryos used in this study were obtained from heterozygous x heterozygous matings 
(TGF-p 1+/- x TGF-pi+/-).
2.2.2 Collection of Embryos for Culture.
Pregnant females from timed matings were killed by cervical dislocation, and a 
vertical incision made through the body wall, enabling the uterus to be removed. 
Decidua were dissected from the uterus, placed 3-4 per dish in Embryo Transfer 
Freezing Medium (Gibco BRL) and visualised using an Olympus SZH stereo 
microscope. The embryos were removed from their decidua using sterile 
watchmakers forceps, being careful not to damage the yolk sac. If to be used for 
culture, any with an opened yolk sac were discarded. Reicherts membrane was 
removed, leaving the yolk sac and amnion intact. The embryos from the TNull line 
were washed in a fresh dish of Embryo Transfer Freezing Medium to remove any 
residual tissue which could have contained maternal TGF-p 1, before placing into the 
culture medium.
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2.2.3 Culture of Post-Implantation Embryos.
Embryos were cultured from 7.5 or 8.5 dpc for 24 hours in 1ml of medium which had 
been equilibrated in a 37°C, 5% CO2  incubator for 2-4 hours. One embryo was 
cultured in each 20ml polypropylene universal (Nunc, Cat.No. 3-64238A). The 
universals were then placed in a 37°C roller incubator (BTC Engineering, Milton, 
Cambridge) for 24 hours, rotating at 60 rpm, during which time a further 1 or 2 
gassings occured. To gas the medium, the tubes were placed in the 37°C, 5% CO2 
incubator with the lids unscrewed for 30-40 minutes, before returning to the roller 
incubator, with the lids tightly screwed back on, for the remainder of the culture 
period. After 24 hours the embryos were fixed in filtered 4% paraformaldehyde 
(PFA) in phosphate buffered saline (PBS), rotating overnight at 4°C, before further 
processing.
2.2.4 Assessment of Embryos.
Embryos were assessed when removed from the culture system using the 
Morphological Scoring System devised by Brown and Fabro (1981) (Table 3). A 
series of developing organs and features of the embryo were observed, and each given 
a rating depending on its development. These ratings were added together to give the 
embryo score. This score was then compared with that of control embryos of 
comparative age (embryos that were taken directly from the uterus and fixed) to 
determine if the cultured embryo had developed as its counterpart in utero.
2.2.5 Preparation of Embryos For Sectioning and Staining.
Embryos were fixed for 4-24 hours in 4% PFA in PBS at 4°C with rotation. This was 
followed by washing in PBS for 30 minutes, 0.85% saline for 30 minutes, two 15 
minute washes in 0.425% saline : 50% ethanol, and finally placed in 70% ethanol. 
Embryos could be stored in 70% ethanol at 48C for a number of weeks. A Shandon 
Citadel Automatic Processor was used to process the embryos further. The cycle 
included three washes in methylated spirits for IV2 , 2 x/2 , and hours; a wash in 
100% ethanol for 2 hours; three washes in xylene, all for ln an hour; and finally two 
washes in 60°C paraffin wax for 2, followed by 4 hours. The embryos were then 
embedded in paraffin wax and stored at 4°C until use.
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Table 3 - The Brown-Fabro Scoring System.
The table shows the scoring system devised by Brown and Fabro (1981). The embryonic 
characteristics listed are analysed in each embryo, and classified into one of the description 
categories. Each of these categories has a score, represented by the numbers at the top of 
the table Once all of the characteristics are examined, the numbers are added together, 
resulting in the embryos total score. This figure represents the developmental stage 
attained by the embryo, and can be used to compare and contrast the development of 
different embryos.
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2.2.6 Preparation of Slides.
Slides were dipped in a 2% 3-Aminopropyl-triethoxysilane (TESPA, Sigma) in 
acetone solution for 5-10 seconds before two washes in 100% acetone, followed by 
two washes in Milli-Q water. They were then baked dry at 42°C before storing in 
boxes at room temperature.
2.2.7 Sectioning of Embryos.
Embryos embedded in paraffin wax were serially-sectioned using a microtome. 5 
micron thick sections were cut and lifted onto a glass slide. A small amount of 30% 
ethanol was placed onto the slide and under the sections to smooth out any wrinkles. 
The sections were then floated onto Milli-R water at 42°C. TESPA-coated slides were 
placed under the floating sections and used to pick them out. The slides were then 
covered, without touching the sections, and left at 42°C until dry.
2.2.8 Pretreatment of Sections Before Staining.
Dewaxing and rehydration of the sections was performed before any staining 
procedure. Slides were placed in 20 microscope slide holders, and soaked in 
Histoclear™ for two 7 minute periods. This was followed by two 2 minute 
immersions in 100% ethanol, then a single immersion for 2 minutes in each of 90%, 
70%, and 50% ethanol dilutions. The sections were then ready for staining.
2.2.9 Dehydrating and Mounting of Sections.
Following staining, the slides were dehydrated through an ethanol series (30%, 50%, 
70%, 90%, 100%, and 100% for 2 minutes each), followed by two soaks in 
Histoclear™ the first 2 minutes, then 7 minutes. Coverslips were mounted onto the 
sections using 300pl of Gurr’s DePeX Neutral Mounting medium (BDH, Cat.No. 
361254D) per slide in a fume hood, and left to dry overnight.
2.2.10 Staining Sections for Haematoxylin and Eosin (H&E).
After the dewaxing and rehydrating process, the sections were dipped in filtered 
Harris’ haematoxylin (BDH, Cat.No. 35128) for 10-30 seconds, rinsed under cold 
running water for approximately 30-60 seconds, then placed in Scott’s tap water (20g 
MgSC>4 , 20g NaHCC>3 / litre of water) for 2 minutes. Following a further rinse in tap 
water, the slides were stained in eosin (5g eosin, 50mls saturated acetic picric acid,
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400mls water, 2.5g potassium dichromate, 50mls absolute alcohol, added in that order 
/ 500mls stock. Diluted 1 in 4.5 with water for working concentration) for 2-5 
minutes before dehydrating and mounting.
2.2.11 Injection of BromoDeoxyUridine into 9.5 dpc Embryos.
BromoDeoxyUridine (BrDU) is a substitute base for thymidine, and is incorporated 
into DNA during the cells DNA replication phase. By using immunohistochemistry, it 
is possible to identify cells which were in s-phase of the cell cycle while the BrDU 
was present. It was used in this study to show whether the endothelial cells of the yolk 
sac were proliferating faster in the homozygote null embryos than in the wild-types of 
the TGF-pi knockout mice, and also to demonstrate the difference in growth rates in 
embryos grown in different media.
To analyse the growth rates of embryos grown in different media, 23 hours after the 
beginning of culture, embryos were removed from the universal into Embryo Transfer 
Freezing medium (Gibco BRL). Using a pulled micropipette, lpl of lOmM BrDU 
(Boerhinger Mannheim) was injected into the yolk sac cavity. The embryo was then 
transferred back into the culture medium and the culture continued for a further hour 
in a 37°C roller incubator. The embryos were then fixed in 4% PFA in PBS at 4°C 
with rotation before further processing.
For the TGF-p 1 knockout analysis, 9.5 dpc embryos from timed TGF-p l +l~ x TGF- 
p l+/- matings were removed from the uterus and dissected in Embryo Transfer 
Freezing medium (Gibco, BRL), leaving the yolk sac and ectoplacental cone intact. 
After injection of lp l of lOmM BrDU into the yolk sac cavity, the embryo was 
cultured in FMP : 50% dCP for an hour at 37°C in a roller incubator. Following the 
culture period, the embryos were fixed in 4% PFA in PBS, scored for phenotype, and 
half of the embryo was removed for genotype analysis. The rest of the embryo and 
yolk sac was fixed overnight at 4°C, constantly rotating, before further processing.
2.2.12 Staining for BrDU in Embryo and Yolk Sac Sections.
Embedded embryos previously injected with BrDU were sectioned, dewaxed and 
rehydrated before staining for the substitute base, BrDU. The slides were manipulated 
in several ways during the staining process. They were held in microscope slide 
holders to be exposed to PBS, hydrogen peroxide, Proteinase K, PBS plus sheep 
serum and bovine serum albumin, which were all in 250ml glass troughs. When the 
slides were in the troughs a very small stirring rod was used to circulate the fluid. For
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the application of the primary blocker, the primary antibody, the secondary antibody, 
ABComplex, and 3,3’-Diaminobenzidine Tetrahydrochloride (DAB), the slides were 
removed from the holders and laid flat in humid trays so that the solution could be 
placed directly onto each section.
After rehydration the sections were washed for three 5 minute periods in PBS, 
followed by blocking of the endogenous peroxidase by incubating in 1.2% hydrogen 
peroxide (4mls 30% H2O2 , 96mls methanol) (Sigma) for 20 minutes. After a further 
three 5 minute washes in PBS, the slides were bathed in Proteinase K (20pg/ml in 
50mM Tris, pH8.0) (Sigma) for 15 minutes at room temperature, followed by another 
three 5 minute washes in PBS. Before adding the primary blocker [5ml PBS, 0.6ml 
1% gelatin (BDH), 60pl 10% bovine serum albumin (BSA) (Sigma), 180pl sheep 
serum (Serotec)], the slides were removed from the holder and placed in a humid 
chamber after drying round each section with a tissue. Care was taken not to let the 
sections dry out. 20-50 pi of the primary blocker was added to each embryo section, 
and left for 30 minutes at room temperature. 10pi of undiluted mouse IgG anti 
BromoDeoxyUridine antibody (Amersham) replaced the blocker on each section, and 
small pieces of coverslips laid on top. The slides were covered, and stored at 4°C 
overnight. The following day the slides were washed three times in PBS containing 
sheep serum and BSA (1ml sheep serum, 1ml BSA / litre of PBS), for 5 minutes each 
time. The coverslips slid off gently into the PBS. Each slide was then dried, carefully 
avoiding the sections, and placed in the humid tray. The pre-blocked, biotinylated 
secondary antibody, sheep anti-mouse antibody (Amersham), was applied, diluted 1: 
500 in the secondary blocker (4.3ml PBS, 0.5ml 1% gelatin, 50pl 10% BSA, 150pl 
sheep serum, 10pi antibody). 20-50pl of this solution was added to each section, and 
left for an hour at room temperature. The three 5 minute PBS washes were repeated 
once more, before the slides were dried, placed in the tray, and the sections exposed 
to the ABComplex (DAKO) for 30 minutes. [ABComplex was made up 30 minutes 
previously by adding one drop of solution A (avidin) and one of B (Biotinylated 
Horseradish Peroxidase) to 5mls of PBS]. A further two 5 minute washes in PBS 
were performed to remove the ABComplex. Back in the tray, 20-50pl of DAB (1 
lOmg tablet of 3,3’-Diaminobenzidine Tetrahydrochloride / 15mls PBS, filtered then 
added 12pl of H2O2) (Sigma) was added to each section for approximately 3-5 
minutes until the brown stain appeared. The slides were then quickly placed in water, 
and rinsed under the tap to prevent over-staining. Dehydration and mounting was then 
carried out.
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2.2.13 Production of Embryo Powder, and Its Use In Pre-Blocking 
Antibody.
14-14.5 dpc embryos were dissected from the uterus and decidua in cold PBS. The 
yolk sac remained attached to the embryo, but the ectoplacental cone was removed. 
Using sterile forceps, the tissue was chopped into as many small pieces as possible, 
before transferring into an ice-cold sterile homogeniser with as little PBS as possible. 
The tissues were homogenised on ice before adding 4 volumes of ice-cold acetone, 
and leaving on ice for 30 minutes. The homogenate was aliquoted into 1.5ml 
eppendorf tubes, and microcentrifuged at 14000 rpm for 10 minutes at room 
temperature in an Eppendorf benchtop microcentrifuge. The supernatant was 
removed, and the pellet washed in ice cold acetone, before spinning for several 
seconds at 14000 rpm to deposit the pellet at the bottom of the tube again. After 
removal of the acetone the pellet was tipped out and flattened as much as possible 
between two pieces of filter paper. This was then covered, and the embryo 
homogenate left to dry overnight at room temperature, before being ground to a fine 
powder. The embryo powder could be stored in an airtight container at 4°C 
indefinitely.
To block the sheep anti-mouse antibody used in the BrDU staining protocol (2.2.12), 
3mg of embryo powder was added to 0.538ml of PBS, and heated at 70°C for 30 
minutes before quenching on ice. To this, 5pl of sheep serum, and 1.25pl of the 
antibody was added, and the solution rotated at 4°C for at least an hour. The embryo 
powder was pelleted after microcentrifugation at 14000 rpm for 10 minutes, and the 
supernatant removed to a new eppendorf. 62pi of 1% gelatin, 6.25pl of 10% BSA, 
and 13.75 pi of sheep serum was added to the supernatant, and the antibody / 
secondary blocker solution was ready for use.
2.2.14 Extraction of Embryonic DNA.
The embryo and its yolk sac were removed from culture and digested overnight in 
lOOpl of lysis buffer (lOOmM Tris-HCl, pH8.5, 0.2% SDS, 5mM EDTA, 200mM 
NaCL) plus lOOpg/ml proteinase K at 55°C. An equal volume of phenol (Biophenol, 
Camlab) was added to the digested embryo, and vortexed for 10 seconds to ensure 
thorough mixing. Centrifugation at 14000 rpm for 2-5 minutes at room temperature in 
an! Eppendorf benchtop microcentrifuge separated out the organic and inorganic 
layers divided by the layer of protein. The top solution was removed without 
disturbing the protein layer, and placed into a new eppendorf. An equal volume of 
chloroform (Fisons) was added, and the solution vortexed for 10 seconds before
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centrifugation as above. The top layer was decanted into another eppendorf and 2 
volumes of ethanol plus l/10th volume of 3M sodium acetate were mixed in. To 
precipitate the DNA the samples were stored at -70°C for at least one hour, followed 
by centrifugation at 14000 rpm for 30 minutes at 4°C. The supernatant was removed 
and the pellet washed twice in 70% ethanol. After air drying, the DNA was dissolved 
in 40pl of TE buffer (lOmM Tris, pH8.0, ImM EDTA).
2.2.15 Measuring the Protein Content of Cultured Embryos.
The Lowry Method (Lowry et a l, 1951) was employed to measure embryonic protein 
content. For protein analysis, the cultured or control embryos and their yolk sacs were 
snap-frozen in liquid nitrogen after scoring. On thawing the tissues were dropped into 
lml of 0.5M sodium hydroxide, and digested for 2-3 hours while rotating at room 
temperature, with occasional pipetting to aid the digestion.
0, 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, and 500jpg/ml protein 
standards were also prepared from a lmg/ml stock of BSA in water. The correct 
volumes for the desired concentrations were added to 0.5ml of 1M sodium hydroxide 
and made up to lml with water. The standards were treated as for the embryonic 
tissues.
During the digestion the solutions required for the assay were prepared, lg of sodium 
tartrate and 0.5g of cupric sulphate were dissolved separately in 50ml of water. When 
both were completely dissolved the two solutions were mixed together. If a 
precipitate formed the solution was discarded. 6mls of the sodium tartrate / cupric 
sulphate solution was then added to 300mls of 2% sodium carbonate in water. 5mls of 
this solution was then added to each of the samples and the standards, followed by the 
addition of 0.5ml of Folin and Ciocalteu’s phenol reagent (BDH). The tubes were 
thoroughly shaken after each addition. 40 minutes was allowed for the colour to 
develop after which the absorbancy of each sample was measured twice using a 
Philips UV/VIS spectrophotometer at A680nm, and the amount of protein present 
was calculated.
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2.3 Cell Culture
2.3.1 Introduction.
CCL64 cells (mink lung epithelial cells, MvlLu) (European Collection of Animal 
Cell Cultures) were cultured in Special Liquid Medium (SLM) (Gibco BRL) 
supplemented with 10% foetal bovine serum (FBS), lOmM glutamine, and 1% 
penicillin/streptomycin (all Gibco BRL), and maintained at 37°C in 75cm tissue 
culture flasks (Nunc) in an atmosphere of 5% CO2 . CCL64 cells are inhibited by 
TGF-pl as long as they do not become confluent, therefore when the cells neared 
75% confluency, generally every 2-3 days, they were split. The medium was removed 
and the cell layer washed lx  in PBS (Gibco BRL), followed by lx  with verscene 
(0.2g KC1, 8g NaCl, 0.2g EDTA, 0.29g NaHCOs, 5ml Pen./Strep., 0.5g D-Glucose / 
500ml water). To detach the cells from the flask they were incubated at 37°C with 
2.5mls of lx  trypsin (Trypsin EDTA in Modified Puck’s saline A, Gibco BRL, 
Cat.No. 45300-027) for approximately 3-5 minutes, following which the trypsin was 
inactivated by adding 7.5mls of serum-containing medium. The cell suspension was 
seeded at 1 in 10, 1 in 5, or 1 in 2 dilutions with new media, and returned to the |C02 
incubator. When required, cell numbers were estimated using a haemocytometer.
2.3.2 Cryopreservation of Mammalian Cell Lines.
Cryopreservation of cells was performed at approximately 75% confluency, that is 5- 
10x10s cells per flask. Cells were harvested as described in 2.3.1. and the trypsin was 
inactivated by addition of media. The cell suspension was placed into a 20ml 
universal tube and centrifuged for 10 minutes at 1500 rpm in a benchtop MSE 
centrifuge. The supernatant was removed and the cell pellet resuspended in lml 10% 
Dimethyl Sulphoxide (DMSO, Sigma) in media. This suspension was deposited in a 
1.8ml cryostat tube (Nunc), wrapped in bubblepak and placed at -70°C for 2 days to 
allow slow freezing.The tubes were , transferred to liquid nitrogen for long term 
storage. When a stock was required, it was thawed at 37°C before plating out in 9mls 
of media in a 75cm2 flask. Following overnight incubation at 37°C with 5% CO2 , the 
medium was removed, the cells washed|2x with PBS, and fresh medium applied.
2.3.3 CCL64 Inhibition Assay.
The CCL64 assay (Danielpour et al, 1989) allows the measurement of active TGF-pi 
in a sample by measuring the amount of tritiated thymidine incorporation by the cells. 
Since CCL64 cells (MvlLu) are inhibited by TGF-pl, if there are high levels of TGF-
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p i, the cells do not proliferate, and therefore do not incorporate tritiated thymidine, 
whereas the reverse is true if there is no TGF-pl in the samples. In this study, the 
CCL64 assay was used to determine the amount of TGF-pi in rat serum and rat 
plasma.
75% confluent cell layers were washed and trypsinised before suspension in lOmls of 
SLM plus 10% FBS. Centrifugation at 1500 rpm for 10 minutes in a MSE bench-top 
centrifuge pelleted the cells, which were then resuspended in lOmls CCL64 assay 
medium (DMEM, 0.1% FBS, lOmM HEPES) to wash the cells and remove the high 
levels of FBS. (FBS contains TGF-ps and would therefore interfere with the assay.) 
The cells were centrifuged once more at 1500 rpm for 10 minutes before resuspension 
at 105 cells/ml in the assay medium. They were seeded at 0.5ml / 5X104 cells per well 
into 24 well plates, and incubated at 37°C in a 5% CO2  incubator for 1-2 hours. A 
titration curve was made using known quantities of TGF-pi (British Biotechnologies, 
Cat.No. 101-B1), from lOpg/ml-lng/ml. The experimental samples were assayed in 
several dilutions, 0.5-100%, with and without the addition of lpl of lOmg/ml TGF-p 
antibody (R&D Systems, Cat.No. AB-101-NA) to determine whether or not any 
inhibition observed was due to TGF-pi in the sample. All serum and plasma samples 
were heated at 94°C for 15 minutes, before the addition of the antibody, to activate 
any latent TGF-p 1 and to inactivate any heat-sensitive stimulatory factors present in 
serum and plasma. All samples were measured in triplicate. After adding the 200pl 
samples to each well, the plates were returned to the incubator for 22 hours. 1.5pCi of 
tritiated thymidine (Amersham) in 100pi of CCL64 assay medium was then added to 
each well, and incubated for a further 2 hours before the medium was aspirated. The 
cells were washed 2x with PBS, then fixed at room temperature with 0.5ml of 3:1 
methanol:acetic acid for an hour. The fixed cells were washed 2x in 80% methanol 
before trypsinisation with 0.5ml of trypsin/verscene (50:50) for an hour at room 
temperature. 0.5ml of 1% SDS was added to each well and left for 5 minutes before 
each sample was transferred to lOmls Ecoscint A (National Diagnostics) in a 
scintillation vial. The amount of tritiated thymidine incorporated was measured using 
a Texas Instruments scintillation counter.
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2.4 RNA Analysis
2.4.1 Extraction of RNA from 1/2 Embryos and Yolk Sacs.
All tips, eppendorfs, and solutions (except those containing Tris, or organic solvents) 
were treated with 0.01% DEPC before sterilisation to prevent the degradation of the 
RNA by RI^Ases. A scaled-down version of the method described by Chomczynski 
and Sacchi (1987) was used to extract the RNA from 8.5 or 9.5 dpc transgenic TGF- 
pl embryos and yolk sacs. 1/2 of the embryo was required for genotype analysis, and 
so only 1/2 was available for RNA extraction. The RNA was extracted separately 
from the yolk sac and the embryo. When dissected free of contaminating material, the 
tissues were placed in eppendorfs and snap-frozen in liquid nitrogen, then stored at 
-20°C until required. Before proceeding with RNA extraction they were thawed on 
ice. 550pi of solution D [4mM guanidinium thiocyanate (Fluka), 25mM sodium 
citrate, 0.5% sarkosyl, O.lmM p-mercaptoethanol (Sigma)] was added to each tube 
and the disaggregation of the tissue aided by pipetting. 25 pi 2M sodium acetate, 
200pl phenol, and 55pi chloroform were added separately with gentle mixing after 
each reagent. Once all three solutions were added, the tubes were vortexed for 10 
seconds before incubation on ice for 15 minutes. The samples were then 
microcentrifuged for 20 minutes at 14000 rpm at 4°C in aq Eppendorf benchtop 
microcentrifuge. The top aqueous layer was transferred to a fresh eppendorf and 
700pl of isopropanol added. The solution was mixed and placed at -20°C for at least 1 
hour to precipitate the RNA. The RNA was pelleted by microcentrifugation at 14000 
rpm for 20 minutes at 4°C, and the supernatant removed. The pellet was redissolved 
in 100pi of solution D, and an equal volume of isopropanol added before a further 
precipitation at -20°C for at least an hour. The tubes were centrifuged for 10 minutes 
at 14000 rpm at 4°C to pellet the RNA, which was then washed 2x in 70% ethanol, 
air-dried and resuspended in 5-10pl of DEPC-treated water. The RNA yield was not 
determined as there was such a small amount it was all required for experimentation.
2.4.2 RNA Gel Electrophoresis.
RNA of unknown concentration from a single 1/2 embryo or yolk sac, or from 3 1/2 
embryos or yolk sacs combined, was run in a 1.5% denaturing agarose gel containing 
16.6% formaldehyde and lx  MOPS (200mM MOPS Sodium salt, 50mM Sodium 
Acetate, lOmM EDTA, pH 7.0). 50% formamide, 2.2M formaldehyde, and lx  MOPS 
was added to 5pl of RNA to a total volume of 10pi, and incubated at 55-60°C for 10 
minutes before quenching on ice. l/6th volume of lOx loading buffer was added (50% 
glycerol, ImM EDTA, pH8.0, 0.25% bromophenol blue, 0.25% xylene cyanol), and
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the samples loaded into the wells. RNA, DNA, or ribosomal RNA ran alongside the 
samples and were used as size markers. Electrophoresis occurred at 50-100V for 4-8 
hours in circulating lx MOPS to prevent depletion of ions at the anode.
2.4.3 Northern Blotting.
After electrophoresis, as described above, the gel was washed for 20-30 minutes in 
Milli-Q water with 2-3 changes to get rid of the formaldehyde. The marker lanes were 
cut off and stained for 10 minutes in 1.5pg/ml ethidium bromide before destaining in 
Milli-Q water for 2-16 hours The markers were then viewed on a UV transilluminator 
and photographed alongside a scale for reference. The rest of the gel was placed on a 
piece of lOx SSC (20x SSC ; 3M sodium chloride, 0.3M sodium citrate) soaked 3MM 
Whatman paper, which was acting as a wick to a reservoir of lOx SSC. Hybond N 
paper was cut to the size of the gel and placed on top, and any trapped air bubbles 
smoothed out. Two pieces of dry 3MM Whatman paper were placed on top of the 
Hybond N, and the area surrounding the gel was sealed with clingfilm. This was to 
prevent the evaporation of the lOx SSC reservoir, and to ensure its passage only 
through the gel. A stack of paper towels were placed on top of the dry Whatman 
paper, followed by a small weight (1kg). The blot was left overnight, and the 
following day the RNA was fixed on to the filter by UV irradiation for 4 minutes. The 
filter was wrapped in clingfilm and stored at 4°C until use.
2.4.4 Random Prime Labelling of DNA.
50-100ng of insert DNA prepared as described in 2.6, was labelled with a 32P dCTP 
(Amersham) using a Boehringer Mannheim random primed DNA labelling kit. The 
insert DNA was combined with Milli-Q water to a total volume of 23pi and heated at 
100°C for 10 minutes before quenching on ice. l/10th total volume (4pl) of reaction 
buffer, lOOmM (2pi) of each dNTP (except dCTP), 1 unit (2pi) Klenow enzyme, and 
50pCi (5pl) of a 32P dCTP was added to the DNA, and the reaction incubated at 37°C 
for 2-4 hours. The mixture was then passed through a Nick column (Pharmacia) with 
2x 400pl of TE buffer (lOmM Tris, pH8.0, ImM EDTA) to remove any 
unincorporated nucleotides, collecting the second 400pi of solution. Determination of 
the specific activity of the probe was performed using a Texas Instruments 
scintillation counter, and if found to be less than 108 cpm/pg the probe was discarded. 
Immediately before use, the probe was boiled at 100°C for 10 minutes to denature the 
DNA, then quenched on ice.
45
2.4.5 Northern Hybridisation.
The Hybond N filter and a fine mesh were soaked in 2x SSC before rolling together 
and placing in a hybridisation bottle with 10-15mls of prehybridisation buffer [5x 
SSC, lx  Denhardts (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA), 50% 
formamide, 0.5% SDS, lOOpg/ml salmon sperm DNA] depending on the size of the 
filter. Incubation occured for 3-5 hours at 42°C. The radioactive probe was denatured 
and added a t3x l07 cpm to the hybridisation buffer (prehybridisation buffer with the 
addition of 10% dextran sulphate). This replaced the prehybridisation buffer, and 
incubation at 42°C continued for a further 16 hours.
2.4.6 Washing of Northern Blot Filters after Hybridisation.
After hybridisation, the Hybond N filter was washed for 10 minutes at 42°C with 2x 
SSC and 0.1% SDS in the hybridisation bottle. The filter and mesh were then placed 
in a box, and washed with 0.2% SSC and 0.1% SDS at 65°C for approximately 15 
minutes with shaking. The counts were checked and washing continued until they 
reached approximately 10 cpm. The filter was exposed to Kodak X-Omat 
autoradiographic film plus intensifying screens, and placed at -70°C. The time period 
before the film was developed depended on the levels of the transcript trying to be 
detected, and on the intensity of the radioactive filter.
2.4.7 Reverse Transcription (RT) of RNA to cDNA.
7pl of RNA (total RNA from 1/2 an embryo, a yolk sac, or 3 1/2 embryos or yolk 
sacs separately combined) was incubated at 90°C for 5 minutes before quenching on 
ice. lpl (50ng) of oligo d(T) was added, followed by incubation at 65°C for 10 
minutes. After quenching on ice 4pl of 5x RT buffer (250mM Tris HC1, pH8.3, 
375mM potassium chloride, 15mM magnesium chloride), 5 pi of 2.5mM dNTPs, lpl 
0.1M DTT, 1.2pl of Moloney Murine Leukemia Virus Reverse Transcriptase (M- 
MLV RT) (Gibco BRL), and 0.8 pi of RNA Guard (RNAse inhibitor)were added and 
the reaction incubated at 37°C for 1 hour. The reaction was stopped by heating at 
95°C for 5 minutes, then quenched on ice. The mixture was stored at -20°C until 
required. As for the RNA from 1h  embryos or single yolk sacs, the yield of cDNA 
was not measured.
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2.4.8 Reverse -Transcription Polymerase Chain Reaction (RT PCR).
4pl of the 20 pi cDNA mixture resulting from reverse transcription was combined 
with 15mM magnesium chloride, lx buffer (Cambio), 50pmoles of the specific sense 
and antisense primers (Table 4), 330mM dNTPs, and 1 unit of Taq polymerase 
(Cambio) in a total volume of 30pl. A layer of mineral oil was added to prevent 
evaporation and the reaction mixture placed in a DNA Thermocycler (Perkin Elmer 
Cetus). Each PCR reaction consisted of the following sequential steps : denaturation 
at 94°C for 1 minute, annealing at 61°C for 1.5 minutes, and elongation at 72°C for 2 
minutes. There were 33 amplification cycles, finally terminating with a 5 minute 
incubation step at 72°C. The PCR products were stored at 4°C until analysed by gel 
electrophoresis on a 1.5% agarose gel.
2.5 Genotyping of TGF-(31 Transgenic Mouse DNA.
2.5.1 Extraction of Mouse Tail DNA.
0.5cm of the tail of an anaesthetised mouse was removed using a hot, sterile scalpel 
blade to ensure cauterisation. The tail tip was placed into 700 pi of tail lysis buffer 
(lOOmM Tris, 0.2% SDS, 5mM EDTA, 200mM sodium chloride / 500mls) containing 
lOOpg/ml proteinase K. Digestion occurred overnight at 55°C, and the tubes 
microcentrifuged at 14000 rpm for 10 minutes at room temperature in an Eppendorf 
benchtop microcentrifuge to pellet the tail debris. The supernatant was decanted into a 
fresh 1.5 eppendorf, and an equal volume of isopropanol added to precipitate out the 
DNA on shaking. Using the end of a sterile yellow tip, the DNA was lifted out and 
placed into another fresh eppendorf. After air drying the DNA was resuspended in 
lOOplof lxTE.
The transgenic embryo DNA was extracted as described in 2.2.14.
2.5.2 Genotyping by Polymerase Chain Reaction (PCR).
Tail DNA and embryo DNA was genotyped by the same method, the only difference 
was the amount of DNA added per reaction. 1 pi of tail DNA was enough to produce a 
result, whereas 3-5pl of embryonic DNA was required. The DNA was subjected to a 
denaturation step of 15 minutes at 94°C before adding to the reaction mix. The 
reaction mixture consisted of 15mM potassium chloride, lx  buffer (Cambio), 
50pmoles of the specific sense and antisense primers (Table 4), 330mM dNTPs, and 1
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A. Primers for Genotyping TGF-p 1 Transgenic Offspring.
No.95 5’ GAG ATG AAG CCC ACT AGA G 3 ’
No.96 5’ CGT GCG CCT GTC GCT TTC TG 3 ’
No.97 5’ GCG GAC TAC TAT GCT AAA G 3 ’
No.98 5’ GGT CAC CCG CGT GCT AAT GG 3 ’
TGFO 5’ AGG GAG CTG GTG AAA CGG AA 3’
PGK-1 5’ TCC ATC TGC ACG AGA CTA GT 3 ’
B. Primers to Amplify TGF-P2.
P25’ 5’ AAA GCC AGA GTG GCC GAG CAG 3 ’
P3 3’ 5’ CAC TTC GCT TTT ATT CGG GAT 3 ’
C. Primers to Amplify TGF-P3.
P3 5’ 5’ TGA GCA AGC TCA GGC TCA CCA 3 ’
P3 3’ 5’ TAG CGC TGC TTG GCT ATG TGC 3 ’
D. Primers to Amplify GAPDH.
GDH5’ 5’ TGA GTA TGT CGT GGA GTC TAC 3 ’
GDH3’ 5’ GGC CAT GTA GGC CAT GAG GTC 3 ’
E. Primers to Amplify Flk-1.
Flk5’ 5’ CAA CAC AGC AGG AAT CAG TC 3 ’
Flk3’ 5’ AAT CTA AGC AGC ACC TCT CTC 3 ’
Table 4 - Oligonucleotides for PCR.
Shown above are the primers required to amplify the normal, and null TGF-pi 
alleles by PCR (A). Primers no.95-98 were used in the same tube to amplify the 
normal TGF-p 1 allele from embryo or tail DNA by nested PCR, as shown in Fig.3. 
Primers TGFO and PGK-1 amplified the null allele in another eppendorf tube, with a 
separate, but identical DNA sample. The primers used to amplify TGF-p2 (B), TGF- 
P3 (C), GAPDH (D), and Flk-1 (E) by RT-PCR are also shown.
All sequences are written 5’-3’.
unit of Taq polymerase (Cambio) in a total volume of 30pi. Nested primers were used 
to identify the normal allele (Fig.3). Two were in the deleted portion of the first exon, 
and the other two in the first intron. The amplification product for the normal allele 
was approximately 625bp. To identify the null allele, one primer was located in the 
first exon, and the second in the Neo cassette, the resulting PCR product being 
approximately 375bp. Before starting the amplification in a DNA Thermocycler 
(Perkin Elmer Cetus), a layer of mineral oil was placed on top of the reaction mixture 
to prevent evaporation. Each PCR cycle consisted of the following sequential steps : 
denaturation at 94°C for 1 minute, annealing at 61°C for 1.5 minutes, and elongation 
at 72°C for 2 minutes. There were 30-35 amplification cycles, finally terminating with 
a 5 minute incubation step at 72°C. The PCR products were stored at 4°C until 
analysed by gel electrophoresis on a 1.5% agarose gel.
2.5.3 Analysis of PCR Products.
The products of PCR were stored at 4°C until analysed. 10 pi of the product was 
mixed with lpl of lOx DNA gel loading dye (0.25% bromophenol blue, 25% ficoll), 
and loaded into the wells of a 1.5% agarose gel containing 1.5pg/ml ethidium 
bromide. A lkb DNA ladder was also loaded as a size marker. The buffer was lx  
TAE (50x TAE: 242g Tris, lOOmls 0.5M EDTA, pH 8.0, 57.1ml glacial acetic acid / 
1 litre), and the gel was run at 150V for approximately 30 minutes. The bands were 
visualised on a UV transilluminator and photographed.
2.5.4 Analysis PCR Products by Southern Methodology.
2.5.4.1 Southern Blotting.
10pl of the PCR product and 3 pi of lOx DNA gel loading dye was run in a 1.5% 
agarose gel as described above. After visualisation under UV, the gel was denatured 
for 15-30 minutes in a solution of 0.5M sodium hydroxide and 1.5M sodium chloride, 
followed by neutralisation in 0.5M Tris and 1.5M sodium chloride for 15-30 minutes. 
The time spent in the solutions depended on the size of the gel. The PCR products 
were transferred to Hybond N by placing the gel on 3MM Whatman paper that had 
been soaked in lOx SSC. The Whatman paper was acting as a wick to a reservoir of 
lOx SSC. A piece of Hybond N was placed on top of the gel, and any air bubbles 
removed. The area around the gel was sealed using clingfilm to prevent evaporation 
of the lOx SSC reservoir. Two pieces of dry 3MM Whatman paper were placed on 
top of the Hybond N, followed by a pack of paper towels, then a small weight (1kg). 
Due to the abundance of PCR products in the gel 3-4 hours blotting was all that was
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required to transfer enough DNA to the filter that would bind probe during Southern 
hybridisation. The filter was removed and placed DNA side down on a UV 
transilluminator for 4 minutes to fix the DNA onto the filter. It was wrapped in 
clingfilm and stored at 4°C until required.
2.5A.2  Southern Hybridisation.
The Hybond N filter and a mesh were pre-soaked in 2x SSC, before rolling together 
and placing in a Hybaid bottle. 10-15mls of PCR prehybridisation buffer (5x SSC, 5x 
Denhardts’, 0.5% SDS, lOOpg/pl E.coli tRNA) was added, and the filter incubated at 
65°C for 2 hours. The prehybridisation buffer was then replaced by hybridisation 
buffer (prehybridisation buffer plus 10% dextran sulphate) containing radioactive 
probe (not less than 108cpm/pg), and hybridised for 3-4 hours at 65°C. The probe was 
made as described in 2.4.4.
2.5.4.3 Southern Washes.
After hybridisation, the filter and mesh were washed in the Hybaid bottle with 2x 
SSC and 0.1% SDS for 10 minutes at 65°C. They were then removed from the bottle 
and placed in a box with 0.2% SSC and 0.1% SDS for 15 minutes at 65°C with 
shaking. If the counts were reduced to between 5 and 20 cps, then the filter was dried 
slightly, wrapped in clingfilm and placed at -70°C with Kodak X-Omat 
autoradiographic film and intensifying screens. The film was developed the following 
day, and if the bands were not intense enough the filter was placed back at -70°C with 
a new film.
2.6 Generation of cDNA Probes.
2.6.1 Constructs for Generating TG F-pi, TGF-03, and 7s RNA 
Probes.
A gene specific mouse TGF-p 1 cDNA (Akhurst et al, 1990) was used for Northern 
analysis of TGF-p 1 gene expression. A 600bp Kpnl - Apal fragment, corresponding 
to the region between amino acids 68 - 268 of the LAP, was derived from the full 
length murine cDNA (Derynck et a l, 1986). This was subcloned into Bluescribe 
(Stratagene) in an antisense orientation with respect to the T3 promoter, and isolated 
using Pst I and Sst I. The TGF-P3 specific probe was a 738bp PCR fragment, coding 
for amino acids 8 - 251 of the LAP, subcloned into Bluescript KS II (by P. Kondaiah
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& F. Denhez). The T3 promoter generated antisense RNA, while the probe used for 
Northern analysis was isolated using Bam HI and Eco RI. The 7s RNA probe was 
obtained from a cDNA library of mouse embryo small RNAs (Bimie e ta l, 1982). The 
clone, pA6, contained 190 of the 280 nucleotides represented in 7s RNA, and was 
isolated using Hinf and Sau 3a
2.6.2 Transfection of Construct into Bacterial Cells.
20-50ng of plasmid DNA containing the required insert was added to 100 pi of DH5a 
competent cells on ice before heat-shocking at 56°C for H /2  minutes. An incubation 
on ice for 2 minutes followed before the addition of 0.5ml of autoclaved L-broth (1% 
bacto-tryptone, 0.5% yeast extract, 1% sodium chloride, pH 7.0), followed by an hour 
in a 37°C shaker (x 225 rpm). The cells were then plated out at 200, 100, and 50pi 
volumes onto agar plates (L-broth plus 1.5% bacto-agar and 50mg/ml ampicillin), and 
incubated at 37°C overnight in an inverted position.
2.6.3 Small Scale Preparation of Plasmid DNA.
During overnight incubation the bacterial cells had proliferated to form colonies on 
the agar plates. One colony was picked and added to 5mls of pre-warmed L-broth 
containing 50mg/ml ampicillin. This was incubated with shaking (x 225 rpm) at 37°C 
overnight. Following the incubation, 1.5mls of culture was placed into an eppendorf 
and microcentrifuged at 14000 rpm for 5 minutes at room temperature in an 
Eppendorf benchtop microcentrifuge. The supernatant was removed and the cell 
pellet resuspended in lOOpl GTE (50mM glucose, 25mM Tris HC1, pH 7.4, lOmM 
EDTA), plus 2mg/ml lysozyme. 200pl of 0.2M sodium hydroxide / 1% SDS was 
added and left on ice until the solution cleared, approximately 5 minutes. Next, 150pl 
of KAW (6M potassium acetate, acetic acid, pH5.4) was added, the tubes mixed 
gently, and then placed on ice for 30 minutes to precipitate the protein. The samples 
were microcentrifuged for 2-3 minutes at 14000 rpm at room temperature, before 
removing and retaining the supernatant. An equal volume of isopropanol was added 
to the solution, and the tubes vortexed, then centrifuged for 5 minutes to precipitate 
and pellet the DNA. The supernatant was discarded, leaving a pellet, which was then 
resuspended in 50pi of sterile TE, plus 50pg/ml of RhiAseA. This was incubated at 
37°C for 30 minutes. Subsequently an equal volume of phenol/chloroform (50:50) 
was added, the tubes vortexed for 10 seconds to ensure proper mixing, and then 
centrifuged for 5 minutes to separate out the organic and inorganic phases. The top 
layer was removed and retained, before adding l/10th volume of 3M sodium acetate 
and an equal volume of isopropanol. The tubes were shaken before placing at -20°C
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for at least 1 hour to precipitate the DNA again. Microcentrifugation at 14000 rpm 
followed for 15 minutes to pellet the DNA which was washed 2x in 70% ethanol, air 
dried, then resuspended in 30pl of TE. 2\i\ of the sample was run on a 1% agarose gel 
containing lpg/ml ethidium bromide to determine the DNA concentration, in 
conjunction with an optical density measurement using a spectrophotometer. 
Approximately 0.5-1 pg/pi was obtained from a small scale preparation.
2.6.4 Medium Scale Preparation of Plasmid DNA.
Once the 5ml culture of transfected DH5a bacterial cells was obtained after overnight 
culture as described in 2.6.2, 200pl was used to inoculate a further 200mls of pre­
warmed L-broth plus 50mg/ml ampicillin. After another overnight incubation period 
at 37°C with agitation (x 225 rpm), the 200ml culture was centrifuged at 3000 rpm for 
10 minutes at 4°C in a Sorvall rotor. The supernatant was discarded, and the cell 
pellet resuspended in 5ml GTE (50mM glucose, 25mM Tris HC1, pH 7.4, lOmM 
EDTA) before the addition of 40mg/ml lysozyme. After incubation on ice for 15 
minutes, lOmls of 0.2M sodium hydroxide / 1% SDS was added, and the solution 
gently mixed before returning to ice for a further 5 minutes. After the solution 
cleared, 7.5mls of KAW (6M potassium acetate, acetic acid, pH5.4) was added, the 
tube inverted, then placed on ice for 20 minutes. A further centrifugation step 
followed for 10 minutes at 3000 rpm at 4°C in a Sorvall rotor to pellet the protein. 
This was removed by filtering the solution through a double layer of gauze. The 
DNA/RNA was then precipitated out of solution by adding 2 volumes of ethanol and 
standing at room temperature for 5 minutes. The tubes were centrifuged for 10 
minutes at 4°C at 3000 rpm to pellet the DNA/RNA. This was then resuspended in 
2mls of TE, and transferred to Falcon 2059 centrifuge tubes. 1.6mls of 5M lithium 
chloride was added, and the tubes placed at -20°C for at least 1 hour. To pellet and 
remove RNA the samples were centrifuged for 10 minutes at 3000 rpm at 4°C. The 
supernatant was retained, and 2 volumes of ethanol were added to precipitate the 
DNA while standing at room temperature for 10 minutes. The DNA was pelleted by 
centrifugation at 3000 rpm for 10 minutes at 4°C, and was then resuspended in 0.4ml 
of TE. This solution was removed and placed into a 1.5ml eppendorf tube. An equal 
volume of phenol was added, and the tubes vigorously vortexed before 
microcentrifugation for 5 minutes at 14000 rpm at room temperature to separate the 
layers. The top layer was removed to a fresh 1.5ml eppendorf tube and an equal 
volume of chloroform was added. Vortexing was required to mix the solutions, before 
centrifugation at 14000 rpm for 5 minutes to separate out the layers again. The top 
layer was retained and 2 volumes of ethanol, plus l/20th volume 4M sodium chloride 
was added. After shaking to mix the liquids the tubes were put at -20°C for at least an
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hour, before spinning for 10 minutes at 14000 rpm at room temperature. The pellet 
was washed in 80% ethanol, and air dried before the addition of 100pi of TE. The 
average yield was 2-4pg/ pl of DNA.
2.6.5 Restriction Endonuclease Digestion.
To isolate the DNA insert, approximately 20pgi of plasmid DNA was combined 
with the appropriate restriction enzymes, at a concentration of 2-3 units/pg DNA, plus 
buffer to a total volume of lOOpl, and incubated at 37°C. After 1-2 hours lpg/ml 
RNAseA was added to remove RNA, and incubation at 37°C continued for a further 
30 minutes. 2pl of the digestion products, plus l/6th volume of gel loading buffer 
(50% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol) was run on a 1% 
agarose gel containing 1.5pg/ml ethidium bromide, lpg/ml of lkb DNA ladder was 
run alongside the samples to confirm the expected size of the insert, and also to 
estimate its concentration when visualised on a UV transilluminator. If the digestion 
was correct and complete the total volume of digestion products were run on a 1% 
low melting point agarose gel for excision and isolation of the insert.
2.6.6 Extraction of DNA Fragments from Low Melting Point 
Agarose Gels.
To isolate the DNA fragment cut out of the plasmid by restriction endonuclease 
digestion, the total volume of the digestion was run in a 1% low melting point agarose 
gel at 50 V for approximately 40-50 minutes. The gel contained 1.5pg/ml ethidium 
bromide and so allowed visualisation of the products on a UV transilluminator. The 
band of the correct size was excised from the gel with a sterile scalpel blade and 
placed into a 1.5ml eppendorf. To remove the DNA from the gel a GeneClean II kit 
(Bio 101 Inc.) was used. The volume of the gel was measured by weight, and three 
volumes of 6M sodium iodide added. This was incubated at 50°C for 5 minutes to 
solubilise the gel, before the addition of 5pl of glassmilk (silica matrix) (5pl per 5pg 
DNA) and incubation on ice for 5 minutes. The mixture was vortexed every 1-2 
minutes to ensure that the glassmilk was exposed to, and binding all of the DNA in 
solution. The glassmilk/DNA was then pelleted by microcentrifugation at 14000 rpm 
for 5 seconds at room temperature before washing in 10-50 volumes of NEW wash 
(sodium chloride, Tris, EDTA, ethanol mixture in kit). The tube was microcentrifuged 
for 5 seconds at 14000 rpm to pellet the glassmilk/DNA again, and the supernatant 
removed. The washing step was repeated twice more before the pellet was 
resuspended in an equal volume of distilled water and incubated at 50°C for 2-3 
minutes to release the DNA from the glassmilk. The glassmilk was pelleted, and the
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water containing the DNA was removed to a fresh eppendorf. The elution step was 
performed twice, lpl of the sample was run in a 1% agarose gel to check that the 
DNA was still present, and to estimate the concentration.
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Chapter 3 
RESULTS
3.1 Analysis of TGF-|3 Levels in Serum and Plasma 
using the CCL64 Assay.
The aim of this project was to investigate the function of TGF-p, specifically TGF- 
pi, during embryonic development by depleting the embryo of TGF-p 1 using either 
antisense I technology or transgenic knockout technology. In vitro post-implantation 
embryo culture was to be utilised to examine the effect of the removal of endogenous 
TGF-pl protein on embryonic development. Since any exogenous TGF-p protein 
may have had an effect on the TGF-pl depleted embryos, a medium which lacked 
TGF-p had to be found. Several different combinations of media were tried, and the 
biological fluids, serum and plasma, were analysed for TGF-p content using the 
CCL64 assay. This bioassay for TGF-p was devised in 1989 by Danielpour et al 
based on the fact that mink lung epithelial cells are potently growth inhibited by TGF- 
p. The cell proliferation rate, as measured by tritiated thymidine incorporation, 
therefore reflects the amount of TGF-p present in the sample. In this project, known 
quantities of recombinant TGF-pi were used as standards, and the serum and plasma 
samples were measured at several dilutions; 1, 10, 20, and 100pi in a total volume of 
200pi of assay buffer. Each sample and standard was assayed in triplicate in each 
experiment. Four different assays on 3 different serum preparations were performed 
to determine the concentration of TGF-pi in rat serum. Likewise, 6 independent 
assays on 5 different plasma preparations were used to determine the concentration of 
TGF- p in rat plasma.
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3.1.1 CCL64 Assay to Measure TGF-pi in Rat Serum.
Before the CCL64 assay was performed, the serum was extracted from rat blood, as 
described in Materials and Methods, and heated for a further 15 minutes at 94°C. This 
step was required to heat-activate any latent TGF-p, and also inactivate any heat- 
sensitive growth stimulatory factors, such as TGF-a. These stimulatory factors were 
previously discovered in a CCL64 assay comparing heated versus un-heated serum 
(Fig.5). Fig.6 is representative of all the assays performed and shows the results of 
one CCL64 assay, analysing 1, 10 and 20 pi dilutions of rat serum in 200 pi of assay 
buffer. Inhibition of cell proliferation was observed when the rat serum samples were 
added, indicating that TGF-p was present However, this inhibition was attenuated 
with increasing amounts of rat serum. This probably indicated the presence of heat- 
stable growth stimulatory factors which were able to override the negative effects of 
serum TGF-p. Thus estimates of TGF-p concentration were only minimal estimates.
The data from the lpl samples were used to estimate serum TGF-pi concentration 
since these contain the lowest levels of interfering growth stimulatory factors. 
Furthermore, to assist in the evaluation of the fraction of growth inhibitory activity 
attributable to TGF-p 1, TGF-p 1 blocking antibody was utilised. The amount of TGF- 
pi was measured as the difference between the samples in the presence or absence of 
lOmg/ml TGF-pl antibody. The antibody alone had no stimulatory or inhibitory 
effect on the cells. When 1 pi of rat serum was analysed and compared to the standard 
curve, the result suggested that there was 125pg/ml of TGF-pi in the sample. When 
lpl rat serum plus antibody was analysed, there was an increase in cell proliferation, 
and comparison with the standard curve suggested that there was 50pg/ml of TGF-pi 
(Fig.6). It appeared therefore, that the antibody had bound to and removed the 
equivalent of approximately 75pg/ml TGF-pi. When the dilution factor was taken 
into consideration, the results of the assays suggested that there was at least 15ng/ml 
TGF-pl in rat serum. This was excessive in quantity compared to an EDso of 50- 
75pg/ml for many biological activities. Serum could therefore not be used in a 
medium for culturing TGF-pembryos.
3.1.2 CCL64 Assay to Measure TGF-pi in Rat Plasma.
TGF-pi levels in rat plasma were analysed using the CCL64 assay. The plasma was 
extracted from blood as described in Materials and Methods, and centrifuged twice at 
14000 rpm for 15 minutes to remove any platelets. This doubly centrifuged plasma 
(dCP) was assayed for TGF-pi concentration after heating at 94°C for 15 minutes to 
heat-activate any latent TGF-p, and inactivate any heat-sensitive growth stimulatory
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Figure 5 - Growth Stimulatory Effect of Rat Serum.
R at serum  was analysed by C C L64 assay to determ ine the presence o f any heat 
sensitive stim ulatory factors. 1, 20, and 100/d samples, in a total o f 200/d  w ith assay 
buffer, were either heated at 94°C for 15 m inutes, before quenching on ice, or were 
left at room  tem perature. They were then assayed in the C C L64 assay, and the level 
o f cell stim ulation  m easured by tritiated thym idine incorporation. 100% tritiated  
thym idine incorporation represents the level with no added components.
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Figure 6 - Concentration of TGF-p in Rat Serum.
The CC L64 assay was used to determ ine the am ount o f T G F-p  in rat serum  (D anielpour etal, 
1989). K now n concentrations (5000pg-0pg/m l) o f recom binant T G F -p  1 (rT G F -p l)  w ere 
assayed to generate a standard “curve”. 1, 10, or 20pl o f rat serum, in a total volum e of 200/d 
w ith assay buffer, were analysed in the same assay. Each standard concentration and rat serum  
sam ple was perform ed in triplicate. To determ ine the approxim ate am ount o f T G F-p  1 in the rat 
serum , lOmg/ml an ti-T G F -p i antibody was added to 1/d rat serum. On com parison with the 
standard curve, there appears to be approxim ately 125pg/ml T G F-p  1 in lp l  o f rat serum . W ith 
antibody, the stim ulation was com parable with 50pg/ml rT G F -p i. This therefore suggests that 
the antibody had bound to and rem oved 75pg/m l T G F-p  1. T aking the d ilu tion  factor into 
consideration, there is therefore a m inimum  of 15ng/ml T G F-p 1 present in rat serum.
RS - rat serum ; A b - an ti-T G F -p i antibody.
factors. Fig.7 is representative of all six assays performed for dCP and shows the 
results of one assay using 1, 10, and 20pi dilutions. Tritiated thymidine incorporation 
was consistently higher in the cells exposed to the plasma samples in comparison to 
the cells exposed to 10 or Opg/ml of rTGF-pi (Fig.7), suggesting that there was no 
TGF-p in the plasma samples. To test the possiblity that there was a very small 
amount of TGF-pi present, but that its inhibitory effect was masked by stimulatory 
factors, lOmg/ml TGF-pi antibody was added to the samples (Fig.7). An increase in 
tritiated thymidine incorporation by the cells was not observed, further supporting the 
finding that there was no detectable TGF-pi in the plasma. dCP therefore appeared 
suitable for use as a medium which lacked TGF-P 1 (ie.< lOpg/ml).
As a potential candidate for culturing post-implantation embryos, plasma appeared 
ideal. Although it was not fully defined, it was a biological fluid and so contained 
many essential components such as glucose, vitamins, and other growth factors that 
are essential for the development of younger embryos ex utero. However, for this 
project, the most important factor was that dCP contained undetectable levels of TGF-
p-
There was one major problem though. Other investigators had previously found 
plasma unsuitable for culturing embryos (Kesby, 1992). Kesby found that with an 
increase in the amount of soluble heparin used to prevent the blood from clotting 
during the extraction procedure, there was a concomitant rise in the number and 
severity of embryonic abnormalities, with significant defects first observed at 20 
IU/ml. However, in this study the heparin was not added as a liquid to the blood, but 
rather as heparin-coated balls, and at a concentration of 10 IU/ml. Whether or not 
plasma prepared in this way would also be toxic to embryos could only be discovered 
by in vitro culture.
3.2 Characterisation of a Post-Implantation Embryo 
Culture System.
Before experiments investigating the role of TGF-p in development could be 
performed, the ability of dCP to support embryonic development had to be assessed. 
Due to the undefined nature of the plasma, it seemed sensible to try and reduce the 
quantity used in the culture medium, thereby decreasing the amount of unknown 
factors. This would also decrease the amount of heparin that the embryos would be 
exposed to. Therefore, instead of using 100% dCP, several different quantities of dCP 
were tried and tested in combination with one of two chemically-defined, commercial
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Figure 7 - TGF-p Concentration in Rat Plasma.
The C C L64 assay was used to determ ine the am ount o f T G F -p l in rat p lasm a 
(D anielpour et al, 1989). K now n concentrations (5000pg-0pg/m l) o f recom binant 
T G F-p 1 were assayed to generate a standard “curve”. 1, 10, 20pl rat plasm a samples 
in a total volume of 200/d with assay buffer, were analysed in the sam e assay. Each 
T G F-p standard and rat plasm a sam ple was assayed in triplicate. T o  determ ine the 
approxim ate am ount o f TG F-p 1 in the rat plasm a, lOmg/ml an ti-T G F -p i antibody 
was added to lp l plasm a samples. As show n above, the results indicated that there 
was no T G F-p  1 present in the plasm a samples. The cells were not inhibited in the 
presence o f the plasm a, and there was no increase in stim ulation when the antibody 
was added.
media; Dulbecco’s Modified Eagles Medium (DMEM) or Foetal Mouse Palate 
Medium (FMP) (Table 1, 2). As the name suggests, FMP was originally used to 
culture and study the development of mouse embryo palates (Shiota et al, 1990), and 
so may have contained components suitable for supporting whole embryo 
development. Rat serum was also used in combination with these media to compare 
with the dCP samples.
NIH or Parkes/NIH mice were used in the initial studies to test the different culture 
media. After culture, the embryos were analysed using the Brown-Fabro scoring 
system (Brown & Fabro, 1981) (Table 3), as described in Materials and Methods. 
However, although several critical embryonic characterisics are assessed using this 
system, the resulting final score is only a reflection of the developmental stage of the 
embryo, and does not reveal whether the embryo has developed normally. For 
example, an embryo may have the physical attributes of a 9.5 dpc embryo, but one of 
these attributes may be abnormal. Therefore, in this project, abnormalities were also 
assessed, and subdivided into “major” and “minor” abnormalities. “Major” 
abnormalities were defects which would seriously affect embryonic development, for 
example, the persistence of open headfolds, whereas “minor” abnormalities were 
small, non-offensive defects, such as a tiny spot of blood in the forebrain, which 
would not affect the continued short-term development of the embryo.
3.2 1 The Use of Standard Embryos as Controls.
A panel of embryo standards was generated using uncultured embryos, against which 
the cultured embryos could be compared. 194 Parkes/NIH or NIH embryos were 
removed from the uterus at a variety of ages (8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75 and 
10 dpc) (Fig.8), and scored by the Brown-Fabro method. Variation between the 
embryos of a certain age group was observed, as indicated by the standard error bars 
in Fig.8, as well as variation between embryos of the same litter. This latter 
observation is a common phenomenon as not all embryos develop at the same rate in 
utero. However, the difference was at most lk  of a day.
3.2.2 7.5 dpc Embryo Culture.
The different media were initially analysed for their ability to support normal 
embryonic development from 7.5 to 8.5 dpc in vitro. 271 NIH or NIH/Parkes 
embryos were cultured in the media for 24 hours, scored and then assessed for 
abnormalities.
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U ncultured em bryos, ranging from  8 .0 -10 .0  dpc w ere rem oved from  the 
u terus, and assessed using the B row n-Fabro  scoring m ethod (1981). A 
num ber o f em bryonic characterisitics are each given a score depending on 
their appearance. These values are then added together to give the em bryos 
score. A higher score indicates a m ore advanced em bryo. Each colum n in 
the graph represents the mean score for the em bryos o f that age.The num ber 
in each colum n represents the num ber o f em bryos exam ined. Vertical bars 
show the standard error o f the mean.
DMEM : 50% rat serum is commonly used by other groups (Tam & Beddington, 
1987; Savatier et al, 1990; Shepard et al, 1993), and supported the development of
7.5 dpc embryos very efficiently in this study (Fig.9, 10). The rate of development 
was slightly delayed by approximately 2-3 hours, and there were a few necrotic 
embryos, but these abberations were not significant when compared with controls. 
From 30 embryos cultured in DMEM : 50% rat serum, 6 were slightly necrotic. If the 
amount of rat serum was decreased to 10%, the embryos continued to grow over the 
24 hour time period, but both the delay in development, and the number of 
abnormalities increased very slightly (Fig.9, 10, Table 5). If DMEM was combined 
with dCP, embryonic development was considerably delayed, at most attaining the 
stage of 8.25 dpc (Fig.9). This was observed for the majority of the 25 embryos 
cultured in DMEM : 50% dCP, and the 26 embryos cultured in DMEM : 10% dCP. 
The most dramatic effect however, was the observed increase in abnormalities when 
DMEM : 50% dCP was used (Fig. 11, Table 5). Major abnormalities were observed in 
6/30 and 5/30 embryos cultured in DMEM : 50% rat serum and DMEM : 10% rat 
serum, respectively, whereas, when DMEM : 50% dCP was used, 16/25 embryos 
were severely abnormal. Table 5 shows the range of abnormalities observed.
Although necrosis was probably a secondary effect, it was the most commonly 
observed problem, accounting for 10 out of the 16 abnormal embryos resulting from 
culture in DMEM : 50% dCP. Although necrotic embryos were observed after culture 
in the other media, it was most severe in the embryos from DMEM : 50% dCP. The 
cells necrosed until embryonic structures were unidentifiable, and only a yellow, 
sticky, ball of cells remained. Other abnormalities included splayed head folds, which 
commonly appeared as if on stalks, and twisted somites or even a total lack of 
somites. When the dCP was decreased to 10%, the range of defects were still 
observed but the number of abnormal embryos decreased to 8 out of 26.
Embryos cultured in FMP : 50% rat serum, and FMP : 10% rat serum developed to 
between 8.25 and 8.5 dpc and exhibited very few abnormalities, 4/26 and 10/67 
respectively (Fig.9, 10, 11, Table 5). When FMP : 50% dCP was used, the embryos 
developed at the normal rate for the 24 hours in vitro, attaining the characteristics of
8.5 dpc embryos, but 8 of the 32 embryos had some sort of serious defect. The range 
of defects observed was as for the DMEM : 50% dCP cultured embryos, but the 
majority had headfold and somite phenotypes, rather then necrosis (Table 5). When 
FMP: 10% dCP was used, 18/31 embryos had a major abnormality, 17 of which were 
necrotic.
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Figure 9 - 7.5 dpc Embryo Culture.
7.5  dpc em bryos were rem oved from the uterus and cultured in a variety o f m edia for 
24 hours. A fter culture, the developm ent o f the em bryos was assessed by the Brow n- 
Fabro m ethod (1981). The graph shows the m ean score for em bryos cultured in each 
o f the media. The num ber in each colum ns represents the num ber o f em bryos cultured 
in that m edium , and the vertical bars are the standard error o f the m ean. The m ean 
score for 8.0 and 8.5 dpc control em bryos are also shown.
Figure 10 - Morphological Analysis of Cultured 7.5 dpc Embryos.
Embryos were removed from the uterus at 7.5 dpc and cultured in a one of a variety of 
media for 24 hours. (A) 8.5 dpc control and (B) an embryo after culture in FMP : 50% rat 
serum. Note the developing corona in the yolk sac, spreading down from the 
ectoplacental cone region. This was also present in the yolk sacs of embryos (C) - (F). 
The embryo in (C) was cultured in FMP: 50% dCP, and is slightly older than the others.
(D) represents embryos after culture in either FMP : 10% rat serum , or 10% dCP, while
(E) is representative of culture in DMEM : 50% rat serum The embryo in
(F) was cultured in FMP : 10% rat serum, and is similar to those cultured in DMEM : 
10% dCP.
a - allantois; be - blood corona; ec - ectoplacental cone; h - headfolds; ht - heart tube; op - 
otic pit; s - somites; t - tail; ys - yolk sac.
Scale bars : (A,E,F) - 320pm ; (B) - 280pm ; (C,D) - 300pm.
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Figure 11 - Abnormalities Observed in Cultured 7.5 dpc Embryos.
7.5 dpc em bryos were cultured for 24 hours before their in vitro developm ent was 
assessed  by scoring  and analysis o f abnorm alities. A num ber o f abnorm al 
phenotypes were observed, and classified into two groups; m ajor, or m inor. M ajor 
abnorm alities were defects that would have resulted in death relatively quickly had 
the culture continued, w hereas m inor abnorm alities would not have. T he graph 
above shows the num ber o f em bryos with m ajor or m inor abnorm alities after 
culture in each medium. The figures above each colum n represent the num ber o f 
abnorm al em bryos / the total num ber o f embryos cultured.
To determine whether these developmental differences were significant, the scores of 
the embryos cultured in each media were analysed and compared by a students t-test. 
(Appendix Al). In brief, there was a significant difference (P<0.05) between the 
embryos grown in several of the media, especially between the media containing 
either DMEM or FMP, and between DMEM plus serum, and DMEM plus dCP.
The results of the 7.5 dpc embryo cultures suggested that DMEM : 50% rat serum and 
FMP : 50% rat serum were the best media in which to culture embryos of this age. 
They were equally effective at supporting development, maintaining normal 
embryonic growth to between 8.25 and 8.5 dpc. However, both of these contain 
serum, and therefore, TGF-b. FMP : 50% dCP did not contain TGF-b, and although 
the embryos developed at the same rate as their in vivo counterparts, there was a 
higher incidence of abnormality. It was therefore difficult to obtain normal in vitro 
development of 7.5 dpc embryos in a medium lacking TGF-P.
3.2.3 8.5 dpc Embryo Culture.
Parkes/NIH and NIH embryos were removed from the uterus at 8.5 dpc and cultured 
in a variety of media (Table 2) to determine which, if any, provided the best support 
for in vitro embryonic development over the 24 hours from 8.5 dpc to 9.5 dpc. 261 
embryos were used in this study.
After 24 hours, the majority of embryos cultured in DMEM : 50% rat serum, and 
DMEM : 10% rat serum had developed to approximately 9.25 dpc (Fig.12, 13). 
However, 6 of the 23 embryos cultured in DMEM : 50% rat serum, and 5 of the 23 
embryos cultured in DMEM : 10% rat serum exhibited some major abnormality 
(Fig. 13, 14, Table 6). 5/6 abnormal embryos cultured in DMEM : 50% rat serum, and 
5/5 in DMEM : 10% rat serum had died during the culture period and were necrotic. 
These necrotic embryos had a grainy appearance, which did not compare to the 
severity of necrosis that was observed in the 7.5 dpc embryos. Some embryos also 
had abnormal forebrain regions, such as open or twisted brainfolds (Table 6). A 
grainy or bumpy yolk sac was found in 1 of the embryos cultured in DMEM : 50% rat 
serum, and in 5 of the DMEM : 10% rat serum embryos. When DMEM was 
combined with dCP embryonic development was delayed and even failed to reach
9.25 dpc (Fig. 12, 13). 10 out of 23 embryos exhibited serious abnormalities; 7 were 
necrotic, and 4 exhibited abnormal forebrain phenotypes (Fig. 13, 14, Table 6). These 
forebrain phenotypes included anencephaly (open brain folds) or hydrocephaly 
(ballooned forebrain cavities). When the amount of dCP was reduced to 10%, the in 
vitro development of the embryos improved (Fig. 12). They developed to between
59
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Figure 12 - 8.5 dpc Embryo Cultures.
8 .5  dpc em bryos w ere rem oved from  the uterus and cu ltured  in a varie ty  o f 
m edia for 24 hours. After culture, the developm ent o f the em bryos was assessed 
by the B row n-Fabro  m ethod (1981). T he graph show s the m ean score  for 
em bryos cultured in each m edium . The num ber o f em bryos cu ltured  in each 
m edium  is represented by the num ber in each colum n, and the vertical bars are 
the standard error o f the m ean. The m ean score for 9 .25 and 9 .5  dpc control 
em bryos are also shown..
Figure 13 - Morphological Analysis of Cultured 8.5 dpc Embryos.
Embryos were removed from the uterus at 8.5 dpc and cultured in a one of a variety 
of media for 24 hours. (A) 9.5-9.75 dpc control and (B) an embryo after culture in 
FMP : 50% rat serum. The embryo in (C) was cultured in FMP : 50% dCP, and (D) 
represents embryos after culture in either FMP : 10% rat serum, or 10% dCP. (E) 
Embryo cultured in DMEM : 50% rat serum, and (F) embryo cultured in DMEM : 
50% dCP.
b - blood; bb - branchial bars; da - dorsal aorta; h - heart; lb - limb bud; oh - open 
headfolds; otv - otic vesicle; ov - optic vesicle; pn - posterior neuropore; s - somites.
Scale bars : (A) - 500pm ; (B-F) - 625pm.
B .
D .
v
O-
%
 O
f 
A
bn
or
m
al
 E
m
br
yo
s
50
4 0 -
10/
23
8/
M
3 0 -
6/
&
5/
33l
5/
22
20 4/ 4/
10-
6/
Major
Abnormalities
Minor
Abnormalities
15/
10
0/ 0/
27 27
4/ 4/
32 32
5/
101 1/ 1/
32 32
Culture Medium
Figure 14 - Abnormalities Observed in Cultured 8.5 dpc Embryos.
8.5 dpc em bryos were cultured for 24 hours before their in vitro developm ent was 
assessed  by scoring  and analysis o f  abnorm alities . A num ber o f abnorm al 
phenotypes were observed, and classified into two groups; m ajor, o r minor. M ajor 
abnorm alities were defects that would have resulted in death relatively quickly had 
the culture continued, w hereas m inor abnorm alities w ould not have. The graph 
above show s the num ber o f em bryos w ith m ajor or m inor abnorm alities after 
culture in each m edium . The figures above each colum n represent the num ber o f 
abnorm al em bryos / the total num ber o f em bryos cultured.
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9.25 and 9.5 dpc, and exhibited a smaller number of major abnormalities in 
comparison to the embryos cultured in DMEM : 50% dCP. (5/22 cf. 10/23) (Fig. 14, 
Table 6). All 5 of the abnormal embryos exhibited necrosis, and 3 had an abnormal 
forebrain. This apparent difference between the capabilities of DMEM : 50% dCP and 
DMEM : 10% dCP to support in vitro development recapitulated the observation 
found with the 7.5 dpc embryo cultures.
In comparison, when 8.5 dpc embryos were cultured in FMP combined with either rat 
serum or dCP, their rate of development was as near normal as could be expected in 
an in vitro situation (Fig. 12, 13, 14, Table 6). FMP : 50% rat serum, FMP : 10% rat 
serum, FMP : 50% dCP, and FMP : 10% dCP all supported development from 8.5 
dpc to between 9.25 and 9.5 dpc. The only difference between the media was the 
number of abnormal embryos after 24 hours in culture (Fig. 14, Table 6). There were 
no abnormalities found in any of the 27 embryos cultured in FMP : 50% rat serum, 
whereas 15 of the 1Q1 embryos cultured in FMP : 10% rat serum showed some 
significant abnormality. All 15 of these abnormal embryos were necrotic, and 1 had 
an abnormal yolk sac. 32 embryos were cultured FMP: 50% dCP, and after 24 hours 
1 embryo exhibited a degree of necrosis. This was the only abnormality seen with this 
culture medium. When the dCP was decreased to 10%, 4 out of 32 embryos were 
significantly abnormal. All of these embryos were necrotic.
To determine whether there was a statistically significant difference between the 
ability of the various media to support embryonic development from 8.5-9.5 dpc, the 
scores in each media were analysed in students t-tests. The results were similar to 
those for the 7.5 dpc embryos. A statistically significant difference was obtained 
when comparing FMP and DMEM-containing media, or DMEM plus serum with 
DMEM plus plasma (Appendix A2).
Statistical analysis of the data suggested that FMP combined with rat serum or dCP 
were the most suitable media in which to culture 8.5 dpc embryos. However, as 
demonstrated by CCL64 assay, only rat serum contains TGF-p, and therefore FMP : 
50% dCP was more suitable for the requirements of this project. 10% rat serum and 
10% dCP in combination with FMP also supported development, but both resulted in 
slightly more abnormalities.
60
3.3 In-Depth Analysis of 8.5 dpc Embryo Culture
Analysis of the 8.5 dpc embryo cultures suggested that further investigation was 
warranted to examine the significant difference in development when embryos were 
cultured in FMP: 50% dCP or 10% dCP, and DMEM : 50% dCP. In a further twelve 
experiments, 30-32 embryos were cultured for 24 hours in each medium. The 
embryos were then assessed using a number of methods. As well as scoring the 
phenotype by the Brown-Fabro method (Brown & Fabro, 1981) (Table 3), and 
recording any abnormalities, the embryos were examined histologically; cell 
proliferation was measured by BrDU incorporation; and embryonic protein content 
was measured. These criteria enabled other aspects of embryonic development to be 
measured and compared, rather than just the morphological appearance.
To circumvent day-to day variation in culture conditions, in each experiment all three 
culture media were tested on litter mates.
3.3.1 Phenotypic Analysis of Embryos After Culture.
26 embryos cultured in DMEM : 50% dCP, 26 in FMP : 50% dCP, and 27 embryos 
cultured in FMP : 10% dCP were morphologically analysed to assess the ability of 
each medium to support development (Fig. 15). The embryonic scores indicated that 
FMP : 50% dCP was more efficient than either FMP : 10% dCP or DMEM : 50% 
dCP, although FMP: 10% dCP was almost as effective, as had been found previously 
(Fig. 12, 14, Table 6). However, when the abnormalities were classified (Table *7), 
FMP : 10% dCP was found to induce more abnormalities, with 8 out of 27 embryos 
exhibiting one or more major defect, in comparison to only 3 out of 26 embryos 
cultured in FMP : 50% dCP. The majority of abnormalities observed in the FMP : 
10% dCP embryos were forebrain defects (6/8) such as anencephaly, or hydrocephaly 
(Table 7). The FMP: 50% dCP defects were equally distributed between the yolk sac 
(2/3), the forebrain (2/3), and necrosis (1/3). In comparison, 24 of the 26 embryos 
cultured in DMEM : 50% dCP exhibited a major defect. All 24 were necrotic, some 
of which had additional defects in the yolk sac, forebrain, or heart. The embryos 
appeared to have died early on in the culture period, as they were all 9 dpc or 
younger.
These results agreed with the preliminary data in|3.2.3. FMP: 50% dCP was the most 
efficient medium to culture embryos from 8.5 to 9.5 dpc, followed closely by FMP : 
10% dCP. DMEM : 50% dCP however, was completely inefficient. Two-sample
61
Figure 15 - Further Analysis of 8.5 dpc Embryo Cultures.
Additional culture experiments were performed using FMP : 50% dCP, FMP : 10% 
dCP, and DMEM : 50% dCP. Embryos were removed from the uterus at 8.5 dpc, and 
cultured in one of the above media for 24 hours. (A) shows one such embryo with the 
yolk sac still intact after culture in FMP : 50% dCP. The yolk sac was removed to 
examine the morphology of the embryo proper (B). (C) and (D) show a FMP : 10% 
dCP cultured embryo, while the embryo in (E) and (F) was cultured in DMEM : 50% 
.dCP.
a - allantois; b - blood; bb - branchial bars; bv - blood vessel; ec - ectoplacental cone; 
h - heart; hf - headfolds; lb - limb bud; otv - otic vesicle; ov - optic vesicle; pn - 
posterior neuropore; s - somites; t - tail; ys - yolk sac.
Scale bars : (A-F) - 560 pm.
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students t-tests demonstrated that there was a significant difference between the 
scores of the embryos cultured in the different media (P^O.05 for all comparisons), 
providing statistical evidence to corroborate the morphological evidence (Appendix 
A3).
In comparison to the preliminary studies, there was a considerably higher number of 
abnormal embryos, for the DMEM : 50% dCP cultured embryos (Table 6, 7). In the 
initial studies, 10/23 embryos had major abnormalities, and 8/23 had minor 
abnormalities, whereas in this study, 24/26 had major abnormalities, and 0/26 had 
minor abnormalities. This may have been due to batch differences of dCP or DMEM. 
However, as the FMP plus dCP media did not show these vastly increased numbers of 
abnormal embryos, it is likely that the DMEM was at fault.
3.3.2 Histology and BrDU Labelling of Cultured Embryos.
Morphological analysis and scoring gives a broad overview of the development of the 
whole embryo, but does not assess the smaller details. The embryos were therefore 
labelled with BrDU for 1 hour and analysed histologically to examine the integrity of 
the cells, tissues, and internal structures, and to estimate DNA synthetic capacity.
Initial difficulties were encountered when trying to administer the BrDU. Four 
methods were tried and tested; culturing the embryos with the yolk sac intact in 
medium containing BrDU; culturing embryos with the yolk sac opened; injecting 
BrDU intraperitoneally into the pregnant female; and injecting BrDU into the yolk 
sac cavity of cultured embryos.
Initially seventeen 9.5 dpc embryos were cultured with the yolk sac intact in FMP : 
50% dCP + 1 pi 10mmol/l BrDU for 2-2.5 hours. Once they were sectioned and 
stained, BrDU was seen to have incorporated into the nuclei of the ectoplacental cone 
but not into any of the yolk sac or embryonic cells. Therefore, the next method 
attempted was to apply the BrDU to the embryos in vivo, based on the idea that the 
BrDU would cross from the mothers blood into the embryo. 500pl of 10mmol/l BrDU 
was injected intraperitoneally into a 30g pregnant female when the embryos were 
approximately 9.5 dpc. 3 females were treated in this way, and left for 1.5, 5 and 6.5 
hours to allow for transfer of the BrDU, before a schedule 1 kill to obtain the 
embryos. 21 embryos were obtained from these experiments, but, again, no staining 
was observed in the embryo or yolk sac, only in the ectoplacental cone. The third 
attempt returned to in vitro methods, but this time the embryos were cultured with 
their yolk sac open for 1.5 hours in the presence of lpl of 10mmol/l BrDU. This
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method was more successful with staining observed in the yolk sac cells, and in 
sporadic regions of the embryo. However, this latter staining appeared to be 
artefactual, and suggested that perhaps the BrDU was too dilute in the 1ml of 
medium. Therefore, because the BrDU was ineffective in 1ml of medium, and that, 
from the intraperitoneal and intact yolk sac culture methods, it appeared as if the 
BrDU was unable to cross the yolk sac, 1 pi of 10mmol/l BrDU was injected directly 
into the yolk sac cavity using a pulled micropipette, and the embryos cultured for 1 
hour in FMP: 50% dCP. This method enabled the BrDU to incorporate into the DNA 
of the cells of the yolk sac and the embryo, and therefore the experimental analysis of 
the cultured embryos could begin.
Seven 8.5 dpc embryos were cultured in FMP: 50% dCP, six in FMP: 10% dCP, and 
six in DMEM : 50% dCP for 23 hours before the injection of lpl of 10mmol/l BrDU 
into their yolk sac cavity. They were then cultured for a further hour to allow 
incorporation of the BrDU, before fixing in 4% PFA, and processing to sections. 3 
additional embryos were removed from the uterus at 9.5 dpc and injected with BrDU 
before culturing for 1 hour in FMP : 50% dCP. These embryos were controls against 
which the cultured embryos could be compared. An immunohistochemical staining 
procedure revealed the cells which had incorporated the BrDU (Materials and 
Methods'), enabling histology and the rates of cell proliferation to be compared 
between the cultured embryos, and with the controls.
Analysis of the control embryo sections enabled normal histology to be observed 
(Fig.l6A). By visualisation, there appeared to be slightly more cells in the control 
sections in comparison with the sections from cultured embryos (Fig.l6B-D), but this 
could have been due to a difference in embryonic age. As mentioned in section |3.3.1, 
delayed development was observed in the cultured embryos, especially those cultured 
in DMEM : 50% dCP. The histology of the embryos cultured in either of the FMP- 
containing media was very similar to that of the controls, with very few pyknotic 
cells, and no evidence of hyper- or hypoplasia (Fig. 16, 17). The only difference seen 
in a few sections of the IMP cultured embryos was that the mesenchymal cells 
appeared to be slightly less densely packed, possibly indicative of oedema. All other 
cell types were normal. The sections of the DMEM : 50% dCP cultured embryos 
clearly illustrated the lack of growth in these embryos, and their demise. Many of the 
cells were pyknotic, and there was very little development of the different tissues and 
organs (Fig. 16,17).
The results of the histological analysis agreed with the previous observations that 
embryos cultured in FMP : 50% dCP and FMP : 10% dCP embryos grow almost as
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Figure 16 - Histological Analysis of 8.5 dpc Cultured Embryos.
B rD U  stained sections o f cultured em bryos w ere analysed histo logically . (A) is a 
section  through a control 9 .5  dpc em bryo. (B ), (C ), and (D) w ere all cu ltured  
em bryos. (B) - FM P : 50%  dCP; (C) - FM P : 10% dCP; (D) - D M EM  : 50%  dCP. 
Note the severely delayed developm ent, and the high am ount o f necrosis (show n in 
m ore detail in Fig. 17) in (D) in com parison to any o f the other exam ples, 
bb - branchial bars; ec - ectoplacental cone; f - foregut; fb - forebrain; h - heart; h f - 
headfolds; nt - neural tube; s - som ites; t - tail; ys - yolk sac.
Scale bars : (A-D) - 375 pm.
Figure 17 - Cell Proliferation in Control and Cultured Embryos.
Control or cultured embryos were subjected to BrDU incorporation in order to 
examine and compare cellular proliferation rates. The ectodermal cells were analysed 
by counting the number of BrDU stained cells (brown) versus the number of non- 
stained cells (blue). (A) control embryo |with a high level of cell proliferation, 
especially in structures near the ectodermal surface of the embryo. At higher 
magnification, the embryos cultured in FMP : 50% dCP (B), or FMP : 10% dCP (C) 
were also observed to have a high rate of proliferation. Embryos cultured in DMEM : 
50% dCP (D) had little BrDU staining as the majority of the cells were necrotic, 
indicated by the small dark spots. (B), (C), and (D) are high magnification 
photographs of the boxed areas in Fig. 16 (B, C, D).
e - ectoderm; f - foregut; n - necrotic cells; nt - neural tube.
Scale bars - (A) - 150pm ; (B,C,D) - 75pm.
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well as their in utero counterparts. As yet a system that is as efficient as the in vivo 
situation has not yet been found, therefore in vitro development will not be as precise 
as in utero. The histology of the DMEM : 50% dCP embryos also reflected the 
morphological analysis at a more detailed level, supporting the observation that this 
medium cannot support the development of 8.5 dpc embryos.
On initial examination of the DNA synthetic rate, sections of embryos that had been 
cultured in the same medium appeared to have comparable amounts of staining 
(Fig. 16). Two embryos from each medium were then chosen for more detailed 
examination by the integrity of their tissues (Fig. 17). By visualisation alone, the 
degree of staining suggested that the fraction of proliferating cells in embryos 
cultured in FMP : 50% dCP, FMP : 10% dCP and controls was very similar, whereas 
the fraction was much less in the DMEM : 50% dCP cultured embryos. There were 
also many pyknotic cells in the DMEM : 50% dCP sections, indicated by highly 
condensed, darkly stained nuclei, the histological manifestation of the necrosis 
observed morphologically (Fig. 17).
To compare proliferative rates in the three media a total of 1000 epithelial cells per 
embryo were counted, and the number of stained and unstained cells noted (Fig. 18, 
Appendix A4). The ectodermal cells which surround the embryo were chosen as they 
were abundant and easy to identify. An average of /39% of cells stained for BrDU in 
the FMP : 50% dCP cultured embryos, j40% in FMP : 10% dCP, 22% in DMEM : 
50% dCP, and 32% in the controls. When the data was statistically analysed by a two- 
sample student t-test, the results indicated that there was a significant difference in 
cell proliferation rates between most of the different samples (P<0.05) (Appendix 
A4). However, only the DMEM : 50% dCP embryos had significantly reduced levels 
of BrDU incorporation. Embryos cultured in either of the media containing FMP 
exhibited higher proliferation rates than the controls. It is possible that the controls 
exhibited a reduced number of proliferating cells in comparison to the FMP-cultured 
embryos due to the labelling procedure. Cultured embryos had been in the medium 
for 23 hours before the addition of BrDU, whereas the control embryos were labelled 
directly after dissection, and may have been in shock.
3.3.3 Protein Analysis of Cultured Embryos.
In contrast to the phenotype of an embryo which does not change in a simple 
quantitative manner over time, the amount of protein in an embryo increases 
logarithmically with age. Protein analysis therefore gives a reliable estimation of 
embryonic development because it is possible to affect the mass of an embryo without
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Figure 18 - BrDU Incorporation in Cultured Em bryos as a 
Measurement of Cell Proliferation.
Culturing embryos were injected w ith lp l o f 10m m ol/l B rD U  to analyse growth 
and developm ent in the different media. BrDU incorporation in the ectoderm al cells 
o f 2 em bryos from each m edium , and two control em bryos was m easured, thereby 
assessing cell proliferation. A total o f 2000 cells w ere coun ted  in each pair o f 
em bryos, and the percentage of cells that were stained w ith BrDU is show n on the 
histogram  above . The vertical bars represent the standard error.
severely affecting the appearance. Therefore, to further analyse the difference in 
embryonic development in each of the media, the protein content of individual 
embryos was measured. Protein extraction and estimation was performed using the 
Lowry method from 15 embryos cultured in FMP : 50% dCP, 17 in FMP : 10% dCP, 
16 in DMEM : 50% dCP, and 6 uncultured, control 9.5 dpc embryos (Lowry et al, 
1951) (Materials and Methods). The cultured embryos were obtained from 5 different 
experiments, and frozen at -20°C until required. All protein samples were extracted 
concurrently, and measured individually, in triplicate, in a spectrophotometer. The 
embryos in each group exhibited a wide range of protein values:- FMP : 50% 
dCP=126-482; FMP: 10% dCP=84-338; DMEM : 50% dCP=109-259; controls=159- 
574 pg/embryo (Fig. 19). Due to the manner by which the protein was extracted, this 
variation could not be attributed to accidental loss during the extraction procedure, 
and so therefore, it had to reflect the variation in the size or developmental stage that 
each embryo had attained. When the protein values were compared with the embryo 
scores, the reason for the variation was confirmed. Embryos with a high score had a 
high protein concentration, while those with a low score had a lower protein 
concentration (Fig 20).
When the protein data was analysed statistically using a two-sample 2-sample 
students t-test, there was evidence for a significant difference (P^0.05) in the protein 
content of embryos cultured in the FMP-containing media, in comparison to the 
embryos cultured in DMEM : 50% dCP (Appendix A5). When FMP : 50% dCP and 
FMP : 10% dCP were compared, the P-value was 0.17, and therefore not statistically 
significant. However, when DMEM : 50% dCP was compared with FMP : 50% dCP, 
the P-value was 0.0024, and with FMP : 10% dCP, P = 0.0079. These values 
represent a highly statistically significant difference. When the protein levels of the 
cultured embryos were compared with controls, only the DMEM : 50% dCP showed 
a significant difference (Appendix A5). The protein levels of embryos cultured in 
FMP: 50% dCP or IM P: 10% dCP were comparable with control embryos.
3.3.4 Conclusions.
The results of the above investigations demonstrated that there was a significant 
difference between the different media in their ability to support the development of
8.5 dpc embryos in culture. FMP : 50% dCP (<5pg/ml TGF-pi) was the most 
efficient at maintaining the growth of the embryos, although FMP : 10% dCP 
(<lpg/ml TGF-pl) was almost as effective. DMEM : 50% dCP did not support 
development, and often resulted in the death of the embryos. Embryos that were 
cultured in the FMP media were very similar to control embryos that had not been
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Figure 19 - Concentration of Protein in Cultured Embryos.
The protein was extracted from em bryos cultured in d ifferent m edia, or control 
em bryos to assess their developm ent. Each em bryo was treated separately, and the 
protein extracted, then m easured in triplicate by the Low ry m ethod (Low ry, 1951). 
The m ean protein concentration for the em bryos in each group is represented  on 
the histogram . The num ber o f em bryos analysed is show n by the figure in each 
colum ns. The vertical bars represent the standard error o f the mean.
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Figure 20 - Com parison of Em bryonic Score and Protein
Concentration.
T o determ ine if  the em bryonic variation in protein concen tration  reflected  the 
vanation  in developm ental stage o f the em bryos after culture, the em bryo scores 
were com pared with the protein concentrations. Each individual point on the graph 
above represen ts an em bryo , w ith  em bryos cu ltu red  in the d iffe ren t m edia  
distinguished by different sym bols (see key). As can be seen, w ith an increase in 
em bryonic score, there was a corresponding increase in protein concentration.
cultured; in cell proliferation rate, histology, and protein content, and only on 
morphological scoring was there a significant difference. This is most likely as a 
result of the nature of the scoring system. There can be a relatively large difference in 
the scores of two embryos if one is only slightly more advanced them the other. By 
incorporating the other investigative techniques, more reliable results were obtained. 
In conclusion, a TGF-pi-depleted medium was identified (FMP : 50% dCP) which 
could support complete development of the embryo in vitro from 8.5 to 9.5 dpc.
66
3.4 Developmental Analysis of Embryos Which Lack 
TGF-01.
Two independent laboratories generated TGF-pi knockout mice using homologous 
recombination techniques (Shull et al, 1992; Kulkami et al, 1993). Both groups found 
that 50% of the TGF-pi_/-, and 25% of the TGF-pi+/_ offspring died pre- or peri- 
natally. These mice were available to us on a mixed genetic background (50% NIH, 
37.5% C57B16, 12.5% 129sv), so we endeavoured to analyse the developmental 
abnormalities which led to the death of the TGF-pi knockout embryos. This work 
was performed in close liason with Dr. Marion Dickson, who determined, by 
genotype analysis of embryos from intercrosses of TGF-pl+/_ mice, that the embryos 
died at 9.5 to 11.5 dpc (Dickson et al, 1995). Independently from, but in collaboration 
with Dr. Dickson, the current project set out to a) characterise the nature of the 
defects appearing in utero, and b) to assess whether the defects were amplified in a 
medium lacking TGF-pi. The reason for this latter objective was that one study had 
suggested that a proportion of the TGF-pi knockout embryos were rescued by 
maternal TGF-pi (Letterio etal, 1994).
3.4.1 Genotype Analysis of TGF- pi Knockout Embryos.
Since it was known that some of the TGF-pi knockout embryos died around 10.5 
days gestation, analysis was performed on embryos of 8.5 and 9.5 dpc. TGF-pi+/- x 
TGF-pi+/_ matings were set up, and the embryos harvested into PBS or Embryo 
Transfer Freezing Medium. After morphological analysis each embryo was digested 
with proteinase K, and the genomic DNA genotyped by PCR analysis utilising two 
sets of oligonucleotide primers as described in Materials and Methods (Fig.3, Table 
4).
One problem encountered during the genotype analysis was that embryonic DNA was 
not as easy to amplify as adult tail DNA, requiring a further 5 PCR cycles in addition 
to the 30 required for tail DNA. There was also a higher failure rate with the 
embryonic DNA. PCR using tail DNA failed approximately 5% of the time, whereas 
with embryonic DNA, it failed approximately 15-20% of the time (Fig.21). As well as 
there being less DNA in the embryonic samples, it is possible that as embryos have 
many different types of proteins expressed, and the tail is predominantly keratin, the 
embryonic proteins may bind to the DNA, and therefore interfere with the PCR. If the 
PCR failed, the DNA was cleaned by a further phenol-chloroform extraction to 
remove any extra protein, before repeating the reaction. Contamination of the samples 
was a very rare occurrence when amplifying tail DNA, but again, occurred slightly
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Figure 21 - Genotype Analysis of TG F-pi Knockout Animals by PCR.
D N A  ex trac ted  from  e m b ry o  sam ple  (A ) o r  ta ils  (B ) w as g en o ty p ed  by  PC R . E ach  
in d iv idual lan e  rep resen ts  a  separa te  PC R  reaction , am p lify ing  e ith e r  the  w ild -type  
T G F -p i  a lle le  (+), o r  the  null a lle le  (-). T h e  p ro d u ct fo r th e  + a lle le  w as 625bp , 
w h ile  the  - a lle le  w as 375 b p . (A ) - L anes 2 and  4  show  ex cep tio n a l co n ta m in a n t 
bands, a lth o u g h  e m b ry o  2 (E 2) w as g en o ty p ed  as T G F - p i+/' as th e  c o rre c t s ized  
b an d  w as p resen t and  in tense . T h e  P C R  fo r  E m b ry o  1 ( E l )  w as rep ea ted . A s can  
be seen  in  (B ), th e re  w as no  con tam in a tio n  fo r the tail D N A  PCR.
L  - 1 kb  L adder.
more often with embryonic DNA. As shown in Fig.21A (lane 2), spurious band 
contamination did occur, but this was extremely rare. More common was the 
detection of the bands for both the null and normal alleles in a single PCR product 
(Fig.21, lane 4). This should not have occurred due to the fact that the alleles were 
amplified separately in different eppendorf tubes, as described in Materials and 
Methods. This observation suggested that there was primer contamination, although it 
is also possible that there was leakage of the PCR products in the adjacent lane while 
loading the gel. However, contamination of either type was usually not a problem as 
the correct sized bands were commonly of a much stronger intensity than the 
contaminants. However, if the results were dubious, then the PCR was repeated.
3.4.2 Analysis of Embryos After Development in vivo.
To determine whether it was possible to recognise the TGF-pl+/" and TGF-pi_/_ 
embryos that would die at 9.5-11.5 dpc, 8.5 dpc embryos were first to be examined 
for abnormalities. 93 embryos were collected from TGF-pl+/,~ intercrosses, and 
analysed phenotypically. All embryos and their corresponding yolk sacs were normal, 
regardless of genotype. Therefore, the embryos destined to die were not 
morphologically discemable at this stage.
Following the lack of abnormal phenotypes in the 8.5 dpc embryos, one hundred and 
sixty-four 9.5 dpc embryos from TGF-pi+/_ x TGF-pl+/_ matings were examined. 
Analysis of the morphological appearance of the conceptuses revealed that, although 
all of the embryos per se were normal, there were a number of yolk sacs exhibiting 
abnormal phenotypes (Fig.22, Table 8). These abnormalities specifically affected the 
vasculature and haematopoietic systems. To determine whether these defects were 
restricted to TGF-pl+/_ and TGF-pi_/_ yolk sacs, and therefore represented the initial 
phenotypic effect of ablation of TGF-pi, lh  of each embryo was used for genotype 
analysis. Of the 164 embryos collected, 156 were successfully genotyped, revealing 
that there were 40 TGF-pl+/+, 78 TGF-pi+/_, and 38 TGF-pi_/_ knockout embryos; 
the expected Mendalian ratio of 1:2:1. Conclusive genotypes could not be obtained 
for the remaining 8 embryos. When the phenotypes and genotypes were compared, 17 
out of 78 TGF-pl+/ yolk sacs, and 23 of 38 TGF-pi^- yolk sacs were abnormal 
(Table 8). These values represent a ratio of 1:1.7:0.4 for the number of normal yolk 
sacs in each genotype, and corresponds with the 25% and 50% loss of TGF-pi+/_ and 
TGF-pi_/_ embryos, respectively (expected 1:1.5:0.5 cf. observed 1:1.7:0.4, P=0.18). 
This indicates that an abnormal yolk sac was probably responsible for embryonic 
lethality.
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Figure 22 - Morphological Analysis of TGF-pl Knockout Embryos.
9.5 dpc em bryos from  T G F -p i+/~ in tercrosses w ere rem oved from  the uterus and exam ined  
m o rp h o lo g ic a lly . (A ) TG F-|31+/- c o n c e p tu s  w ith  n o rm a l y o lk  sac  v a s c u la tu re  and  
haem oglobinisation. (B) T G F - p l /_ conceptuses with d isorganised vasculature, and (C) no vessels 
or blood. (D) T G F -p l+/_ yolk sac w ith a w ell-developed  vasculature, bu t severe anaem ia. (E) 
M orpho log ica lly  norm al T G F -p F /_ em bryo . A t 9 .5 -9 .7 5  dpc, the  em b ry o s  w ere u su a lly  
phenotypically norm al, regardless of the phenotype o f the yolk sac.
a - allantois; bb - branchial bars; bv - blood vessel; ec - ectoplacental cone; h - heart; lb - lim b bud; 
otv - otic vesicle; ov - optic vesicle; s - som ites; ys - yolk sac.
Scale bars : (A,D) - 600pm  ; (B,C,E) - 560pm .
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A variety of abnormal vascular and haematopoietic phenotypes were observed in both 
the TGF-pi+/_ and TGF-pi_/_ yolk sacs. The normal yolk sac at 9.5 dpc has an 
extensive, although not yet fully mature vasculature, which contains red blood cells 
(Fig.22). In contrast, many of the abnormal TGF-pi+/_ and TG F-pi/_ yolk sacs had a 
reduced number of vessels, which often appeared to be delicate and disorganised 
(Fig.22). This was often accompanied by the blood leaking out of the vessels, either 
into the yolk sac cavity, or between the endodermal and mesothelial cell layers 
throughout the yolk sac. However, the most severe phenotype was when the yolk sac 
appeared to have developed normally to approximately 8.5-9 dpc, but had failed to 
undergo vasculogenesis, with the result that, although blood islands and an extending 
corona were present, no actual blood vessels had formed (Table 8).
Anaemia was also observed in the abnormal TGF-pi+/_ and TGF-pi_/_ yolk sacs, 
either in association with, or separately from, the vasculature defect (Fig.22, Table 8). 
Some yolk sacs exhibited both defects, while others had a normal vasculature, but 
lacked red blood cells, or conversely, had many red blood cells but no vessels in 
which to contain them (Fig.22). The severity of the anaemia also varied, from the 
presence of pale blood, to a lack of red blood cells altogether.
Combining the phenotypic and genotypic data indicated that the abnormal yolk sac 
phenotypes were restricted to the TGF-pi+/_ and TGF-pi_/_ yolk sacs, and were 
therefore likely to be as a result of reduced levels of TGF-pi. 3 out of 40 TGF-pl+/+ 
embryos did appear to have delicate vessels, but the blood was still contained within 
the vessels, and showed no leakage as observed in the TGF-P+/- and TG F-pl/_ yolk 
sacs. The other 37 TGF~pi+/+ yolk sacs all had extended, strong blood vessel 
systems, which contained red blood.
3.4.3 Post-Implantation in vitro Culture of TG F-pi Knockout 
Embryos.
Although the abnormalities observed in the embryos in vivo were restricted to the 
TGF-pi+/_ and TGF-pi^- yolk sacs, some TGF-pi+/_ and TGF-pi_/_ yolk sacs were 
normal (Fig.22). Letterio et al (1994) suggested that a percentage of the embryos with 
reduced levels of TGF-pi may be rescued by maternal TGF-pi. Therefore, to test this 
theory, embryos from TGF-pi+/_ x TGF-pl+/- matings were removed at 8.5 dpc, 
before any defects were detectable, and cultured in FMP : 50% dCP for 24 hours. 
This was performed to determine if a greater percentage of the embryos developed the 
yolk sac phenotypes when removed from the exogenous maternal source of TGF-pi.
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93 embryos, from 13 matings, were cultured separately in 1ml of medium to avoid 
any possible rescue of TGF-pl+/_ or TGF-p l _/_ embryos by their TGF-pl+/+ siblings. 
After culture, the embryos and yolk sacs were morphologically assessed, before 1/2 of 
each embryo was used for genotyping, and the rest was fixed in 4% PFA, and stored 
for reference, or for histological analysis.
3.4.3.1 Morphological Analysis of Cultured Embryos.
Despite the absence of defects when the 8.5 dpc embryos were placed in culture, the 
phenotypes observed after in vitro culture were the same as those observed in vivo, 
namely a reduced number of vessels, delicate vessels, or no vessels, with or without a 
degree of anaemia (Fig.23, Table 9). These defects were, again, mainly restricted to 
the TGF-p 1+/- and TGF-p 1-/- yolk sacs, although 4 of the 34 TGF-p 1+/+ yolk sacs did 
have delicate vessels, and in one of these the blood had leaked into the yolk sac 
cavity. However, 8 out of 37 TGF-pi+/_ embryos had an abnormal yolk sac; 5 with 
delicate or disorganised vasculature, and 3 were completely devoid of vessels. Of the 
22 cultured TGF-pi■/■ embryos, there were 6 yolk sacs with delicate or disorganised 
vessels, and another 5 with no vessels at all. As for the in vivo study, anaemia was 
only observed in TGF-pi+/_ or TGF-pi_/_ yolk sacs, regardless of the presence or 
absence of vasculature defects (Table 9). In general, all embryos per se, independent 
of the genotype, were phenotypically normal after 24 hours in culture. However, 
when the yolk sac vasculature developed no further than the blood island stage, 
development of the embryo was correspondingly delayed (Fig.23).
To determine if there was an increase in the number of abnormalities in the absence 
of maternal TGF-p 1, the number of defective yolk sacs in in vivo (Table 8) and in 
cultured embryos (Table 9) was compared. There was an identical number of 
abnormal TGF-pi+/_ yolk sacs in both studies (22%), whereas there were fewer 
defective TGF-pi~/_ yolk sacs in the in vitro study (50% cf. 60%). Therefore, when 
embryos were removed from maternal TGF-p 1 and cultured in vitro, the number of 
abnormal yolk sacs did not increase. However, these results do not dismiss the 
possibility that maternal TGF-p 1 is rescuing a percentage of the embryos, but rather 
suggests that if it does transpire, then it does so before 8.5 dpc.
3.4.3.2 Histological Examination of Cultured Embryos.
For a closer examination of the yolk sacs and embryos, 10 of the 9.5 dpc TGF-pi 
knockout embryos which had been examined morphologically, were also sectioned, 
and analysed histologically. 3 TGF-p 1+/+ and 7 TGF-Pl-/_ embryos were examined.
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Figure 23 - Morphological Analysis of Cultured TGF-pi Knockout Embryos.
8.5 dpc embryos from TGF-p l +/_ intercrosses were removed from the uterus and 
cultured in FMP : 50% dCP for 24 hours. They were morphologically analysed after 
culture, followed by genotypic analysis. (A) TGF-p 1+/+ yolk sac with well-developed 
vasculature, and (B) its 9.5 dpc embryo. (C) TGF-p l+/_ conceptus with a few vessels 
which appear delicate. The blood has leaked into the yolk sac cavity. (D) TGF-p 1_/' 
yolk sac with no vessels or blood, although there is a little blood in the embryo 
proper. (E) TGF-p yolk sac with persistent blood islands indicating the delayed 
development of the yolk sac vasculature, and (F) delayed embryo dissected out from 
the yolk sac in (E).
a - allantois; bb - branchial bars; bi - blood island; bv - blood vessel; ec - 
ectoplacental cone; h - heart; lb - limb bud; s - somites; ys - yolk sac.
Scale bars : (A,C,E) - 560pm ; (B,F) - 375pm ; (D) - 450pm.
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All 3 TGF-pi+/+, and 3 of the TGF-pl_/_ yolk sacs were morphologically normal, 
while the other 4 TGF-pl_/_ yolk sacs exhibited abnormal phenotypes. For 
comparison, three 9.5 dpc NIH/Parkes embryos were also analysed. Some of the 
sections were stained with H&E, while others were utilised for BrDU analysis.
In agreement with the morphological study, the histology of the embryos per se was 
normal, regardless of genotype. However, variations were observed in the yolk sacs 
(Fig.24, 25). The mesothelial and endodermal layers of the NIH/Parkes yolk sacs 
were closely apposed, except in small regions where they were separated by the 
endothelial cells of a blood vessel. 2 of the 3 TGF-p 1+/+ yolk sacs, and all 3 of the 
phenotypically normal TGF-p l _/_ yolk sacs also exhibited this close apposition. 
However, all of the sections of the abnormal TGF-p 1-/- samples exhibited shearing of 
the yolk sac layers, especially in regions where the endoderm was buckled. The 
buckling probably occurred as a result of the embedding process, and was found in 
embryo sections of all genotypes. There were also large regions where the yolk sac 
was not wrinkly, but the layers had separated regardless. When the histological and 
morphological data were compared, these large gaps were found specifically in the 
yolk sacs with delicate vessels in which the blood had leaked out and flowed free 
between the endoderm and mesothelial cell layers.
The data above suggested that the connections between the different cell types were 
weakened by the lack of TGF-pi, either directly or indirectly. Some of the cell 
connections may have been relatively strong, but not strong enough to withstand the 
wrinkling of the yolk sac during embedding, whereas the observation of sheared 
regions in areas where there was no wrinkling suggests that some of the cell 
connections had already broken in vivo. Therefore, the TGF-pl+/_ and TG F-pi/_ 
embryos that survive gestation may do so because the cell connections in these yolk 
sacs remain strong, and keep the different cell layers closely apposed.
Analysis of the morphological and histological data for the abnormal TGF-p 1+/+ yolk 
sac indicated that this yolk sac was slightly underdeveloped in comparison to the 
other samples. It is therefore possible that the cell connections were also 
underdeveloped, with the result that the cell layers sheared during the embedding 
process.
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EndotheliumEndoderm
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Blood Cell Progenitor
Figure 24 - The Layers of the Yolk Sac of a 9-9.5 dpc Mouse 
Embryo.
Schem atic diagram  o f the 9-9 .5  dpc yolk  sac in cross section. The 
three cell layers o f the yolk sac are shown, and labelled, w ith the blood 
progenitor cells w ithin the vessel.
A.
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m
Figure 25 - Histological Analysis of 9.5 dpc Yolk Sacs.
T he structure o f the yolk sacs in the T G F -p l knockout conceptuses was analysed from 
haem atoxylin  and eosin stained sections. (C) TGF-|31+/+ yolk sac with the m esothelial 
and endoderm al layers c lo se ly  apposed , excep t w here there  is a vessel. (A) An 
abnorm al T G F -p i_/'  yo lk  sac w here the layers are not c lo se ly  apposed , and the 
endoderm  has buckled. (B) T G F - p l /_ yolk sac in w hich the layers have separated  
w ithout buckling o f the endoderm , and created very large vascular channels 
b - blood cell; e - endoderm al cell; et - endothelial cell; m - m esothelial cell; v - vessel; 
vc - vascular channels.
Scale bars : (A,B,C) -75 pm.
3.4.4 Bromo-Deoxy Uridine (BrDU) Labelling of TGF-pi Knockout 
Embryos.
From in vitro studies, TGF-pi has always been considered to be an inhibitor of cell 
proliferation (Moses etal, 1985; Ohta etal, 1987). It would therefore be expected that 
depletion of the protein would result in increased proliferation. However, by 
morphological analysis, neither the TGF-pl+/_ or TGF-pi_/_ embryos or yolk sacs 
appeared hyperplastic. To verify this, BrDU labelling was utilised to examine the cell 
proliferation rates. 36 embryos from 5 TGF-pi+/_ x TGF-pl+/_ matings were removed 
from the uterus at 9.5 dpc, and 1 pi of 10mmol/l BrDU was injected directly into the 
yolk sac cavity using a pulled micropipette. The embryos were then cultured for 1 
hour in FMP : 50% dCP, enabling the BrDU to be incorporated. After culture, they 
were analysed phenotypically before half of the embryo was removed for genotyping, 
and the remainder of the embryo plus yolk sac was processed for sectioning.
The rate of DNA synthesis in the cells of the yolk sac, and in two types of epithelial 
cells in the embryo was analysed in 3 normal TGF-pi+/+ and 3 phenotypic TGF-pl_/_ 
samples.
3.4.4.1 Yolk Sac Cells.
At 9.5 dpc the yolk sac consists of three different cell types (Fig.24). The endodermal 
cell layer is the outer layer of the yolk sac. This is closely apposed to the mesothelial 
cell layer, which lines the yolk sac cavity. In certain regions of the yolk sac, this close 
apposition is interrupted by the presence of endothelial cells forming the vessels of 
the yolk sac (Fig.26). To examine the cell proliferation rate in the yolk sac, all of 
these cell types were initially counted together, with approximately 1000 cells 
counted per yolk sac (ie. 3000 per genotype). On comparison of the number of BrDU 
stained cells in the different genotypes, it was noted that the proliferation rates of 
TGF-pi+/+ and TGF-pl_/_ yolk sacs were not significantly different (Fig.27, 
Appendix A6). However, counting all of the cells together may have masked a 
phenotypic difference in only one cell type. Therefore, it was decided to examine 
each cell type individually.
Approximately 1500-3000 endodermal, mesothelial and endothelial, or endothelial 
cells alone were counted in the TGF-pi+/+ and the TGF-pi"^* yolk sacs (Fig.26, 27, 
Appendix A6). The number of cells stained for BrDU in each cell type was compared 
between the genotypes using a two-sample students t-test. The results indicated that 
there was no significant difference (P<0.05) in the rate of cell proliferation in any of
72
Figure 26 - BrDU Incorporation in TGF-pi Knockout Conceptuses.
Cell proliferation rates were exam ined in T G F -p l+/+ and T G F -p F /_ em bryos and yolk sacs using 
BrD U  incorporation  and stain ing  techniques. The ectoderm  and  the neural tube ep ithelia  in the 
em bryo p roper, and all three cell types in the yolk sac w ere analysed. (A) T G F -p i+/+ em bryo 
show ing ex tensive  sta in ing  in m any tissue types, w hich w as a lso  observed  in the T G F -p i_/_ 
em bryo (C). The T G F -p l+/+ (D) and T G F -p i '/_ (B) yolk sacs also  had com parab le  am ounts of 
staining.
e - ectoderm al cell; et - endothelial cell; f - foregut; m - m esothelial cell; nt - neural tube.
Scale bars : (A,C) - 150pm  ; (B ,D) - 75pm .
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Figure 27 - Cell Proliferation Rate in T G F -p i+/+ and T G F-pi_/- Embryos 
And Yolk Sacs.
T o determ ine w hether there was a difference in the cell p roliferation rate in the T G F - p i_/_ 
em bryos due to  the ab lation  o f a po ten t growth inh ib ito r, the DNA synthetic  ra te  w as 
m easured by the incorporation of BrDU. The num ber o f stained cells in the em bryo o r yolk 
sac was com pared betw een 3 T G F ~ pi+/+ a n d 3 T G F-pH * sam ples. In the yolk sac (A ), the 
cells were analysed in 4  different ways - by counting all cell types together, the m esothelial 
and endothelial cells together, the endoderm al cells alone, or the endothelial cells alone. In 
the em bryo (B), tw o types of epithelial cells were exam ined - the surrounding ectoderm al 
cells, and the neural tube epithelial cells. Approximately 3000 cells were counted per cell type 
per genotype.The colum ns in the graph show the m ean percentage o f stained cells from  the 3 
em bryos o f each genotype. The standard error of the m ean is shown by the vertical bars.
the three cell types in TGF-P 1+/+ and TGF-pi‘/_ yolk sacs (Appendix A6). This was 
especially important for the endothelial cells as it suggests that although these were 
the cells affected in the TGF-p T/_ yolk sacs with defective vasculature, the phenotype 
was not due to abnormal cell proliferation.
The above BrDU data suggests that TGF-pi does not have any growth inhibitory 
action on any of the yolk sac cell types at this stage of development. Statistically, the 
data for the TGF-p 1+/+ and TGF-p I 1' yolk sacs was not significantly different, and in 
all of the cell types examined there was actually slightly less proliferation in the TGF- 
p i-/- yolk sacs than in the TGF-pl+/+ yolk sacs. The BrDU analysis therefore 
coincides with the morphological data, and shows that hyperplasia of the yolk sac 
does not occur in the absence of TGF-pi. It also indicates that the defective 
phenotypes are not a result of abnormal cell proliferation.
3.4.4.2 The Embryo Proper.
As was found for the yolk sacs, hyperplasia was not observed in any of the embryos 
when they were examined morphologically or histologically, regardless of genotype, 
or phenotype of its corresponding yolk sac. To support this, cellular proliferation was 
assessed by BrDU incorporation in TGF-pl+/+ and TGF-p embryos. Two 
epithelial cell types were examined, namely the ectoderm cells surrounding the 
embryo, and the neural tube epithelia (Fig. 26, 27). For each of the 3 TGF-p 1+/+, and 
the 3 TGF-pi‘/_ embryos, 1000 cells of each type were counted, and the results 
analysed statistically (Appendix A7). There was no significant difference in 
proliferation rates of either of the cell types between the two genotypes.
These results agree with the descriptive analysis for the lack of hyperplasia in the 
phenotypic TGF-p T/_ embryos, and again asks whether TGF-p 1 has an growth 
inhibitory role in the developing embryo. It may be, however, that TGF-p 1 has an 
inhibitory effect in the embryo at a later stage in development.
3.4.5 Culture of TGF-pi Knockout Embryos in FMP : Rat Serum.
As mentioned previously (section 3.2.1), rat serum contains a substantial amount of 
TGF-pi. In connection with the hypothesis that maternal TGF-p 1 rescues a 
percentage of abnormal TGF-pl knockout embryos in utero (Letterio etal, 1994), this 
project examined whether serum TGF-pl could rescue the embryos destined to die. 
Seventy-four 8.5 dpc embryos from 9 TGF-pi+/_ x TGF-pi+/- matings were cultured 
in FMP : 50% rat serum for 24 hours before morphological analysis. 19 control
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Parkes/NIH embryos from 4 litters were simultaneously cultured in FMP : 50% rat 
serum.
The results were surprising (Table 10). Contrary to the rat serum having a beneficial 
effect on the embryos, it actually induced more abnormalities (Fig.28). After culture, 
46 of the 75 embryos were defective (Table 10). The abnormal embryonic phenotypes 
included stunted development, hydrocephaly, anencephaly, and severe necrosis. 48 of 
the 75 yolk sacs were also abnormal (Fig.28, Table 10); the phenotypes including 
disorganised vessels, bubbles in the yolk sac, and a reduced number of vessels. These 
abnormalities were observed in conceptuses of all genotypes, thereby suggesting that 
they might be artefactual. However, the control Parkes/NIH embryos were also 
cultured in FMP : 50% rat serum, and all 19 were normal after 24 hours in culture 
(Fig.28). This result suggested that the FMP : 50% rat serum was not generally toxic 
to embryos, but that it specifically affected the TGF-pl knockout embryos.
3.4.6 Culture of TGF-pi Knockout Embryos in FMP : 50% dCP 
plus TGF-pi.
Subsequent to the results obtained when TGF-pi knockout embryos were cultured in 
FMP: 50% rat serum, an investigation was performed to determine whether the TGF- 
P in the rat serum was responsible for the observed increase in embryonic lethality. If 
embryonic abnormalities were not observed, these experiments would also investigate 
whether rTGF-pl could rescue any of the phenotypic embryos.
To determine a tolerable concentration of rTGF-pi, ninety-two 8.5 dpc embryos from 
15 Parkes/NIH matings were cultured in FMP: 50% dCP + variable concentrations of 
TGF-pi (1000-25pg/ml) for 24 hours. Only the embryos cultured with 35pg or 
25pg/ml rTGF-pi survived the culture period. Therefore, the medium chosen to 
culture embryos from TGF-p l +/_ x TGF-p l +/_ matings was FMP : 50% dCP + 
25pg/ml TGF-pl.
Fifty-one 8.5 dpc embryos from 6 TGF-pi+/_ x TGF-p l +/_ litters were cultured for 24 
hours. During the culture period, 49 of the 51 embryos had died, regardless of 
genotype. Both the embryos and the yolk sacs exhibited defects (Fig.29, Table 11). 
To examine whether the 25pg/ml of rTGF-pi was toxic to the TGF-pl knockout 
embryos, a further 19 TGF-pi+/_ intercross embryos were cultured in FMP: 50% dCP 
+ lOpg/ml TGF-pl. 11 of these embryos died (Table 11). Genotype analysis 
identified 5 TGF-p l'/_, 3 TGF-p 1+/-, and 3 TGF-p 1+/+ embryos, indicating that death 
was indiscriminate of genotype.
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Figure 28 - Culture of TGF-pi Knockout Embryos in FMP : 50% Rat Serum.
A ttem pts w ere m ade to  rescue the abnorm al phenotypes by cu ltu ring  8 .5  dpc em bryos in a 
m edium  contain ing  T G F -p l. (A) N orm al Parkes/N IH  em bryo after cu lture  in FM P : 50%  rat 
serum. (B) T G F-p  1+/" conceptus after culture. The yolk sac was bubbly although there were som e 
vessels present, and the em bryos developm ent was delayed. (C) A severely necrosed T G F-p  l _yL 
em bryo. T he yolk sac vasculature developed to the blood island stage, then stopped. (D) T G F- 
p i +/+ em bryo, delayed by approxim ately 0.5-0.75 days. Note the persistent open headfolds. 
b - bubble; bb - branchial bar; bi - blood island; bv - blood vessel; h - heart; lb - lim b bud; n - 
necrotic tissue; ohf - open headfolds; ov - optic vesicle; s - som ite; ys - yolk sac.
Scale bars : (A,B) - 500pm  ; (C,D) - 365pm .
Yolk Sac 
Phenotypes
Number of Yolk 
Sacs with 
Phenotype 
(Total = 75).
Embryo
Phenotypes
Number of 
Embryos with 
Phenotype 
(Total = 75).
Normal 27 (36%) Normal 29 (39%)
Necrosis 5 (7%) Necrosis 28 (37%)
Bubbly 10 (13%)
Stunted
Development 13 (17%)
“Skeletal” 3 (4%) Hydrocephaly 1 (1%)
Disorganised
vessels 7 (9%) Anencephaly 5 (i%)
Reduced or no 
vessels 25 (33%)
Anaemia 1 (1%)
Table 10 - Culture of TGF-p 1 Knockout Embryos in FMP : 50% Rat Serum.
8.5 dpc TGF-pi knockout embryos were cultured in FMP : 50% rat serum for 24 hours to 
examine whether the TGF-p in the serum could rescue any of the TGF-p l +/_ or TGF-pl^- 
embryos destined to have an abnormal yolk sac. Instead of rescuing the embryos, the rat 
serum appeared to induce more abnormalities, regardless of genotype, with the embryos 
per se also affected. The defects and the number of samples which exhibited each 
phenotype are listed in the table above.
“skeletal” = transparent yolk sac, with no vessels, but thin processes attaching the yolk sac 
to the embryo. Looked like thin, long bones, therefore “skeletal”.
Figure 29 - Culture of TGF-pi Knockout Embryos in FMP : 50% dCP + TGF-pi.
8.5 dpc em bryos were cultured for 24 hours in FM P : 50%  dC P + 25 pg/ml T G F-p 1. (A,B) 
N orm al P arkes/N IH  em bryo  a fte r  cu ltu re. (C) T G F -p  1+/+ concep tu s w ith  abnorm al 
vasculature. There are no proper vessels, but connections throughout the yolk  sac. (D) A 
severely  necrosed T G F -p i+/_ em bryo. T his yolk  sac exhib its the “ ske le ta l” phenotype, 
where thin processes attach the yolk sac to the em bryo.
bb - branchial bar; be - blood corona; bv - blood vessel; ec - ectoplacental cone; h - heart; 
lb - lim b bud; n - necrotic em bryo; ov - optic vesicle; sp - “ skeletaF’processes; ys - yolk 
sac.
Scale bars : (A,C,D) - 5 0 0 pm  ; (B) - 365pm .
A. B.
Embryo
Phenotypes
Number of Embryos 
with Phenotype / 
Medium
25pg/ml
TGF-pi
lOpg/ml
TGF-pi
Normal 2
(4%)
8
(42%)
Necrosis 38
(74% )
11
(58%)
Stunted
Development 9
(8% )
5
(26%)
Hydrocephaly 1
(2%)
1
(5%)
Anencephaly 4
(8%)
Ballooned
Allantois 1
(2% )
Yolk Sac 
Phenotypes
Number of Yoik Sacs 
with Phenotype / 
Medium
25pg/ml lOpg/ml
TGF-pi TGF-pi
Normal 0 4
(0%) (21%)
Necrosis 2 3
(4%) (15%)
Bubbly 16 4
(31%) (21%)
“Skeletal” 19 5
(37%) (26%)
Disorganised
vessels 2 3
(4%) (16%)
Reduced or no
vessels 42 4
(82%) (21%)
Anaemia 1 2
(2%) (11%)
Table 11 - Culture of TGF-pi Knockout Embryos in FMP : 50% dCP + rTGF-pi.
Embryos were cultured in FMP : 50% dCP + rTGF-pl to investigate whether the defects 
observed after culture in FMP : 50% rat serum were as a result of the TGF-pl present in the 
serum. If the embryos did not develop abnormally, it would also examine if rTGF-pl could 
rescue any of the phenotypic embryos. (A) Fifty-one 8.5 dpc embryos from TGF-pi+/“ 
intercrosses were cultured for 24 hours in FMP : 50% dCP + 25pg/ml TGF-pi, before 
morphological examination. The embryos and yolk sacs exhibited a range of abnormalities, 
regardless of genotype. To examine whether 25pg/ml rTGF-bl was toxic to the embryos, the 
concentration added to the medium was decreased to lOpg/ml (B). 19 embryos were cultured in 
this medium, and after culture they also exhibited defects. The range of phenotypes and their 
frequency after culture in both FMP : 50% dCP + 25pg/ml, and lOpg/ml rTGF-p 1 is shown in 
the table above.
“skeletal” = transparent yolk sac, with no vessels, but thin processes attaching the yolk sac to 
the embryo. Looked like thin, long bones, therefore “skeletal”.
These results show that the addition of very small amounts of TGF-pi to the culture 
medium of 8.5 dpc TGF-pl knockout embryos does not rescue any embryos, but 
rather that the exogenous TGF-pi is detrimental to their development. The range of 
abnormal phenotypes was the same as that observed when the embryos were cultured 
in FMP : 50% rat serum, suggesting that TGF-p may be the causative factor.
3.4.7 An Investigation to Determine the Reason for Embryonic 
Lethality in Cultured TGF-pi Knockout Embryos.
Studies were performed to investigate why embryos from TGF-pi^' intercrosses died 
when cultured in FMP : 50% rat serum, or FMP: 50% dCP + 25pg/ml TGF-p 1. There 
were two possibilities. Either gestation in a TGF-pl +l~ mother conferred a higher 
sensitivity to TGF-p 1 in the embryos than gestation in a TGF-p 1+/+ mother, or the 
genetic background of the embryos endowed a susceptibility to TGF-pl. If embryos 
gestated in a TGF-pi+/_ mother did have increased TGF-pi sensitivity, then TGF- 
P l +l+ intercross embryos would develop normally in FMP: 50% rat serum and FMP: 
50% dCP + 25pg/ml TGF-pl. However, if the genetic background of the TGF-pi 
knockout mice was responsible, then the embryos from TGF-p l +l+ intercrosses would 
also incur abnormalities, and die in culture. Therefore, sixty-one 8.5 dpc embryos 
from 6 TGF-p l +l+ intercrosses were cultured in FMP: 50% rat serum, or FMP : 50% 
dCP + 25pg/ml TGF-pi. FMP : 50% dCP was the control medium. A further forty- 
one 8.5 dpc embryos from TGF-pi+/_ intercrosses were cultured to directly compare 
with the TGF-pl+/+ intercross embryos, alongside 15 control Parkes/NIH embryos. 
Embryos from each mating were divided between all three media to account for day- 
to-day variation.
As expected, the Parkes/NIH embryos developed normally, while the number and 
severity of the abnormalities observed in the TGF-p l +l~ intercross embryos after 
culture in the different media was as before (Table 10, 11).
Of the TGF-p 1+/+ embryos, eighteen 8.5 dpc embryos were cultured in FMP : 50% 
dCP (Fig.30, Table 12). After 24 hours, all were phenotypically normal, except for 2 
which were slightly necrotic. When FMP : 50% rat serum was used, 9 out of 17 
embryos were abnormal after culture. However, as with the TGF-p l+l~ intercross 
embryos, more abnormal embryos resulted from culture in FMP : 50% dCP + 
25pg/ml TGF-pi. Only 4 of the 17 cultured embryos could be classified as normal, 
while the other 13 were defective. The phenotypes were similar to those observed in 
the embryos from TGF-pl+l~x TGF-pl+/_ matings (Fig.30, Table 12).
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Figure 30 - Culture of Embryos from TGF-|31+/+ Intercrosses.
8.5 dpc em bryos from  T G F -p i+/+ x TG F-|31+/+ m atings w ere cu ltured  for 24  hours in 
FM P : 50%  rat serum , o r FM P : 50%  dC P + 25pg/m l T G F -p i. (A) D issected  yolk sac 
w ith  com ple te ly  d iso rgan ised  vascu la tu re , and (B) delayed  em bryo , e q u iv a len t to 
approx im ately  9 dpc, a fter cu lture in FM P : 50%  rat serum . N ote the persis ten t open 
headfolds. (C) Severely delayed em bryo, approxim ately 8 .5-8.75 dpc, and (D) extrem ely 
necrotic yolk sac and em bryo after culture in FM P : 50% -dCP + 25pg/m l TG F-P 1. 
be - blood channel; bv - blood vessel; ec - ectoplacental cone; h - heart; hf - headfolds; n - 
necrotic em bryo; s - som ite; vv - vitelline vessel; ys - yolk sac.
Scale bars : (A) -300pm  ; (B ,C ,D ) - 450pm .
F
M
P
: 5
0%
 
dC
P 
+ 
25 
pg
/m
l 
T
G
F-
pl
.
(T
ot
al
 n
o. 
of 
em
br
yo
s 
cu
ltu
re
d=
17
)
4 
(2
4%
)
13 
(7
6%
)
FM
P 
: 5
0%
 
Ra
t 
Se
ru
m
(T
ot
al
 n
o. 
of 
em
br
yo
s 
cu
ltu
re
d=
17
)
St'w'
00 9 
(5
3%
)
FM
P 
: 5
0%
 
dC
P
(T
ot
al
 n
o. 
of 
em
br
yo
s 
cu
ltu
re
d=
18
)
16 
(8
9%
) /"■N#
W
<N
cd
Id 0tH
a oVh 0O wo
£ <
cd
Cfl
4JU3■M
3u
o
t*.a
aH
QQ.I
fe
0
H
+
+
CO.1
fc
O
H
(11 « 34—> • •-<
QQ.
GO.
a
of 
ge
sta
tio
n 
in 
aT
G
F
-p
l+/
_ 
m
ot
he
r, 
or 
th
eir
 g
en
eti
c 
ba
ck
gr
ou
nd
. 
M
an
y 
of 
the
 
TG
F-
p 
1+
/+ 
em
br
yo
s 
cu
ltu
re
d 
in 
thi
s 
ex
pe
ri
m
en
t 
we
re
 
als
o 
ab
no
rm
al
 a
fte
r 
cu
ltu
re
 
in 
FM
P: 
50%
 
rat
 s
er
um
, o
r 
FM
P: 
50%
 
dC
P 
+ 
25
pg
/m
l 
TG
F-
p 
1. 
Th
e 
tab
le 
ab
ov
e 
lis
ts 
the
 r
at
io
 
of 
no
rm
al 
ve
rs
us
 a
bn
or
m
al
 e
m
br
yo
s 
aft
er
 c
ult
ur
e 
in 
eac
h 
m
ed
iu
m
. 
Th
is 
in
di
ca
ted
 
tha
t 
the
 
ge
ne
tic
 
ba
ck
gr
ou
nd
 
of 
the
 
T
G
F-
pl
 
kn
oc
ko
ut
 e
m
br
yo
s 
co
nf
er
re
d 
a 
se
ns
iti
vi
ty
 
to 
cu
ltu
re
 
in 
th
ese
 m
ed
ia
. 
FM
P: 
50%
 
dC
P 
wa
s 
the
 
co
nt
ro
l 
me
diu
m 
in 
wh
ich
 
em
br
yo
s 
fro
m 
bo
th 
cr
os
se
s 
de
ve
lop
ed
 
no
rm
al
ly
.
This data suggests that the increased number of defective phenotypes observed in 
TGF-pi knockout embryos after culture in FMP : 50% rat serum, or FMP : 50% dCP 
+ 25pg/ml TGF-pi were as a result of their genetic background. The successful 
culture of the Parkes/NIH embryos in each of the media, demonstrated that the FMP: 
50% rat serum, or FMP : 50% dCP + 25pg/ml TGF-pl media were not inducing the 
defects themselves.
3.5 Analysis of TGF-|32, TGF-^3, and Flk-1 in the 
TGF-^1 Knockout Embryos.
As mentioned in the Introduction, all three TGF-ps have a high degree of structural 
and functional similarity, especially TGF-pi and TGF-P3. It was therefore postulated 
that TGF-P2, or TGF-P3 may assume the role of TGF-p 1 in the transgenic TGF-p 1 
knockout embryos, thereby rescuing a number of the TGF-pl+/_ and TGF-pi_/_ 
embryos. An increase in the amount of TGF-P2 and/or TGF-p3 might be required to 
perform this additional role. The RNA levels of the two TGF-p isoforms were 
therefore analysed in the knockout embryos, using Northern analysis, and the Reverse 
Transcription Polymerase Chain Reaction (RT-PCR).
These methodologies were also used to examine the expression of Flk~l, a tyrosine 
kinase receptor for vascular endothelial cell growth factor (VEGF) which is 
specifically expressed in endothelial cells (Ferrara & Henzel, 1989). This was 
performed to examine whether the vascular abnormality observed in the TGF-pi 
knockout yolk sacs was a result of defective endothelial cell differentiation.
When the RNA from individual half embryos of 8.5 or 9.5 dpc, and individual whole 
yolk sacs were analysed by Northern, TGF-p and Flk-1 transcript levels were below 
the level of detection. Therefore, to obtain transcript levels that could be detected by 
Northern blotting, several RNA samples from genotypically and phenotypically 
identical embryos were pooled. Three 9.5 dpc TGF-p l +/_ x TGF-p 1+/* litters were 
used, resulting in 10 TGF-pl+/+, 10 TGF-p l +/_, and 8 TGF-pi_/- embryos. Half the 
embryo was used for genotyping, and the other half for RNA extraction. Three half 
embryo or 3 yolk sac RNA samples were then combined and subjected to Northern 
blot analysis, as described in Materials and Methods.
Bands were observable when the blot was probed with TGF-p3. The 3.5kb TGF-p3 
mRNA transcript was identified, and found in both embryo and yolk sac samples of 
all genotypes (data not shown). It was observed that neither the yolk sac or embryo of
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any genotype or phenotype had increased levels of TGF-|33, suggesting that this 
isoform was not upregulated in response to a decrease in TGF-p 1. However, the 
phenotypic TGF-pi_/‘ samples exhibited slightly reduced TGF-P3 transcript levels in 
comparison with the other samples. The level of RNA present in each sample was 
therefore examined using 7s RNA.
7s RNA is normally ubiquitous and abundant in all cells. When the blot was probed 
with 7s RNA, it was noted that the phenotypic TGF-p 1-/- embryos and yolk sacs 
contained considerably less 7s RNA than the other genotypes (Fig.31), thereby 
explaining the reduction in TGF-p3 transcript levels also found in these samples. The 
reduction in the level of 7s RNA in the phenotypic TGF-p l _/_ samples was observed 
in a further 2 Northern blots containing individual half embryo, and yolk sac RNA. 
This may have been due to an increase in cell death within these embryos, or the 
conceptuses could have been of a smaller size.
Due to the fact that Northern methodology was unable to detect TGF-P2 or Flk-1 
transcripts, an attempt was made using RT-PCR. This method enables the detection of 
a transcript that is present in very small amounts. Primers were designed specific for 
the transcript of interest (Table 4). RT-PCR was also performed for TGF-p3 to 
consolidate the Northern analysis, and for GAPDH. GAPDH transcripts are present in 
equal amounts in most cell types, and therefore can be used as a control.
To detect the expression of the different mRNA transcripts in embryos or yolk sacs, 9 
TGF~pi+/+, 27 TGF-pi+/_, and 14 TGF-P l~/_ conceptuses were obtained from 6 TGF- 
p i+/" x TGF-p 1+/- matings. These samples were treated like those for the Northern 
analysis to obtain pooled RNA samples, before reverse-transcribing and using in the 
RT-PCR, as described in Materials and Methods. The RT-PCRs were performed 
twice.
When the RT-PCR products were analysed after electrophoresis in an agarose gel, the 
results indicated that there was no difference in TGF-P2 mRNA levels between the 
TGF-pi knockout embryos or yolk sacs of different genotypes or phenotypes 
(Fig.32). This suggested that TGF-P2 was not up-regulated in response to a decrease, 
or the absence of TGF-pi in the TGF-pi knockouts. The RT-PCRs for TGF-p3 and 
for GAPDH both failed.
Interestingly, the results for Flk-1 strongly suggested that there was a difference in 
Flk-1 expression between the samples (Fig 33). However, instead of a difference in 
the phenotypic yolk sacs, as was expected, the expression levels were found to differ
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Figure 31 - Detection of 7s RNA.
T o  be a b le  to  d e te c t TG F-j32, T G F -p 3 , o r  Flk-1 t ra n s c r ip ts  in  th e  T G F - p i  
k n o ck o u t em b ry o s, o r yolk sacs by  N o rth ern  a n a ly s is  o r P C R , the  R N A  from  3 
1/2 em b ry o s, o r 3 yo lk  sacs had to  be com bined . C o m b in ed  R N A  sam p les  w ere  
o b ta in e d  fro m  c o n c ep tu ses  o f  lik e  g e n o ty p e  a n d  p h e n o ty p e . T h e  p h o to g ra p h  
above show s an  au to rad iograph  o f a  N o rth ern  b lo t co n ta in in g  the co m b in ed  R N A  
sam p les  p ro b ed  w ith  7s RN A. T h is  w as p e rfo rm ed  to  en su re  tha t the  R N A  w as 
p resen t, and  c o u ld  be de tec ted . N o te  the  d e c re a se d  lev e ls  o f 7 s  R N A  in  the  
pheno typ ic  T G F -p l  /_ em bryo  and  y o lk  sac sam ples.
+ P  - A bnorm al yo lk  sac phenotype.
-P  - N orm al y o lk  sac phenotype.
E - 1/2 E m b ry o  sam ples.
Y S -Y o lk  Sac Sam ples.
G eno type + / +  + / — + / — —/ — —/ —
P henotype 1-P -P1 + P  + P ' '-P  -P ' '+P  + P ' ' P P '
m
^  443  bp
G eno type + / +  + / — + / — —I — —I — B .
P henotype -P -P + P  ' + P 11-P * - P 1 + P  ' + P 1 ‘-P ' -P '
4 4 3  bp
Figure 32 - TGF-p2 RT-PCR with Embryo and Yolk Sac RNA.
T he co m b in ed  R N A  from 9 .5  dpc T G F - p 1 kno ck o u t em bryos, o r y o lk  sacs 
w as rev e rse-tran scrib ed  befo re  u sin g  in  the  PC R . T h e  p h o to g rap h s  ab o v e  sh o w  the  
resu lts  o f  one such  PCR fo r T G F -p 2 . T h e re  w ere  tw o  sam p les  o f  e a c h  g en o ty p e  p lus 
p h en o ty p e  fo r bo th  em bryos (A ) an d  y o lk  sacs (B ). T h e  tra n sc rip t s iz e  w as 4 4 3 bp. 
T he d iffu se  bands at the bottom  o f  the  p h o to s  are  excess p rim ers.
+P - Abnormal yolk sac phenotype.
-P - Normal yolk sac phenotype.
G eno type
P heno type
+ /+  + / — + / — —/ — _ / _
i  ^ 11 I ■■■ - ^ - T — !— ■ r - L - .
-P  -P  + P  +P -P  -P  + P  + P  -P -P
A.
4 6 9  bp
G eno type
P heno type
+ / +  + / -  + / — / -  - / -
j_______ii ----- 1 i----------- 1 r
-p  -P  + p  + p  -P  -P  + p  + p  -P  -p
I I I I I I
B
4 6 9  bp
Figure 33 - Flk-1 RT-PCR with Embryo and Yolk Sac RNA.
T h e  c o m b in e d  R N A  fro m  9 .5  d p c  T G F -P  1 k n o c k o u t e m b ry o s , o r  y o lk  sacs  w as  
re v e rs e - tra n s c r ib e d  b e fo re  u s in g  in  th e  P C R . T h e  p h o to g ra p h s  a b o v e  sh o w  the  
re su lts  o f  o n e  su ch  P C R  fo r  the  e n d o th e lia l ce ll re c e p to r  ty ro s in e  k in ase , Flk-1. 
T h e re  w e re  tw o  R N A  sam p les  o f  each  g en o ty p e  p lus p h e n o ty p e  fo r bo th  em b ry o s  
(A ) an d  y o lk  sacs  (B ). T h e  tran sc rip t s ize  w as 469bp . T h e  in ten se  d iffu se  ban d s a t 
the  b o tto m  o f  the  p h o to g rap h s a re  p robab ly  p rim er d im ers.
+P - Abnormal yolk sac phenotype.
-P - Normal yolk sac phenotype.
in the embryos. The RT-PCR products showed a reduced Flk-1 expression in the 
TGF-pl-/- embryos that had been contained within a phenotypic yolk sac. All other 
embryos, had approximately equal amounts, regardless of their genotype, or the 
phenotype of their yolk sac. Some of the yolk sac samples perse also showed reduced 
Flk-1 transcript levels, but these were not consistent with genotype or phenotype, and 
were therefore ambiguous (Fig.33)
The major quandary with the Flk-1 results is the difference in the TGF-J31-/- embryos 
per se, which do not have a phenotype, but no consistent difference in the phenotypic 
yolk sacs. This is also in disagreement with earlier results from Dr.M.Dickson, who 
found a difference between the expression of Flk-1 in the yolk sacs of different 
genotypes by whole-mount in situ hybridisation (Dickson et al, 1995). However, as 
for the RT-PCR, Dr.M.Dicksons experiments were performed only twice, and would 
need to be repeated to attain significant numbers and results. One further difference 
between Dr.M.Dicksons results and the RT-PCR results found in this study was the 
age of the conceptuses. Dr.M.Dickson examined 8-8.5 dpc embryos, whereas the RT - 
PCR utilised 9.5 dpc embryos.
3.6 Maternal or Paternal Imprinting of TGF-pi.
Genomic imprinting is the specific inactivation of the maternal or paternal copy of a 
gene. Imprinted genes identified so far include Igf2, Igf2r, H19, and insl and ins2 
(DeChiara et al, 1991; Bartolome et al, 1991; Giddings et al, 1994). A gene may be 
imprinted in all cells of the body, or only in a specific tissue, as is the case with 
insulin 1 and 2, which are imprinted only in the yolk sac (Giddings etal, 1994).
A number of observations on the TGF-pi knockout mice suggested that TGF-pl 
might also be imprinted. When a female TGF-pi+/_ was crossed with a male TGF- 
p l+/+, the ratio of +/- : +/+ offspring was 0.8 : 1. However, the offspring of the 
reciprocal cross were in the ratio of 1 : 1 (Dickson\etal, 1995). This suggested that 
the paternal copy of the TGF-pi gene was imprinted or there was a maternal 
biological effect in TGF-p 1 females. The fact that the abnormal phenotypes observed 
in the TGF-p 1+/- and TGF-pi-/- embryos were restricted to the yolk sac, suggested 
that, like insl and ins2, TGF-pi may be imprinted specifically in the yolk sac. To 
investigate these hypotheses, reciprocal male-female crosses were used to determine 
whether the gene was imprinted on the maternal or paternal allele. Seven 9.5 dpc 
embryos were removed from a female TGF-pi+/+ x male TGF-p 1+/- mating, and 8 
from a male TGF-pi+/+ x female TGF-p 1+/- mating. Half of each embryo was used
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for genotyping, whilst RNA was extracted from the other half embryo and from 
individual yolk sacs. Each embryo and yolk sac RNA sample was then subjected to 
Northern blot analysis, as described in Materials and Methods. The 2.7kb TGF-pi 
transcript was detected in embryo and yolk sac samples of both crosses (Fig 34) 
suggesting that TGF-p 1 is not imprinted, either throughout the conceptus, or 
specifically in the yolk sac. However, Northern analysis could not exclude the 
possibility of cell-type specific imprinting in a small population of cells.
The reason for different +/-: +/+ ratios in reciprocal crosses must therefore be due to 
a biological maternal effect. This is most likely to be a reduction in circulating levels 
of TGF-p 1 in the TGF-p l +/_ mother in comparison to the TGF-p 1+/+ mother. This 
could be examined by analysing TGF-pi levels in the serum of these animals by 
CCL64 assay.
79
d V  X ?  + / +
A.
G eno type +/+ +/+ + /- + /- +/+ 
1 1 1 1 1
Sam ple i i iYS E YS E YS E YS E YS E
2 .7  kb.
¥ +/- c? +/+
B
G eno type +/+ +/+ 
1 1
+ /- + /-  
i i
Sam ple ' y s  e m y s  e " y s  e 1 YS E’
2.7  kb.
Figure 34 - TG F-pi Imprinting.
T h e  R N A  from  in d iv idual 1/2 em b ry o s (E ) o r th e ir  y o lk  sa cs  (Y S ) w as  p robed  
w ith  a  T G F -P  1 cD N A  to  d e te rm in e  if  th is  gene  w as im p rin ted . C o n c e p tu se s  
fro m  re c ip ro c a l  T G F - P l +/_ x T G F - p l +/+ m a tin g s  w e re  u se d . I f  p a te rn a l  
im p rin tin g  w as p resen t, one  w ou ld  ex p ec t to  see  lo ss o f  ex p re ss io n  o f  the  T G F - 
p l  gen e  in  h e te ro zy g o u s  o ffsp rin g  w h en  the  fa th e r  w as the so u rc e  o f  th e  w ild - 
type  a lle le  (ie  w h en  m o th e r w as T G F -p  l +/~) (B ). T h is  is c le a rly  n o t the  case , as 
the  2 .7 k b  T G F -P  1 tra n sc rip t w as d e te c te d  in b o th  y o lk  sa c  an d  e m b ry o s  o f  
h e te ro zy g o u s em bryos, regard less  o f  the d irec tion  o f  the cross.
Chapter 4 
DISCUSSION
4.1 Introduction.
This thesis presents data obtained from in vivo and in vitro analyses of TGF-pi 
knockout embryos (Shull et a/, 1992; Kulkarni et al, 1993). Previous studies 
demonstrated the expression pattern of TGF-pi mRNA and protein during 
embryogenesis, and also suggested possible actions of this growth factor in vivo 
(Heine\etal, 1987; Lehnert & Akhurst, 1988; Akhurst etal, 1990; Roberts & Spom, 
1990, for review). However, its true importance in vivo could not be elucidated until it 
was possible to remove the protein, and examine the consequences of this action. This 
was recently achieved by two separate groups using gene targeting by homologous 
recombination to selectively knockout the TGF-pi gene, and create transgenic null 
mice (Shull et al, 1992; Kulkarni et al, 1993). Surprisingly, mice of all genotypes 
were bom, suggesting that TGF-pl was not as important for foetal development as 
had been thought. However, on closer examination it was apparent that a percentage 
ofTG F-pi+/- and TGF-p l _/_ embryos died in utero. The work accomplished in this 
project set out to determine the cause of this prenatal lethality, and found that 
abnormal yolk sac development resulted in the death of approximately 50% of TGF- 
p i_/_, and 25% of TGF-p l +/_ embryos.
A second objective of the work was to investigate whether the surviving embryos 
were rescued by maternal TGF-pi. As the yolk sac phenotype was first observed at
9.5 dpc, 8.5 dpc embryos from TGF-p 1+/- x TGF-jpi+/_ matings were cultured in a 
novel post-implantation embryo culture system depleted of TGF-p 1. It was expected 
that, if maternal TGF-pl was rescuing the abnormal embryos at this stage, then there 
would be an increase in embryos manifesting the abnormal phenotype after in vitro 
culture. No increase in abnormal embryos was observed after 24 hours. This did not
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exclude the possibility that maternal TGF-p 1 rescues embryos in vivo, but suggests 
that if it does occur, then it does so before 8.5 dpc.
4.2 Post-Implantation Embryo Culture in TGF-(31- 
Depleted Medium.
One of the main methods to be employed in this project was post-implantation 
embryo culture. As no-one in the research group had previously used in vitro post­
implantation embryo culture, existing culture media and techniques were compared. 
In addition, this work required that the medium be depleted of TGF-p. Therefore, 
existing and novel culture media were analysed for TGF-p content.
In the past, the first successful post-implantation embryo culture experiments were 
performed with 100% rat serum, a medium which is still in use today (Steele & New, 
1974; New et al, 1976; Pratten et al, 1988; Walsh et al, 1993). However, it has since 
been discovered that although a percentage of the medium has to be rat serum, it is 
possible to use a combination of rat serum, with a chemically-defined, commercial 
medium, or with saline (Tam & Beddinton, 1987; Savatier et al, 1990; Shepard et al, 
1993; Guest et al, 1993; Smoak et al, 1993; Augustine et al, 1993; Akawaza et al, 
1994). As yet, a medium that can support early post-implantation embryonic 
development without containing serum, or some other undefined biological 
component has not been found (Cockroft, 1979; Priscott etal, 1983).
In this analysis, rat serum or plasma was combined with commercial media. Normal 
embryonic development occurred when 50% or more of the medium was defined. 
This reduced the amount of unknown factors, and saved on the precious commodity 
of rat serum or plasma.
4.2.1 The Use of Dulbeccos’ Modified Eagles Medium.
DMEM : 50% rat serum has been successfully employed by other groups (Tam & 
Beddington, 1987; Savatier et al, 1990; Kesby, 1992; Shepard et al, 1993). These 
studies used mouse embryos of 8-10 dpc, or rat embryos of the equivalent stages. The 
culture periods lasted for 20-48 hours, with one or two changes of the medium. The 
medium was also gassed intermittently to maintain a pH of 7.1-7.3, and the oxygen 
concentration was adjusted to be optimal for the age of the embryo. 5% 0 2, 5% C02j 
and 90% N2 was used for early somite embryos, 20% 0 2, 5% C02j and 75% N2 for 
10-15 somite embryos, 40% 0 2, 5% C 02j and 55% N2 for 20-30 somite embryos, and
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95% 0 2, 5% C02 for 30 somite embryos and above (New et al, 1976; Morriss & 
New, 1979; Cockroft, 1990). None of these studies reported any abnormal embryos 
resulting from the in vitro culture, implying that the use of DMEM : 50% rat serum 
was ideal for standard practice. However, the results with DMEM : 50% rat serum in 
this project were relatively poor.
Cultures of 7.5 dpc embryos were quite successful, although there were a few necrotic 
embryos, and development was slightly delayed in comparison to embryos 
developing in vivo. However, when 8.5 dpc embryos were cultured in DMEM : 50% 
rat serum, as well as necrosis, a number of embryos also exhibited structural 
abnormalities. This discrepancy between the 7.5 and 8.5 dpc embryo cultures 
suggested that DMEM : 50% rat serum was only suitable for culturing younger 
embryos. The older embryos may have been utilising more of the nutrients in the 
medium. Embryos do exhaust the medium of certain factors during development, and 
so changing the medium of the 8.5 dpc embryos during the course of the culture 
period would have revealed if depletion of nutrients was resulting in the necrosis and 
developmental defects (Priscott et al, 1983; Pratten et al, 1988).
In contrast, other groups have successfully cultured 8-10 dpc embryos in DMEM : 
50% rat serum. The deleterious effect seems to be specific to this study, although it 
must be pointed out that not all of the embryos were abnormal. As the other studies 
were not analysing culture methods, it is possible that they did not report any 
abnormal development. Nevertheless, there were two major differences between the 
cultures performed in this project, and in the other studies. One is the strain of mice 
used, and the other is the gas equilibration of the media.
In this study, outbred NIH/Parkes or inbred NIH mice were used, whereas others use 
outbred PO (Pathology, Oxford) mice, or Wistar rats (Tam & Beddington, 1987; 
Savatier et al, 1990; Kesby, 1992). Culture of the embryos may differ due to strain 
variation in the level of nutrients required, the speed at which the nutrients are utilised 
during embryogenesis, or differences in sensitivity to certain factors present in the 
medium. Data in support of strain variation was obtained in the current study by the 
culture of wild-type TGF-pi knockout embryos in a number of different media. As 
described previously, 8.5 dpc embryos from Parkes/NIH or NIH matings developed 
normally in either FMP : 50% dCP or FMP : 50% rat serum. However, only FMP : 
50% dCP could support the normal development of 8.5 dpc embryos from TGF-pi+/+ 
x TGF-p l +l+ matings. Culture in FMP : 50% rat serum for 24 hours resulted in 
abnormal embryonic development. Therefore, there appeared to be a difference 
between the genetic background of the Parkes/NIH and NIH embryos in comparison
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to the TGF-pl embryos which determined their suitability to culture in FMP: 50% rat 
serum.
The other major difference between this study and others involves the equilibration of 
the medium. It is suggested that for culturing 8.5 dpc embryos, the medium is pre- 
equilbrated with 5% O2 , 5% C02j and 90% N2 (New et al, 1976; Morriss & New, 
1979; Cockroft, 1990). Those studies found that if early somite embryos were 
exposed to more than 10% 0 2, there was a concommitant increase in the number, and 
the severity of defects in the cultured embryos. The neural tube was most commonly 
affected, specifically in the brain area, with defects ranging from failure of the 
anterior neuropore to close, to wide-open neural folds the length of the head (New et 
al, 1976, Morriss & New, 1979). However, very early on in this project, it became 
apparent that when 5% 0 2, 5% C02} and 90% N2 was used, many of the media 
became acidic very rapidly during the culture period with the result that the embryos 
died. Therefore, an attempt was made to culture the embryos in medium equilibrated 
with 20% 0 2, 5% C 02> and 75% N2. The cultured embryos showed no obvious 
increase in defects as a result of this change, regardless of the medium they were 
cultured in, and the pH was maintained at 7.1-7.4 for at least 14-16 hours, before the 
medium was gassed again. In contrast, other groups do use 5% 0 2, 5% C 02, and 90% 
N2 after equilibrating the medium overnight in 5% C 02 in air (Tam & Beddington, 
1987; Savatier et al, 1990), and do not obtain pH problems.
Apart from pre-equilibrating with 5% C 02 in air, the only other difference between 
the current study and others was the volume of medium, and the size of the culture 
bottles used. 1ml of medium in a 20ml Universal was used in this study to culture 1 
embryo, whereas 3 or 6mls of media were used to culture multiple embryos in 30 or 
60ml bottles in the other groups (Cockroft, 1979; Morriss & New, 1979; Tam & 
Beddington, 1987; Savatier et al, 1990). It is possible that the increase in medium, 
and the larger volume of the 30 or 60ml bottle would retain more of the gas mixture, 
thereby enabling the pH to be maintained for a longer period of time. This could be 
investigated by culturing embryos in varying volumes of DMEM : 50% rat serum in a 
variety of different sized bottles, and gassing the medium with 5% 0 2, 5% C 0 2} and 
90% N 2.
4.2.2 The Use of Foetal Mouse Palate Medium.
Previously, FMP, a serum-free culture medium, had been used to culture isolated 
foetal mouse palates (Shiota et al, 1990). As this was successful without the need for 
the addition of serum, in this study, an attempt was made to use FMP as a fully 
defined medium for whole embryo culture. Both 7.5 and 8.5 dpc embryos were 
cultured in this media. The results indicated that although FMP alone could not 
support embryonic development, it was extremely effective when combined with rat 
serum, especially when used with 8.5 dpc embryos. 50% serum was most efficient, 
but it was possible to decrease the organic component down to as little as 10%, and 
still maintain relatively good development. In FMP : 10% rat serum, the most 
common problem was necrosis, rather than embryonic abnormalities. However, 
because the necrosis was not severe, if the culture time period was reduced from the 
24 hour period used here, to perhaps 12 hours, then it would be unlikely that necrosis 
would occur at all. It may also be possible to culture older embryos, approximately 11 
dpc and on, in FMP without supplementation (J.McCluskey, pers. comm.). FMP 
appears to be an extremely useful medium for post-implantation embryo culture.
4.2.3 The Use of Rat Plasma in Embryo Culture.
Although rat serum is commonly used, plasma has been utilised very rarely as an 
embryo culture medium. Both of these fluids are obtained from blood, but their 
collection and their components differ. Serum is an amber-coloured liquid which is a 
by-product of blood coagulation, whereas plasma is the natural liquid component of 
blood which contains all the blood cells, fat globules, coagulating factors, etc. To 
prepare serum, the blood is allowed to clot, whereas it is imperative that clotting does 
not occur if plasma is required.
The first plasma samples that were used for culturing embryos were obtained using 
calcium chelating anticoagulants. However, once in the culture medium these agents 
upset the physiological concentration of free calcium ions in the embryo (Ellington, 
1983; Smedley & Stanisstreet, 1985). Therefore heparin, a naturally occurring 
anticoagulant, is now used to prepare plasma for use in embryo culture (Kesby, 
1992). When plasma was first used for culture, pre-somite and early somite embryos 
with intact yolk sacs and Reicherts membranes were cultured in 100% plasma in 
watchglasses exposed to air, but only very limited development was observed 
(Nicholas & Rudnick, 1934). Plasma was only used again when more advanced 
culture methods had been devised, and rather than simply using watchglasses exposed 
to air, roller bottles were utilised, with intermittent gassing of the medium. However,
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once again, early somite embryos were cultured in 100% heparin-plasma (Sanyal & 
Wiebe, 1979), with the result that embryonic development was significantly retarded. 
Kesby (1992) suggested that the resulting abnormalities were due to the large 
concentrations of heparin used by Sanyal & Wiebe (1979) to extract the plasma. The 
minimum amount required for successful plasma extraction is recorded as 
approximately 20 IU/ml (Young & Bermes, 1986), whereas Sanyal & Wiebe had 
used 100 IU/ml. Therefore, Kesby (1992) examined if the observed abnormal 
embryonic development was a result of the heparin concentration by culturing 
embryos in DMEM : 50% plasma, using plasma samples that had been extracted with 
10-80 IU heparin per ml blood. The results indicated that embryos were affected by 
heparin at a concentration as low as 5 IU heparin per ml media. Therefore, most 
investigators decide not to use plasma for in vitro post-implantation embryo culture. 
However, there were several advantages for the use of plasma in comparison to serum 
in this project, and so another investigation into the use of plasma as a post­
implantation embryo culture medium was performed here.
4.2.3.1 Rat Plasma in comparison to Serum for Embryo Culture.
As mentioned previously, one of the most important factors of the culture medium 
required for this project was that it lacked TGF-p. Plasma was considered for using in 
the culture medium, as it was already known that if the platelets were removed there 
would probably be no, or undetectable amounts (<25pg/ml) of TGF-p remaining 
(Danielpour et al, 1989). Platelets are one of the most abundant sources of TGF-p in 
the body, and once they were removed, it was thought that the TGF-p would also be 
removed (Van den Eijnden-van Raaij et al, 1988). Therefore, in an attempt to deplete 
the TGF-p from the plasma, the plasma was subjected to a further centrifugation 
process, thereby removing the platelets.
Analysis of the TGF-p levels in this centrifuged plasma (dCP) indicated that there 
were very, very low levels present (<25pg/ml). When the serum was analysed for 
TGF-p, it was found to contain much greater amounts (17ng/ml). This difference 
between plasma and serum TGF-p concentration could be as a result of a number of 
factors. Firstly, the method of preparation. With the formation of a clot for serum, it is 
possible that the platelets rupture releasing their contents into the serum. As the clot is 
prevented from forming by anticoagulant agents in the preparation of plasma, the 
platelets remain intact Second, the extra centrifugation steps that the plasma sustains, 
but not the serum, may remove the TGF-p within the platelets as described above. Or 
thirdly, the anticoagulation agent, heparin, may bind to and effectively remove the 
activity of TGF-p. Latent TGF-p 1 is known to bind to heparin-Sepharose, suggesting
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the presence of a specific heparin binding site in the LAP (Wakefield et al, 1989). 
However, regardless of the way in which TGF-p is depleted from the plasma, it is 
depleted to such an extent that it is undetectable by a highly sensitive CCL64 assay.
The CCL64 assay uses mink lung epithelial cells, cells which are growth inhibited by 
TGF-p in vitro (Danielpour et al, 1989). However, in almost every assay performed, 
there was a slight growth stimulatory effect at low concentrations of the standard 
rTGF-pi. Although this stimulatory effect at low levels has not been observed in most 
other studies, including CCL64 assays (Baird & Durkin, 1986; Frater-Schroder et al, 
1986; Longstreet et al, 1992; Zauli et al, 1993; Slager et al, 1993; Raynal & 
Lawrence, 1995), there are a few other investigations where it has been detected. 
These include the growth stimulatory effect of 25pg/ml TGF-p on porcine aortic 
smooth muscle cells in culture, and the increase in endothelial cell proliferation 
peripheral to the site of TGF-pi application in chorio-allantoic membranes (Yang & 
Moses, 1990; Hwang etal, 1992).
It was this stimulation at low rTGF-p concentrations that suggested that there was no, 
or very, very low levels (<10pg/ml) of TGF-pl present in plasma. The cells were not 
inhibited in the presence of dCP, and there was no significant increase in tritiated 
thymidine PH) incorporation when the anti-TGF-p 1 antibody was applied. However, 
the fact that there was no statistically significant decrease in 3H incorporation when 
the antibody removed the protein also suggested that growth stimulatory levels of 
TGF-pi were not present either. If stimulatory levels of TGF-P were present, then the 
proliferation of the cells should have significantly decreased with the removal of the 
protein.
Detection of the low level of TGF-pl that stimulated the cells also suggested that in 
the current study, the CCL64 assay was particularly sensitive. Other studies fail to 
detect a difference between concentrations of TGF-p 1 below approximately 50-75 
pg/ml (Longstreet et al, 1992; Zauli et al, 1993; Slager et al, 1993). The reason for 
the increased sensitivity of the cells to TGF-p in this study in comparison to others 
could be due to the quality of the cells in culture. Certainly, mink lung epithelial cells 
do lose their inhibition to TGF-p if they become confluent in vitro. It is also possible 
that other groups do not observe a stimulatory effect due to the quality of their 
recombinant TGF- p i.
The fact that TGF-pi was depleted from the plasma raises the possibility that other 
growth factors may also have been removed by the processing of the plasma. It would
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therefore be interesting to analyse the dCP for proteins such as platelet-derived 
growth factor, or epidermal growth factor.
The observation that TGF-p was absent from dCP made the plasma ideal for embryo 
culture use in this project. Therefore, attempts were made with the dCP to see whether 
it would support embryonic development, or would induce abnormalities as had been 
observed in the other studies (Nicholas & Rudnick, 1934; Sanyal & Weibe, 1979; 
Kesby, 1992).
4.2.3.2 DMEM or FMP plus Rat Plasma.
To analyse the effectiveness of dCP for whole post-implantation embryo culture, dCP 
was combined with DMEM or FMP and used to culture 7.5 and 8.5 dpc embryos for 
24 hours. As described in 4.2.2, when embryos were cultured in DMEM : 50% rat 
serum, there was a difference in the number of abnormalities depending on the age of 
the embryo. However, when DMEM was combined with rat plasma, defective 
phenotypes were observed in embryos cultured from 7.5-8.5 dpc, or from 8.5-9.5 dpc. 
There was also an increase in the number of abnormal, and necrotic embryos, 
especially in the 7.5 dpc cultures. These results therefore appeared to suggested that 
the plasma was harmful to the embryos. However, when the dCP was combined with 
FMP, the 7.5 and 8.5 dpc embryos developed well, with only a few abnormal and/or 
necrotic embryos observed after culture. This observation thus refuted the hypothesis 
that the defective phenotypes in DMEM : 50% dCP were as a result of the plasma. 
Therefore, it had to be an effect of the plasma in combination with the DMEM.
From the observed increase in necrosis when dCP was used rather than rat serum, the 
initial implication was that the DMEM : 50% dCP was nutritionally deficient. If this 
were the case, media with a decreased amount of plasma would be even more 
nutritionally insufficient. This was found to be true for embryos cultured in IMP : 
10% dCP. These embryos did not develop to the same stage as their counterparts in 
FMP : 50% dCP, and also developed more abnormalities, especially for the 7.5 dpc 
embryos. However, 7.5 or 8.5 dpc embryos cultured in DMEM : 10% dCP developed 
further, resulting in an approximately 50% decrease in the number of abnormal or 
necrotic embryos, in comparison to the embryos cultured in DMEM : 50% dCP. This 
statistically significant difference strongly suggested that DMEM : 50% dCP was not 
nutritionally deficient, but rather that it was toxic. With an increase in plasma, there 
was an increase in toxicity. It is possible that there is a factor(s) present in DMEM, 
which is not found in FMP, which reacts with a factor(s) present in the plasma. This
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might result in the formation of toxic metabolites, which impinge on, and disrupt 
embryonic development.
These observations also agreed with those of Kesby (1992). In his study, the heparin- 
plasma was combined with DMEM, with the result that the embryos grew 
abnormally. Kesby also combined heparin with DMEM : 50% rat serum, and 
observed abnormal development, therefore suggesting that the heparin was the 
teratogenic agent. However, in this study, the heparin-plasma was successful at 
supporting embryonic development when in combination with FMP. This therefore 
suggests that the heparin alone is not harmful, but that there is a toxic effect when 
DMEM is combined with heparin-plasma. To determine whether it is the heparin or 
some other factor in the plasma which reacts with the DMEM, plasma would need to 
be prepared without using heparin. Proof that heparin was the aggrevating factor 
would be provided if embryos developed normally when cultured in this plasma in 
combination with DMEM. However, the major problem is that the only other 
anticoagulating agents are calcium chelating which cannot be used, as described 
previously.
As well as combining the plasma with FMP, the current study differed from Kesbys’ 
study (1992) in a number of the steps taken to prepare the plasma. In both studies, the 
rats were anaethetised with diethyl ether for blood removal. Although 20 IU heparin 
per ml blood has been reported as the concentration required for the successful 
extraction of plasma from whole blood (Young & Bermes, 1986; Kesby, 1992), only 
10 IU/ml was utilised in this study, resulting in only 5 IU/ml in the culture medium. 
In addition, the blood was added to a tube containing heparin-coated balls, rather than 
adding liquid heparin. Both the reduction in concentration, and the method of heparin 
application may have increased the suitability of heparin-plasma for embryo culture. 
The heparin-plasma was then extracted by centrifugation, although in Kesbys’ study, 
the blood was only centrifuged for 5 minutes at 3500 rpm, in comparison to 2 
centrifugations of 20 minutes and 10 minutes at 2400 rpm in this study to ensure that 
there was no accidental transfer of red blood cells. All samples were heated at 56°C 
for 30 or 40 minutes. However, Kesby does not appear to have gassed the plasma 
preparations, whereas in this study a gas mixture of 5% 0 2, 5% C 02> and 90% N2 was 
introduced into the plasma. This was performed to displace the ether, which can be 
harmful to the embryos. Finally, in the current study, the plasma preparations were 
centrifuged twice at 14,000 rpm, for 15 minutes, removing the platelets and perhaps 
other components with adverse affects on embryonic culture. For example, fat 
globules were observed to have been displaced from the plasma as a result of the 
centrifugation.
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All of these differences may have had an effect on the suitability of plasma for in 
vitro post-implantation embryo culture, but the major difference may be the reduction 
in the level of heparin used. Nevertheless, the data presented in this thesis suggests 
that plasma can be used to culture post-implantation embryos, but only in 
combination with FMP.
It was also noted in this study, that FMP, either in combination with rat serum or dCP, 
was more efficient than DMEM for culturing embryos in vitro, especially 8.5 dpc 
embryos.
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4.3 Analysis of TGF-pi Knockout Embryos.
TGF-p has been the focus of many studies over the years since its discovery as a 
factor capable of transforming normal rat kidney fibroblasts in culture (Delarco & 
Todaro, 1978). Its genetic, molecular, and biochemical properties have been analysed, 
and compared in different species, different tissues, and different cell types. Potential 
actions were also identified based on expression patterns and in vitro assays. 
However, any definitive roles and actions could not be known until the protein was 
analysed in vivo. This was recently performed by selectively disrupting the TGF-pi 
gene by homologous recombination, thereby preventing translation of the wild-type, 
functional protein (Kulkami et al, 1993). Analysis of the offspring identified that the 
major role of TGF-pl in mice is in the control of the immune system. However, 
another critical role for TGF-pl was identified in the embryos that could not survive 
gestation.
4.3.1 8.5 and 9.5 dpc TGF-pi Knockout Embryos.
Preliminary studies on the identification of yolk sac abnormalities in the TGF-pi 
knockout conceptuses were made by Dr.Marion Dickson (Dickson et al, 1995). These 
studies were extended by Dr.Dickson and myself, both working independently, but in 
a complementary fashion.
In the current study, embryos from TGF~pi+/- x TGF-p 1+/- intercrosses were initially 
examined at 8.5 dpc. There was no observable phenotypic difference between TGF- 
p i+/+, TGF-pi+/_, or TGF-p 1-/- embryos at this stage (Dickson et al, 1995). TGF-pi 
gene expression is first detectable by RT-PCR at the pre-implantation stage (Rappolee 
et al, 1988), but all three TGF-pi genotypes were present at 8.5 dpc, and in the 
expected Mendelian ratio of 1:2:1. This suggested that either TGF-pi is not a 
prerequisite for development before or around the time of implantation, or that the 
pre-implantation embryo has a lower threshold requirement for TGF-p 1, which is met 
by the oviduct and uterine levels of the maternal protein.
By in situ hybridisation, TGF-pl is first detected at high levels at 7.5 dpc, within the 
blood islands of the yolk sac, the mesoderm of the allantois, and the cardiogenic 
mesoderm of the embryo, specifically the pro-angioblast progeniters (Akhurst et al, 
1990). The exact function of TGF-pl within these cells is not known, but it appears 
from the normal appearance of the TGF-p 1+/- and TGF-pl ;- yolk sacs at 8.5 dpc that 
the protein is not critically involved in the progression of the blood islands to the 
corona. Neither the differentiation of the angioblasts in the cardiogenic mesoderm, or
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the joining of the allantois to the ectoplacental cone was analysed in this study, 
although, by visual observation alone, there did not appear to be any defects in the 
formation of the chorio-allantoic connection.
At 7.5 dpc, the blood islands of the yolk sac contain haemangioblasts, which give rise 
to endothelial and haematopoietic cell lineages (Sabin, 1920; Wilt, 1965; Miura & 
Wilt, 1969). Haemangioblasts and both descendant lineages express TGF-pi RNA 
from 7.5 dpc until much later in development (Akhurst et a l , 1990). The TGF-pl 
expressed in the blood islands may have a role in the formation of these cell types, 
and therefore have a role in haematopoiesis and vasculogenesis. This idea is also 
supported by the observation of expression of TGF-p 1 in the blood cells in the foetal 
liver, and early embryonic endothelial cells (Heine et al, 1987; Lehnert & Akhurst, 
1988; Gatherer e tal , 1990; Akhurst etal, 1990).
Embryos from TGF-p l +l~ x TGF-pl +l~ matings were examined at 9.5 dpc, either 
direct from the uterus, or after 24 hours in culture. At this stage, some of the TGF- 
pl'1'^  and TGF-p T/_ embryos were distinguishable from their TGF-pi+/+ littermates. 
The observable phenotypic differences in both cultured and non-cultured embryos 
were within the yolk sac, affecting either the vasculature or the red blood cells. Some 
of the yolk sacs contained only delicate and disorganised vessels, others had a 
reduced number of vessels, while others lacked vessels altogether. Varying degrees of 
anaemia were also observed in a number of yolk sacs. These defects were consistent 
with the expression pattern data for TGF-pl activity in haematopoiesis and 
vasculogenesis, especially within the yolk sac (Akhurst et al, 1990), and would 
suggest a very localised (autocrine) mode of action for TGF-pi.
4.3.1.1 Formation of the Yoik Sac.
In the mouse, the yolk sac protects, oxygenates, and feeds the developing embryo. It 
starts to develop during the blastocyst stage when the embryo consists of the 
trophoblast, the blastocyst cavity, and the inner cell mass (ICM). The ICM 
differentiates into a bilaminar layer made up of primitive ectoderm and primitive 
endoderm. Cells from the endoderm form the parietal endoderm by migrating along 
the entire inner surface of the trophectoderm, and secreting Reichert's membrane 
(Gardner, 1982). The remainder of the primitive endoderm forms a layer of visceral 
endoderm around the egg cylinder. The yolk sac forms in the region where 
mesoderm, formed during gastrulation, is found apposed to the visceral endoderm. 
During development, this enlarges considerably, eventually residing against the 
parietal endoderm (Slack, 1983). At approximately 7.5 - 8 dpc, distinct regions of the
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mesothelium are induced to proliferate by the underlying endoderm, and become the 
haemangioblasts of the blood islands (Miura & Wilt, 1969). The outer 
haemangioblasts differentiate into endothelial cells which anastamose to form blood 
vessels in a process called vasculogenesis. Angiogenesis occurs at a later stage by the 
sprouting of existing vessels. Primitive haematopoiesis also occurs in the yolk sac by 
the formation of blood cells from the inner haemangioblasts. There is evidence for 
and against the involvement of these primitive blood cells in definitive 
haematopoiesis which occurs in the foetal liver at a later stage (Moore & Metcalf, 
1970; Medvinsky etal, 1993; Godin e tal , 1993).
Molecular analysis of vasculogenesis has only recently been performed, and has 
grown rapidly with the advances in knockout methodology.
4.3.1.2 Molecular Aspects of Yoik Sac Vasculogenesis.
Vascularisation of the yolk sac is controlled by a variety of molecules. The 
extracellular matrix is important in the formation of vessels, enabling the endothelial 
cells to migrate, and form cohesive tubes. A transgenic knockout line was recently 
generated for the ECM protein fibronectin (FN), and was found to be embryonic 
lethal (George et al, 1993). On analysis of the embryos, it was discovered that 
development of the yolk sac vasculature stopped at the blood island stage and that the 
endodermal and mesothelial cell layers had separated. FN is, therefore, a prerequisite 
for the development of a normal vasculature. Certain ceil surface receptors which 
interact with the ECM are also crucial. Removal of the a vp3 integrin results in a 
phenotype similar to the FN knockouts, but disrupts angiogenesis, not vasculogenesis, 
and so the embryos survive to a slightly later stage (Brooks et a l , 1994). The a5- 
integrin knockouts also develop blood vessels, but these vessels are weak, and the 
blood leaks into the yolk sac cavity. This “leakage” phenotype was also observed in 
the FN knockouts, and occasionally in the TGF-p 1 knockouts (Yang et al, 1993; 
George et al, 1993; Dickson et al, 1995). The Ia5 mutants also fail to develop a 
functioning chorio-allantoic connection, with the result that intra-embryonic 
circulation is impaired.
Five receptor tyrosine kinases (RTK) which are almost solely expressed in the 
endothelial cell lineage have also been identified. The five RTKs can be divided into 
two groups, based on structural similarities (Hunter & Lindberg, 1994). The first 
group contains Flt-4, and the receptors for vascular endothelial cell growth factor 
(VEGF) Flk-1 and Flt-1 (Ferrara & Henzel, 1989; De Vries etal, 1992; Pajusola etal, 
1992; Millauer et al, 1993), while the second group contains Tie and Tek (=Tie-2)
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(Dumont et al, 1992, 1994; Sato et al, 1993). Expression analysis and knockout 
experiments suggest that each of these RTKs exerts a different effect on endothelial 
cells. Knockout experiments revealed that Flt-1 is required for normal vessel 
assembly, but not for endothelial cell formation, whereas Flk-1 seems to affect the 
haemangioblasts of the yolk sac, and is therefore required for blood island formation 
and vasculogenesis (Fong et al, 1995; Shalaby et al, 1995). Tie and Tek, although 
structurally similar, were also revealed to have different roles by knockout analyses 
(Sato et al, 1995). Tie is needed for the structural integrity of the endothelial cells, 
whereas Tek is required for angiogenesis.
As the expression data, and the phenotypes of the TGF-pl knockout embryos 
examined in this study revealed, TGF- pi appears to be another molecular control of 
yolk sac vasculogenesis. The appearance of the affected yolk sacs was surprisingly 
similar in the fibronectin (FN) (George et al, 1993) and some of the TGF-pi 
knockouts. The development of the vascular system was arrested at the blood 
island/corona stage, and the jendodermal and mesothelial cell layers were found to 
separate. This evidence suggests that TGF-p 1 affects the ECM molecules in the yolk 
sac, which maintain the integrity of the yolk sac layers, and help to support the 
developing tubes. TGF-p is known to directly affect ECM, by controlling the 
production of certain ECM proteins, the degradation of the matrix, and the expression 
of integrins, but as yet, the composition of the ECM in the TGF-pl knockouts has not 
been examined (Seyedin etal, 1985; Laiho etal, 1986; Varga etal,  1987; Ignotz & 
Massague, 1987; Pearson eta l, 1988; Overall etal,  1989). FN production is directly 
affected by TGF-pi in vitro (Ignotz & Massague, 1986; C.J. Roberts et al, 1988), and 
examination of the expression of this ECM molecule in the TGF-pH- yolk sacs in 
comparison to the TGF-pl+/+ yolk sacs would reveal whether FN is affected in the 
TGF-pi knockouts. It would also be interesting to analyse the converse, that is, 
whether the expression of TGF-p 1 is affected by the depletion of FN in the FN 
knockouts. This would reveal whether the expression of TGF-p 1 is indirectly affected 
by the composition of the ECM.
However, TGF-pi is also known to act directly on endothelial cells in culture. 
Therefore, it is possible that the defective vessels result from the lack of the direct 
effect of TGF-pl on endothelial cells. Previous studies have shown that in 2- 
dimensional culture, TGF-pi inhibited the proliferation of endothelial cells (Baird & 
Durkin, 1986; Frater-Schroder etal, 1986). Conversely, TGF-p stimulated endothelial 
cells to differentiate and form tubes in a 3-dimensional collagen gel, without affecting 
their proliferation (Madri et al, 1988). These cells were also found to have increased
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expression of FN, PECAM, and integrins, and they formed new tight cell junctions 
(Merwin etal, 1990; Basson etal, 1992; Madri etal, 1992).
To examine whether TGF-pi affects the proliferation of endothelial cells in vivo, the 
current study utilised BrDU incorporation to analyse the proliferation rates of these 
cells in TGF-p 1 knockout conceptuses. There was no significant difference in the 
proliferation rates of the endothelial cells in either the yolk sac or the embryo proper 
between TGF-p 1+/+ and TGF-p T/_ conceptuses. This suggested that endothelial cells 
are not growth inhibited by TGF-pl. Like the endothelial cells in the collagen gel, 
endothelial cells in vivo are supported on all sides. Therefore it is possible that TGF- 
p i. in vivo, does not affect endothelial cell proliferation, but rather differentiation 
(Madri et al, 1988). This could be examined in the TGF-p 1+/+ and TGF-p I 1' yolk 
sacs by analysing the expression of endothelial cell differentiation markers.
Any of the endothelial cell specific tyrosine kinase receptors can be used to determine 
the differentiative state of endothelial cells. Flk-1, one of the vascular endothelial cell 
growth factor receptors, is expressed at 7.0 dpc in the extraembryonic and embryonic 
mesoderm (Millauer etal, 1993; Dumont etal, 1995). When Flk-1 was disrupted by 
homologous recombination, normal blood island formation did not occur in the yolk 
sacs of homozygote embryos, with the result that neither vessels or blood were able to 
form (Shalaby etal,  1995). The early expression of Flk-1, and the absence of blood 
islands or vessels in the knockout implicate a role for this TK receptor in the 
differentiation of the endothelial cells. The differentiative stage that the cells had 
reached was examined by analysis of the other endothelial cell receptor tyrosine 
kinases. The markers for endothelial precursors, Flt-1, Flt-4, and Tie were detectable 
in Flk-1 homozygous embryos (Dumont et al, 1992; 1995; Kaipainen et al, 1995). 
However, Tek, a TK receptor involved in angiogenesis, and therefore, after terminal 
differentiation of the endothelial cells, was not detectable (Korhonen et al, 1994; 
Dumont et al, 1995; Sato et al, 1995). This suggested that there were endothelial 
precursor cells present in the Flk-1 knockouts, but they were prevented from 
differentiating any further. An analysis of these TK receptors in the TGF-pl knockout 
yolk sacs would indicate if the endothelial cell lineage had separated from the 
haemangioblasts at all, and if so, what stage of differentiation the cells had attained.
The phenotype of the Flk-1 homozygote yolk sac was also similar to the TGF-pi 
knockouts, with both haematopoiesis and vasculogenesis affected. However, it 
appears as if Flk-1 has effect before TGF-pi. Flk-1 expression is detected 0.5 dpc 
before TGF-pl, and the defective phenotype is observed approximately 1 day earlier, 
when the Flk-1 -/_ yolk sacs fail to develop blood islands (Millauer et al, 1993;
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Dumont et al, 1995; Shalaby et al, 1995). However, preliminary expression studies 
performed by Dr.M.Dickson suggested that Flk-1 expression is reduced in the TGF- 
p i-/- yolk sacs at 8.5 dpc in comparison to TGF-p 1+/+ yolk sacs (Dickson et al, 1995). 
As this did not reflect a reduction in endothelial cells as shown by BrDU analysis, it 
suggested that there was defective endothelial cell differentiation. Flk-1 is expressed 
before TGF-p 1, therefore the reduction in the number of Flk-1 expressing cells 
suggests that TGF-p 1 may be required to maintain the differentiative state of the cells. 
Although thorough quantitative studies are still to be performed, analysis of Flk-1 
enabled defective TGF-pl knockout embryos to be detected before any 
morphological phenotype.
4.3.1.3 Molecular Aspects of Haematopoiesis
The development of the blood was also affected in a percentage of the TGF-pi+/- and 
TGF-pi_/* yolk sacs. As for vasculogenesis, the molecular aspects of haematopoiesis 
have only recently been investigated.
Primitive haematopoiesis occurs in the yolk sac at approximately 8-9 dpc, whereas 
definitive haematopoiesis occurs in the liver at approximately 14 dpc. There is 
controversy regarding the involvement of primitive blood cells in definitive 
haematopoiesis. Initial evidence suggested that the blood cells from the yolk sac 
migrated and formed a colony within the liver (Moore & Metcalf, 1970). However, 
more recently, the idea is that definitive haematopoiesis occurs independently from 
the yolk sac (Medvinsky et a l, 1993; Godin et al, 1993). This latter hypothesis is 
supported by the fact that each type is regulated by a separate group of molecules. 
Using knockout methodologies, GATA-1, GATA-2, and tal-l/SCL were all found to 
be involved in primitive haematopoiesis (Pevny et al, 1991; Weiss et al, 1994; Tsai et 
al, 1994; Shivdasani et al, 1995), whereas dominant white spotting, steel, c-myb, 
retinoblastoma, c-kit, erythropoietin, and the erythropoietin receptor gene products all 
regulate definitive haematopoiesis (Russell et al, 1968; Chui et al, 1974; Mucenski et 
al, 1991; Lee et al, 1992; Ogawa et al, 1993; Wu et al, 1995). There does not appear 
to be any cross-regulation, but all of these proteins appear to be crucial for 
haematopoiesis. Embryos that lack any of the above proteins do not complete 
gestation due to severe anaemia of either immature, nucleated yolk sac blood cells, or 
the mature liver blood cells.
As mentioned previously, a role for TGF-p 1 in haematopoiesis was postulated from 
the expression of the RNA and protein in the haematopoietic lineages that descended 
from the haemangioblasts in the yolk sac (Akhurst et al, 1990). The TGF-pi
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knockout embryos with defective yolk sacs were found to die at approximately 10.5 
dpc, and both Dr.M.Dickson and I found that some of these yolk sacs were anaemic 
(Dickson et al, 1995). Therefore, TGF-pl also appears to be involved in the 
regulation of primitive haematopoiesis. However, it is possible that the anaemia in the 
TGF-pi+/_ or TGF-pT/_ yolk sacs is a secondary effect. Both foetal and adult 
haematopoiesis depend on a normal ECM, and stromal-cell interactions, and therefore 
the defective vasculature in some of the TGF-pl knockouts may have affected 
haematopoiesis (Patel & Lodish, 1994; Rafii et al, 1994; Buzby et al, 1994). 
However, the appearance of the haematopoietic and endothelial defects in the TGF-pi 
knockout yolk sac did not always coincide. Defective vasculature was observed in 
yolk sacs with an abundance of blood, and normal vasculature was present in yolk 
sacs which were anaemic. The presence of blood in the FN, and a5-integrin 
knockouts also supports the development of blood cells in an abnormal environment 
(George et al, 1993; Yang et al, 1993), even though previous studies had suggested 
that FN was a (prerequisite for erythroid development (Patel & Lodish, 1987).
In the current study, although the anaemia was obviously due to a reduction in 
haemoglobinised cells, there were significant numbers of circulating cells in these 
yolk sacs. TGF-pi was therefore affecting either the proliferation of the 
haemoglobinised cells, or the haemoglobinisation process itself. To investigate 
whether proliferation or differentiation was affected, Dr.M.Dickson analysed the 
expression of £-globin in 8.0 and 9.5 dpc conceptuses from TGF-pi intercrosses 
(Wilkinson et al, 1987; Dickson et al, 1995). £-globin is a marker for the 
haemoglobinisation of the red blood cells, thereby indicating their differentiative 
state. No difference could be detected between the genotypes in embryos and yolk 
sacs of 8.0 dpc. At 9.5 dpc, it was found that the percentage of blood cells staining 
with the probe was identical in TGF-p l-/_ and TGF-pi+/+ yolk sacs. However, the 
total number of red blood cells hybridising with the probe in the TGF-p 1_/- yolk sacs 
was up to 90% less than in the TGF-pi+/+ yolk sacs. This suggested that the anaemic 
phenotype observed in the TGF-pl  ^yolk sacs resulted from a reduction in the total 
number of blood cells differentiating from the haemangioblasts.
One other interesting observation obtained from analysing the TGF-p 1 embryos with 
anaemic yolk sacs was the presence of blood within the dorsal aorta at approximately
9.5 dpc. This was observed in Dr.M.Dicksons’ studies, and both the in vivo and in 
vitro analyses in my own project. 9.5 dpc is prior to the formation of a functional 
foetal liver, and therefore, definitive haematopoiesis. It is possible that this blood 
represents the multipotential haematopoietic cells that arise in the paraaortic 
splanchnopleura (P-Sp) from 8.5-9.5 dpc (Godin et al, 1995). This group suggested
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that there are two sites of haematopoiesis at 8.5 dpc, the yolk sac and the P-Sp. If this 
is true, then the results from the TGF-pl knockouts suggest that TGF-pi is only 
involved in yolk sac haematopoiesis. Molecular analysis of other controlling factors, 
such as GATA-1 and GATA-2, in the P-Sp blood would determine whether it was 
distinct from both yolk sac, and liver haematopoietic events.
4.3.1.4 The Role of TGF-pl in Vasculogenesis and Haematopoiesis.
Although the yolk sac as the initial site of the effect of TGF-pi deficiency is in 
agreement with previous expression studies (Akhurst et al, 1990), the actual effect 
itself is inconsistent with the postulated roles for the protein. As TGF-pi was 
suggested to be a potent inhibitor of endothelial and haematopoietic cells, it was 
expected that there would be over-production of red blood cells and hyperplasia of the 
endothelial cells (Heimark et al, 1986; Muller et al, 1987; Ohta et al, 1987; Ottman & 
Pelus, 1988). However, as discussed, there was, in fact, a decrease in the number of 
red blood cells, and no effect on the proliferation of the endothelial cells. This data 
suggests that the effect of TGF-p 1 in vivo is in the control of haematopoietic and 
endothelial cell differentiation. It may also be that the phenotypes of the TGF-pi 
knockout yolk sacs were actually an indirect effect of lack of TGF-p 1, such as 
modulation of the ECM, or of the expression of other growth factors.
4.3.1.5 Phenotype of the TGF-pl Knockout Embryos.
In this study, and the analyses performed by Dr.M.Dickson, the morphological 
appearance of the embryo per se at 9.5 dpc was surprisingly normal in all genotypes, 
whether the yolk sac was normal or abnormal. There was a slight delay in 
development, approximately 0.5 dpc, and a little necrosis in the embryos with 
defective yolk sacs, but this was likely to be an effect of yolk sac insufficiency. On 
analysis of the limited embryonic vasculature which had developed by this stage, the 
structure of the vessels appeared normal. This was a surprising result as high levels of 
TGF-pi have been detected in these endothelial cells (Akhurst et al, 1990). It is 
possible that the endothelial cells within the embryo are more sensitive to TGF-pi, 
and therefore lower levels are required to elicit a response. The maternal TGF-pl 
(TGF-pi+/-) crossing the placenta may be sufficient for the embryonic endothelial 
cells, but insufficient for the yolk sac cells. Indeed, one group observed that when the 
embryos were not exposed to maternal TGF-p 1 by gestation in a TGF-pl-/- female, 
the TGF-pl-/- offspring had severe cardiac abnormalities (Letterio et al, 1994). When 
Dr.M.Dickson examined 3 12.5 dpc TGF-pi-/- embryos from a TGF-p 1-/- mother, 
abnormal heart development was also observed (Dickson et al, 1995). However, each
97
of these embryos also exhibited a defective yolk sac, and therefore, the heart defects 
may have been a secondary defect. Ventricular hyperplasia and hypertrophy can result 
from defective pressure in the cardiovascular system (Heine e ta l, 1985).
It is also possible that TGF-pl only exerts an effect on the endothelial cells of the 
yolk sac, and that the expression in the embryonic endothelial cells is non-functional. 
The Zebrafish mutation, cloche, influences both endothelial and haematopoietic cell 
lineages, but only the endothelial lining of the heart, the endocardium, is affected 
(Stainier et al, 1995). The identity of the mutated protein which results in this 
phenotype is not yet known.
Due to embryonic death occuring at approximately 9.5-11.5 dpc, it was impossible to 
identify any other defects which may have occured at a later stage of development as 
a result of the lack of TGF-p 1. This included definitive haematopoiesis, although at 
9.5-10.5 dpc Dr.M.Dickson noted that the liver appeared to be developing normally 
(Dickson etal, 1995).
4.3.2 Autocrine or Paracrine Mode of Action.
Analysis of mRNA and protein expression patterns in the embryo suggest that the 
TGF-ps may have both paracrine, and autocrine modes of action (Millan et al, 1991; 
Pelton et al, 1991). For example, in many sites of epithelial-mesenchymal 
interactions, such as in the developing salivary glands, tooth, and heart, there is 
mirror-image expression of the mRNA in the epithelium, and the protein in the 
mesenchyme, suggesting that there is paracrine activity (Akhurst, 1994). However, 
there are also sites where the mRNA and protein are detected in the same cells, for 
example, in cardiomyocytes (Dickson etal, 1993).
In the TGF-p 1 yolk sac, if the defective vasculature was as a result of disrupted ECM, 
this would strongly support a paracrine activity for the TGF-p produced in the yolk 
sac endothelial cells. However, as TGF-pi RNA is expressed in the haemangioblasts, 
the endothelial cells, and the haematopoietic cells (Akhurst et al, 1990), and these are 
the cells affected in the abnormal yolk sacs, this suggests that the mode of TGF-pi 
action is autocrine. Determination of the site of TGF-p 1, and TGF-p receptor proteins 
in the yolk sac would help to elucidate whether the protein acts through a paracrine, 
or an autocrine activity. If they were present in the ECM, then it would be a paracrine 
activity, whereas if they were present in the endothelial and haematopoietic cells, this 
would indicate an autocrine activity.
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As mentioned above, within the embryo proper the endothelial cells did not appear to 
be affected by the lack of TGF-p 1 in the knockouts. Previously, expression studies 
had found that TGF-pl mRNA was expressed in the endothelial cells (Akhurst et al, 
1990), but the protein was not (Pelton et al, 1991). This would suggest a paracrine 
mode of action for the TGF-pl produced by these cells, which would explain the lack 
of abnormal phenotype in the vasculature of the embryos in the TGF-pl knockouts. 
The target for the protein producedlby these cells is unknown.However, it is possible 
that the effect of removing this TGF-pi would have been identified at a later stage, if 
the embryos had survived. But it is also possible that the protein is non-functional. 
Nevertheless, these endothelial cells did not appear to be affected by the lack of TGF- 
pi at 9.5 dpc. Again, analyses of the receptor expression patterns would help to 
elucidate whether the TGF-pi produced by the embryonic endothelial cells has an 
autocrine, or paracrine activity, if any activity at all.
4.3.3 The Rescue and Range of Phenotypic Embryos.
As discussed, a wide range of phenotypes were observed in the TGF-p l-/_ embryos. 
Either they were defective, with abnormal yolk sac vasculature, or anaemia, or both, 
or they were perfectly normal and the mice survived to approximately 3 weeks post­
partum. The percentage of TGF-p 1-/- embryos that survived gestation may have been 
able to do so as a result of maternal transfer of TGF-p 1, as shown by 125I-TGF-p 
transmittance from mother to pup (Letterio et al, 1994). This hypothesis was also 
supported by the observation that TGF-p l +/_ embryos from TGF-jpi+/- intercrosses 
were rescued after being transferred into a TGF-p 1+/+ mother (Dickson etal, 1995).
In this project the role of maternal TGF-P 1 was investigated by the removal and 
culture of 8.5 dpc embryos from TGF-pl intercrosses in a medium lacking TGF-p. If 
maternal TGF-pi was responsible for rescuing the embryos, it was expected that there 
would be an increase in the number of defective embryos in the TGF-pl-depleted 
environment. There was no increase in abnormalities. However, this does not 
conclusively indicate that maternal TGF-pi is not rescuing some of the knockout 
embryos. Although the embryos were removed before the appearance of any 
phenotypic differences, maternal TGF-p 1 may have already exerted its affect by this 
stage. As described previously, there is an observable difference in Flk-1 expression 
in the abnormal TGF-p 1_/- yolk sacs before the appearance of any defects. Maternal 
TGF-pi may also have been bound to the ECM in the embryos, and thereby 
transferred over into the culture system.
99
As well as maternal TGF-pl, the other TGF-p isoforms may also be involved in the 
rescue of the TGF-pi_/- embryos. Examination of endogenous TGF-p2 and TGF-p3 in 
the embryo and the yolk sac showed that they were not up-regulated. However, it is 
possible that the maternal isoforms are involved. TGF-p2 is unlikely to be responsible 
since neither endothelial or haematopoietic cells respond to this isoform (Ohta et al, 
1987; Ottman & Pelus, 1988; Merwin et al, 1991; Qian et a l, 1992). However, 
maternal TGF-p3 may have a role (Greycar et al, 1989; Cheifetz et al, 1990). 
Analysis of TGF-p3 levels, especially in TGF-p 1-/- mothers which give birth to TGF- 
p i-/- pups, would help to determine whether this factor is involved in the rescue of the 
abnormal phenotypes.
None of the above hypotheses however explain why only a percentage of TGF-p l'/_ 
embryos are rescued. It appears that even though individual embryos may have been 
of the same genotype, there were other genetic variabilities which affected their 
phenotype. Other transgenic knockout mice, such as the fibronectin mice, exhibited a 
variable phenotype, which has been ascribed to genetic polymorphisms as a result of 
the use of a mixed genetic background (George et a l, 1993). The TGF-p 1 knockouts 
analysed in the current study were also on a mixed genetic background (50% NIH, 
37.5% C57/B16, 12.5% 129sv). Therefore, polymorphisms in modifier genes of TGF- 
pi may be responsible for both the percentage of embryonic rescue, and the precise 
defects observed in the individual conceptuses. The gene(s) affected may include 
those involved in the control of circulating maternal TGF-pl, or genes that would 
affect the ability of the embryos to respond to or take-up maternal TGF-pi. 
Preliminary investigations by others in the laboratory have indeed provided 
compelling evidence for genetic factors influencing the outcome of the TGF-pi 
phenotype. When analysed on a 93% C57B16 genetic background there is complete 
(100%) prenatal lethality of TGF-pi*/_ animals, whereas on a 93% NIH genetic 
background there is only <15% prenatal lethality. Genetic breeding experiments have 
already shown a genetic linkage between prenatal lethality at one major locus 
(Bonyadi & Akhurst, pers. comm.).
One example of a defect resulting from a mutation in a gene involved in the response 
to TGF-p is the hereditary disorder haemorrhagic telangiectasia type 1, the effects of 
which include vascular dysplasia, and recurrent haemorrhage. Endoglin, a TGF-p 
type III receptor, is thought to be a likely candidate gene for the disease (McAllister et 
al, 1994). The type III receptors do not appear to be necessary for TGF-P signalling 
(Cheifetz et al, 1990) but disruption of endoglin would probably affect TGF-p 
binding to the signalling receptors. Although this is indirect evidence, it also supports
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the role for TGF-p in vascularisation, a role that was strongly implicated in the 
current study.
4.3.4 Conclusions.
The major outcome of this study was that the abnormal phenotype resulting from 
removal of functional TGF-pl was in full accordance with its initial site of high 
expression in the yolk sac, and its postulated role in haematopoiesis and 
vasculogenesis. The data also suggested that the role of TGF-p 1 in vivo is not as a 
endothelial and haematopoietic growth inhibitor, but rather as a regulator of 
endothelial differentiation and haematopoiesis. Whether TGF-p 1 acts directly on 
these cells, or indirectly through the modulation of the expression of other 
growth/differentiation factors, or the ECM is not yet known. Analysis of the 
expression of ECM proteins, and differentiation markers will help to elucidate the 
defective phenotypes observed in the TGF-pl knockout conceptuses, and also reveal 
the mode of action of TGF-pl on endothelial and haematopoietic cells of the yolk 
saq  .....................................................................................................................................
Further investigations are also required to determine the reason for the dichotomy in 
embryonic survival. As mentioned in 4.3.3, genetic polymorphisms may be 
responsible, possibly affecting maternal TGF-p 1 circulatory levels, or the ability of 
the embryos to take-up or respond to maternal TGF-p 1. Maternal levels could be 
examined by performing CCL64 assays on serum samples from females of different 
genotypes, while the ability of the embryo to respond could be analysed by examining 
the expression of the TGF-p receptors, and the intracellular signalling systems.
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APPENDIX A 
STATISTICAL DATA.
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Amendment to Statistical Data.
It should be noted that due to the large sample sizes, and therefore the large number of 
students t-tests performed using individual values, only the P-values in close proximity of 
0.0001 Should be considered as significant. Further statistical tests utilising the data 
presented here would determine those P-values that indicate true statistical significance.
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FM P: 50% dCP 
(33.63)
FM P: 10% dCP 
(29.30)
FM P: 50% dCP 
(33.63)
FM P: 10% dCP 
(29.30)
0.022
DMEM: 50% dCP 
(19.93)
0.0000 0.0000
Appendix A3 - In-depth Analysis of 8.5 dpc Embryo Cultures.
A further twenty-six or twenty-seven 8.5 dpc embryos were cultured in each of the 
following media; FMP : 50% dCP, FMP : 10% dCP, and DMEM : 50% dCP. After 
culture, the embryos were scored by the Brown-Fabro method (1981). The mean 
score for each medium is shown in brackets. To determine whether there was a 
statistically significant difference between the scores of the embryos cultured in the 
different media they were compared by a 2-sample students t-test. The results are 
shown above. A statistically significant difference was indicated by a P-value < 0.05.
As mentioned in the Results section, this data should be considered in conjunction 
with the number of embryonic abnormalities resulting from culture in each medium.
FMP: 50% dCP 
(777/2000)
FM P: 10% dCP 
(790/2000)
DMEM: 50% dCP 
(429/2000)
FM P: 50% dCP 
(777/2000)
FM P: 10% dCP 
(790/2000) 0.73
DMEM: 50% dCP 
(429/2000) 0.0000 0.0000
Control
Embryos
(638/2000)
0.0025 0.0003 0.0001
Appendix A4 - BrDU Incorporation in Cultured 8.5 dpc Embryos.
Embryos in culture, or control embryos were injected with 1 |xl 10mmol|/l BrDU (See 
Materials & Methods). This was performed to assess the proliferation rates of the embryos, 
and thereby determine whether there was any variation in growth between the embryos 
cultured in different media. After immunohistochemistry, the number of cells stained for 
BrDU was visible. A total of 2000 ectodermal cells surrounding the embryos were counted, 
and the number of stained cells noted (figures in brackets). The data was statistically 
compared between the different media using a 2-sample students t-test, and the results are 
shown in the table above. A statistically significant difference is indicated by a P-value < 
0.05.
FM P: 50% dCP 
(276)
FMP: 10% dCP 
(229.7)
DMEM: 50% dCP 
(170.7)
FM P: 50% dCP 
(276)
FM P: 10% dCP 
(229.7)
0.17
DMEM: 50% dCP 
(170.7)
0.0024 0.0079
Control Embryos 
(387)
0.21 0.092 0.034
Appendix A5 - Protein Concentrations in Cultured Embryos.
As described in the Materials & Methods section, the protein was extracted from each 
cultured embryo using the Lowry method (1951). The concentration of protein reflects the 
developmental stage and condition of the embryos after culture. Therefore, to determine 
whether there was a statistically significant difference between the embryos cultured in each 
medium, the protein values for each culture group were statistically analysed by 2-sample 
students t-tests. A resulting P-value< 0.05 indicates a statistically significant difference. The 
results are presented in the table above.
The numbers in brackets represent mean protein concentrations for the embryos cultured in 
that medium.
Stained vs Total Number of 
Cells Counted in TGFpi+'+
Stained vs Total Number of 
Cells Counted in TG Fpi;
All Yolk Sac Cells 1056/3041 1047/3036
P-Value 0.94
Mesothelial + 
Endothelial Cells
935/2160 1028 / 2700
P Value 0.22
Endodermal Cells 1418 / 2413 932/2800
P Value 0.2S
Endothelial Cells 586/1735 459/1541
P Value 0.18
Appendix A6 - BrDU Incorporation in the Yolk Sacs of TGF-pi Knockout Embryos.
To determine whether there was a difference in cell proliferation rate in the TGF-|31+/+ and 
TGF-pi^' embryos, lpl 10mmol /l BrDU was injected into the yolk sac cavity before culture 
for 1 hour in FMP : 50% dCP (See Materials & Methods). After immunohistochemistry, the 
number of cells stained for BrDU was visible. A range of cell types were analysed in the yolk 
sac with a total of approximately 3000 cells counted per cell type, per genotype, as shown 
above. The data was statistically compared between the different genotypes using 2-sample 
students t-tests. A P-value < 0.05 represents statistical significance.
Stained vs Total Number of 
Cells Counted in TGFpi+/+ 
Embryos
Stained vs Total Number of 
Cells Counted in TGFpT; 
Embryos
Surrounding Epithelial 
Cells
958/3000 922/3000
P Value 0.17
Neural Tube Epithelial 
Cells
953/3000 907 / 3000
P Value 0.29
Appendix A7 - BrDU Incorporation in TGF-pi Knockout Embryos.
To determine whether there was a difference in cell proliferation rate in the TGF-pl+/+ and 
TGF- p i-/- embryos, lpl lOmmol/ /I BrDU was injected into the yolk sac cavity before culture 
for 1 hour in FMP : 50% dCP (See Materials & Methods). After immunohistochemistry, the 
number of cells stained for BrDU was visible. Two epithelial cell types were analysed in the 
embryo proper, with a total of 3000 cells counted per cell type, per genotype. The data was 
statistically compared between the different genotypes using 2-sample students t-tests, and the 
results are shown above. A P-value < 0.05 represents statistical significance.
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